data_2bdo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2bdo _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.414 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.543 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.465 HG22 ' CG1' ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG2' ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.613 ' CD1' ' CD2' ' A' ' 152' ' ' LEU . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.468 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 95' ' ' PRO . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo . . . . . 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.88 0.371 . . . . 0.0 110.775 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.466 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.611 ' CE2' ' CG ' ' A' ' 95' ' ' PRO . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.473 HG21 ' CG2' ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.419 HG23 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.513 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.513 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.458 HG12 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.516 HG22 ' NE2' ' A' ' 126' ' ' GLN . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 126' ' ' GLN . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.532 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.464 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.513 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.532 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.442 HG21 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.506 HG12 ' CG1' ' A' ' 153' ' ' VAL . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.432 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.419 ' HA ' HG23 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.524 HG22 ' CE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.489 ' N ' HG21 ' A' ' 138' ' ' ILE . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.464 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.47 ' HB2' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.464 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.483 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.613 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.506 ' CG1' HG12 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.478 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.543 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.432 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.415 -0.274 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.559 ' CE1' HD11 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.52 HG13 ' CG1' ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.47 ' OG ' ' HB2' ' A' ' 150' ' ' GLU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.461 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CE2' HD11 ' A' ' 138' ' ' ILE . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.465 ' N ' ' HB2' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.584 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 69.7 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.707 0.289 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.584 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 136' ' ' LYS . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.425 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.573 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.515 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 119' ' ' GLU . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.447 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.425 ' O ' ' HG3' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.454 ' HE3' ' HB3' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.454 ' HB3' ' HE3' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 115' ' ' LEU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' A' ' 128' ' ' GLU . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.512 ' CG1' HG11 ' A' ' 153' ' ' VAL . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.463 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.448 ' HB1' ' O ' ' A' ' 136' ' ' LYS . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.581 HD11 ' CE2' ' A' ' 91' ' ' PHE . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.492 ' N ' HG21 ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.525 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.465 ' HB2' ' N ' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.462 ' CG1' HG12 ' A' ' 140' ' ' VAL . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.47 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.57 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.512 HG11 ' CG1' ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.52 ' CG1' HG13 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.559 HD11 ' CE1' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.463 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.54 -0.224 . . . . 0.0 112.54 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.495 ' NE2' ' HB2' ' A' ' 131' ' ' LYS . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.448 HG22 HG11 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.411 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.498 HG11 ' N ' ' A' ' 89' ' ' GLY . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.498 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.572 ' CE1' ' O ' ' A' ' 92' ' ' TYR . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' O ' ' CE1' ' A' ' 91' ' ' PHE . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.572 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.2 Cg_endo . . . . . 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.491 ' CG2' HG11 ' A' ' 109' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.468 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.513 ' N ' ' HG3' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.538 HG23 ' CE1' ' A' ' 102' ' ' PHE . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.571 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.528 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.529 ' CE ' ' HB3' ' A' ' 125' ' ' ASN . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB3' ' CE ' ' A' ' 123' ' ' MET . 5.8 t30 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' N ' ' A' ' 115' ' ' LEU . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 130' ' ' ASP . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.495 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 109' ' ' VAL . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.48 HG12 ' CG1' ' A' ' 153' ' ' VAL . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.468 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.421 ' HB3' HG12 ' A' ' 105' ' ' VAL . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.514 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 151' ' ' PRO . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.568 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.466 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.466 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.432 ' O ' HG11 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.511 ' N ' ' OE1' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 140' ' ' VAL . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.495 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.48 ' CG1' HG12 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.486 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.424 HG21 ' N ' ' A' ' 156' ' ' GLU . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.424 ' N ' HG21 ' A' ' 155' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.565 -0.214 . . . . 0.0 112.565 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.468 HG22 ' HB3' ' A' ' 151' ' ' PRO . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.452 HG22 HD13 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.433 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.537 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.537 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CE2' HD12 ' A' ' 138' ' ' ILE . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 91' ' ' PHE . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.484 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.445 HG21 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.511 ' HB3' ' CD1' ' A' ' 117' ' ' ILE . 54.0 Cg_endo . . . . . 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.51 HG22 ' CD ' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.458 ' HA ' HG13 ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.47 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.521 HG22 ' CB ' ' A' ' 113' ' ' ASP . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.434 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.521 ' CB ' HG22 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.571 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.513 HG22 ' ND2' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.525 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.429 ' CD ' ' HE1' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.526 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.526 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.503 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.45 ' N ' HG21 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.555 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.539 ' CG2' ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.507 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.412 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.579 HD12 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.528 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.484 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.444 ' O ' HG21 ' A' ' 90' ' ' THR . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.416 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB3' HG22 ' A' ' 82' ' ' ILE . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.568 HD21 ' CD1' ' A' ' 91' ' ' PHE . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 152' ' ' LEU . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.454 HG11 HG22 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.452 HD13 HG22 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.507 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.582 ' CD2' ' CB ' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.456 HG22 HG13 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 153' ' ' VAL . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.43 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.409 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.522 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.522 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.477 ' OG1' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.526 ' CD1' HD21 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.435 ' C ' ' HB2' ' A' ' 142' ' ' SER . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.455 ' O ' HG21 ' A' ' 94' ' ' THR . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.558 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo . . . . . 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.5 pptp? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.709 0.29 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.559 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.466 ' HA ' ' HG2' ' A' ' 107' ' ' GLN . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.453 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.419 ' CG2' ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.466 ' HG2' ' HA ' ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.445 ' N ' ' HD3' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.559 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.494 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.477 ' OE1' ' OG1' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.41 ' HB2' ' HE1' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' CB ' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.432 ' HA ' HG22 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.553 ' CB ' ' CE ' ' A' ' 123' ' ' MET . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 129' ' ' ALA . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.582 ' CB ' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.445 HG22 HG21 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.45 ' HD3' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.419 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.47 HG21 ' N ' ' A' ' 139' ' ' LEU . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.47 ' N ' HG21 ' A' ' 138' ' ' ILE . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.511 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 139' ' ' LEU . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.512 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.512 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 89' ' ' GLY . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.454 ' O ' HG21 ' A' ' 140' ' ' VAL . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.526 HD21 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 83' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.456 HG13 HG22 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.437 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.45 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.357 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.445 ' O ' HD11 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HD13 ' A' ' 155' ' ' ILE . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.499 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.415 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.448 HG11 ' N ' ' A' ' 89' ' ' GLY . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.519 ' CA ' HG21 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.568 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.468 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.46 HG21 ' HA ' ' A' ' 101' ' ' ALA . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.579 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.0 Cg_endo . . . . . 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 11.2 mtpt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.455 ' OE1' ' HA ' ' A' ' 104' ' ' GLU . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.47 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' A' ' 133' ' ' GLY . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.458 ' HB2' HG13 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.404 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.486 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.489 HD11 ' HB3' ' A' ' 95' ' ' PRO . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.439 HG22 ' ND2' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.538 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.401 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 127' ' ' ILE . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.453 ' N ' ' O ' ' A' ' 128' ' ' GLU . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.415 ' CG2' ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.449 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.568 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.458 HD23 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.515 HG13 ' CB ' ' A' ' 91' ' ' PHE . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.519 HG21 ' CA ' ' A' ' 90' ' ' THR . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.458 ' HG2' HD23 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.508 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.518 HD13 ' CG2' ' A' ' 83' ' ' VAL . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.528 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.465 ' O ' HD11 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.553 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.553 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.489 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.575 ' CZ ' HD11 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.517 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.492 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.562 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo . . . . . 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.882 0.372 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.492 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 103' ' ' ILE . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.517 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.537 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' A' ' 107' ' ' GLN . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.488 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.465 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.409 HD22 ' SG ' ' A' ' 116' ' ' CYS . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.534 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.503 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 90' ' ' THR . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.461 ' HE1' ' HB2' ' A' ' 125' ' ' ASN . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.458 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 123' ' ' MET . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.503 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.437 HG23 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.437 ' N ' HG23 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.478 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 132' ' ' SER . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.491 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.537 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.422 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.453 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.575 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.49 HD13 ' CB ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.514 HG12 ' CG1' ' A' ' 146' ' ' VAL . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.473 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.459 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 3.2 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.459 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.521 HG21 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.427 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.468 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.49 ' CB ' HD13 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.511 ' O ' ' CG2' ' A' ' 153' ' ' VAL . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 152' ' ' LEU . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 137' ' ' ALA . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.528 ' CD1' ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.422 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.62 -0.192 . . . . 0.0 112.62 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.578 ' CD2' ' HB3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.491 HG21 ' N ' ' A' ' 83' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.491 ' N ' HG21 ' A' ' 82' ' ' ILE . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.452 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.543 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.543 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.502 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.574 ' CD2' HG13 ' A' ' 140' ' ' VAL . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.498 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.463 ' HD2' ' OG1' ' A' ' 94' ' ' THR . 89.1 Cg_endo . . . . . 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm . . . . . 0 N--CA 1.456 -0.158 0 CA-C-O 121.067 0.46 . . . . 0.0 109.958 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.498 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.572 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.452 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.434 ' HA ' HG13 ' A' ' 135' ' ' VAL . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.452 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.453 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.458 HD21 ' HB ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.401 ' N ' HG21 ' A' ' 117' ' ' ILE . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.506 ' O ' ' CG ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.416 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.5 ' CE ' ' CB ' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.5 ' CB ' ' CE ' ' A' ' 123' ' ' MET . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.458 ' HB ' HD21 ' A' ' 115' ' ' LEU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.417 ' N ' ' OE1' ' A' ' 128' ' ' GLU . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.578 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.558 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.458 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.458 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.466 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 91' ' ' PHE . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.533 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.533 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.51 ' N ' ' O ' ' A' ' 89' ' ' GLY . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.438 ' HA ' HG23 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HG3' HG21 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.518 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.436 HG21 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.508 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.55 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.58 ' NE2' ' CD1' ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.525 HG22 ' CG1' ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.42 HG22 HD13 ' A' ' 155' ' ' ILE . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.443 ' O ' ' HB3' ' A' ' 120' ' ' ALA . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.544 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.473 ' O ' ' O ' ' A' ' 95' ' ' PRO . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo . . . . . 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.863 0.363 . . . . 0.0 110.912 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.575 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.516 ' CG2' HG11 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.427 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.431 HG11 ' O ' ' A' ' 136' ' ' LYS . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.436 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 110' ' ' ASN . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.575 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.533 ' CG2' ' HG3' ' A' ' 119' ' ' GLU . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.527 ' N ' ' CG2' ' A' ' 117' ' ' ILE . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.533 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 88' ' ' VAL . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.499 ' CE ' ' HE2' ' A' ' 124' ' ' MET . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.496 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.499 ' HE2' ' CE ' ' A' ' 122' ' ' LYS . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.496 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.486 ' O ' ' N ' ' A' ' 115' ' ' LEU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.52 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.437 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.498 HG11 ' CG1' ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.431 ' O ' HG11 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.428 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 150' ' ' GLU . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' O ' ' A' ' 141' ' ' GLU . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.52 HD21 ' CD1' ' A' ' 91' ' ' PHE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.506 HG23 ' CD1' ' A' ' 138' ' ' ILE . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.525 ' CG1' HG22 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.58 ' CD1' ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.565 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.518 ' OG ' ' CD2' ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.427 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.453 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.566 ' HA ' ' N ' ' A' ' 147' ' ' GLU . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.49 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CD1' HD21 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.564 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.517 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.517 HG21 ' CA ' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo . . . . . 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.842 0.353 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.517 ' CA ' HG21 ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.496 ' CG2' HG12 ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.496 HG12 ' CG2' ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' A' ' 110' ' ' ASN . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.565 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.482 HD13 ' CZ ' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.496 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.419 ' HB1' ' HE3' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.519 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.519 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 3.5 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.428 ' C ' HG22 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.457 ' HD3' ' HG3' ' A' ' 156' ' ' GLU . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.517 ' CD1' HG23 ' A' ' 153' ' ' VAL . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.41 HD11 ' N ' ' A' ' 139' ' ' LEU . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.489 HG21 ' CG ' ' A' ' 150' ' ' GLU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.517 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.564 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.566 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.508 ' CB ' ' CG2' ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.489 ' CG ' HG21 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.581 HD21 ' CD1' ' A' ' 91' ' ' PHE . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 138' ' ' ILE . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.49 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.457 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.542 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.578 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 152' ' ' LEU . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.486 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.487 ' CE1' ' HB3' ' A' ' 152' ' ' LEU . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 94' ' ' THR . 52.2 Cg_exo . . . . . 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.511 HG12 ' CG1' ' A' ' 109' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.445 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.508 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.511 ' CG1' HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.576 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.52 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.481 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.424 ' C ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.452 ' O ' ' HG3' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.506 ' HE2' ' CA ' ' A' ' 122' ' ' LYS . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.523 ' HE2' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.479 ' CE ' ' HD3' ' A' ' 122' ' ' LYS . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.523 ' CB ' ' HE2' ' A' ' 123' ' ' MET . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.539 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.527 HG12 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.491 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.465 ' HB1' ' O ' ' A' ' 136' ' ' LYS . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.48 HG21 ' N ' ' A' ' 139' ' ' LEU . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.48 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.507 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.46 ' HA ' HG23 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.471 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.45 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.487 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.527 ' CG1' HG12 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.488 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.542 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.535 -0.226 . . . . 0.0 112.535 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.513 ' CE1' ' HB2' ' A' ' 131' ' ' LYS . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.575 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.405 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.429 ' HA ' HD13 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.542 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.542 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.465 ' O ' HG21 ' A' ' 94' ' ' THR . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.467 HG23 ' HA ' ' A' ' 101' ' ' ALA . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 94' ' ' THR . 39.4 Cg_exo . . . . . 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 94' ' ' THR . 7.1 ttpt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.842 0.353 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.467 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.548 ' CE2' HD11 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.522 HG23 ' CG2' ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.458 ' OE2' ' HB2' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.475 HG12 ' HB3' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.517 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.517 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.447 HG21 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.456 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.501 ' CG2' ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.456 ' CD2' ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.548 HD11 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.507 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.534 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.448 ' HD3' ' HE2' ' A' ' 124' ' ' MET . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.51 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' HG22 ' A' ' 117' ' ' ILE . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.51 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.456 ' HB ' ' CD2' ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.49 ' N ' ' OD1' ' A' ' 130' ' ' ASP . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.513 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.461 ' N ' HG21 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.516 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.522 ' CG2' HG23 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.465 ' O ' HG11 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.475 ' HB3' HG12 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.563 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 152' ' ' LEU . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.482 ' O ' ' O ' ' A' ' 141' ' ' GLU . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.534 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 88' ' ' VAL . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.457 ' HA ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.469 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.46 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.462 HG23 HD13 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.492 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.516 ' CG2' ' O ' ' A' ' 134' ' ' THR . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.449 ' N ' HG21 ' A' ' 155' ' ' ILE . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.518 ' NE2' HD11 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.562 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.413 HG21 ' CE1' ' A' ' 81' ' ' HIS . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 149' ' ' ASP . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.519 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.465 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.582 ' O ' ' CD1' ' A' ' 92' ' ' TYR . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.455 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.584 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.1 Cg_endo . . . . . 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.844 0.354 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.584 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.523 ' CD1' ' O ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.522 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.484 ' N ' HG11 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.535 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' A' ' 133' ' ' GLY . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.512 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.523 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.583 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.507 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.48 HG22 ' ND2' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.529 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.517 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.517 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.439 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.512 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.535 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.533 HG22 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.418 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.457 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.506 HG21 ' N ' ' A' ' 139' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.506 ' N ' HG21 ' A' ' 138' ' ' ILE . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.5 ' CG1' ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.465 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.455 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.551 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.526 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.526 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.411 ' CG2' ' HB2' ' A' ' 91' ' ' PHE . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.457 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.453 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.499 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.504 HD21 ' CD1' ' A' ' 91' ' ' PHE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 115' ' ' LEU . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.464 ' CG1' HG13 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.518 HD11 ' NE2' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.544 -0.223 . . . . 0.0 112.544 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.48 ' CE1' HG21 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.48 HG21 ' CE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.472 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' ' CB ' ' A' ' 150' ' ' GLU . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.516 ' O ' ' N ' ' A' ' 148' ' ' PHE . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 146' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.617 ' CD1' ' CD2' ' A' ' 152' ' ' LEU . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.511 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.572 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.4 Cg_endo . . . . . 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.059 0.457 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.511 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.501 HD11 ' NE2' ' A' ' 107' ' ' GLN . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.501 ' NE2' HD11 ' A' ' 103' ' ' ILE . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.451 ' CG1' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.486 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.529 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.509 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.533 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.433 ' OE1' ' HE3' ' A' ' 124' ' ' MET . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.431 ' HB1' HG13 ' A' ' 118' ' ' VAL . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.545 ' CE ' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.462 ' HA ' HG21 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.545 ' OD1' ' CE ' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.481 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.493 ' O ' ' N ' ' A' ' 115' ' ' LEU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.529 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.511 ' O ' ' CG2' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.486 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.565 HD11 ' CE2' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.525 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.48 ' O ' ' HB2' ' A' ' 141' ' ' GLU . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.471 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 89' ' ' GLY . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.535 ' CB ' ' HB3' ' A' ' 85' ' ' SER . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.525 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.438 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.592 ' CE1' ' CD1' ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.427 ' HA ' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.458 HG11 ' O ' ' A' ' 146' ' ' VAL . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.485 ' N ' HG21 ' A' ' 146' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.574 ' O ' ' CG ' ' A' ' 92' ' ' TYR . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.577 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo . . . . . 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.9 mmtm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.905 0.383 . . . . 0.0 110.765 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' ' HG2' ' A' ' 95' ' ' PRO . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.49 HD11 ' NE2' ' A' ' 107' ' ' GLN . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 106' ' ' GLY . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.48 ' N ' HG11 ' A' ' 105' ' ' VAL . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.49 ' NE2' HD11 ' A' ' 103' ' ' ILE . 37.1 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HD2' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.505 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.463 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.476 HG21 ' N ' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.463 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.43 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.526 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.484 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.522 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.418 ' HB2' ' HE1' ' A' ' 124' ' ' MET . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.526 ' O ' ' CG2' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.458 ' N ' HG21 ' A' ' 127' ' ' ILE . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.505 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.468 ' N ' ' OD1' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.476 ' N ' HG21 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.451 HG12 ' CG1' ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.524 HG12 ' CG1' ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.474 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.458 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.524 ' CG1' HG12 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.465 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.457 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.495 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 152' ' ' LEU . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.592 ' CD1' ' CE1' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.214 0 N-CA-C 112.773 -0.131 . . . . 0.0 112.773 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.583 ' ND1' ' CD1' ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.44 HG21 ' N ' ' A' ' 83' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 153' ' ' VAL . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.451 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.502 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.516 HG11 ' N ' ' A' ' 89' ' ' GLY . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.516 ' N ' HG11 ' A' ' 88' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.571 ' CZ ' HD11 ' A' ' 138' ' ' ILE . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.477 ' HB3' HD11 ' A' ' 117' ' ' ILE . 35.2 Cg_endo . . . . . 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.901 0.381 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.553 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.441 ' CD1' ' N ' ' A' ' 103' ' ' ILE . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.447 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.447 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.528 ' O ' ' CA ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.464 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.422 HG21 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.553 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.477 HD11 ' HB3' ' A' ' 95' ' ' PRO . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.469 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.465 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.526 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.526 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.526 ' CE ' ' HE2' ' A' ' 122' ' ' LYS . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.526 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.424 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB2' ' O ' ' A' ' 130' ' ' ASP . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.465 ' OG ' HD12 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.447 HG22 ' CG2' ' A' ' 109' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.405 ' CG ' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.571 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.471 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.501 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.556 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.524 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.464 HG13 HD22 ' A' ' 152' ' ' LEU . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.451 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.459 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.473 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.473 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.461 HG21 ' O ' ' A' ' 137' ' ' ALA . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.583 ' CD1' ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.405 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.427 ' CA ' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.522 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.501 HG11 ' N ' ' A' ' 89' ' ' GLY . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.501 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.525 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.521 ' NE ' HD13 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.406 ' HB3' ' CZ ' ' A' ' 102' ' ' PHE . 58.7 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.616 ' CZ ' ' CG2' ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.493 ' CD1' ' N ' ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.496 HG21 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.434 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.521 HG13 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.434 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 110' ' ' ASN . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.521 ' CB ' HG13 ' A' ' 109' ' ' VAL . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.616 ' CG2' ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.461 ' O ' ' N ' ' A' ' 127' ' ' ILE . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.53 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.511 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.5 ' OE1' ' CE ' ' A' ' 124' ' ' MET . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.467 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.505 ' CE ' ' ND2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.511 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.53 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.445 ' O ' HG21 ' A' ' 155' ' ' ILE . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 103' ' ' ILE . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.521 HD13 ' NE ' ' A' ' 93' ' ' ARG . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.497 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.455 ' HA ' ' HB3' ' A' ' 91' ' ' PHE . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.47 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.47 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 91' ' ' PHE . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.448 HG21 ' O ' ' A' ' 152' ' ' LEU . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.52 HG12 ' CD2' ' A' ' 81' ' ' HIS . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.427 ' OXT' ' CA ' ' A' ' 80' ' ' GLY . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' N ' ' A' ' 155' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.537 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.509 ' HB2' ' CD2' ' A' ' 152' ' ' LEU . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.421 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.507 HG11 ' N ' ' A' ' 89' ' ' GLY . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.507 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.493 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CE2' HD12 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.453 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.531 HG23 ' CB ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.414 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 51.8 Cg_endo . . . . . 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.531 ' CB ' HG23 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.459 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.524 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.458 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 27.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.458 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.524 ' CG1' ' CG2' ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.407 HG22 ' OG ' ' A' ' 132' ' ' SER . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.514 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.519 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.429 ' O ' ' HG3' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.519 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.451 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.519 ' CE ' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.519 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.518 ' N ' ' O ' ' A' ' 124' ' ' MET . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.598 ' N ' ' CD1' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.433 ' N ' HG21 ' A' ' 127' ' ' ILE . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.407 ' OG ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.511 ' CG1' HG11 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.43 ' N ' ' O ' ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.579 HD12 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.514 ' CG2' ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.527 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.504 ' N ' ' O ' ' A' ' 89' ' ' GLY . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.502 ' N ' HG13 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.514 ' HB3' ' CG2' ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.571 HD21 ' CD1' ' A' ' 91' ' ' PHE . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.511 HG11 ' CG1' ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.505 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.504 ' N ' ' O ' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' A' ' 80' ' ' GLY . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.565 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.503 HG11 ' N ' ' A' ' 89' ' ' GLY . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG11 ' A' ' 88' ' ' VAL . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.517 ' CB ' HG13 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.451 ' O ' ' SG ' ' A' ' 116' ' ' CYS . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.465 ' O ' HG22 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 93' ' ' ARG . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo . . . . . 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.788 0.328 . . . . 0.0 110.886 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.428 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.444 HG23 HG22 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.496 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.576 ' N ' ' CG1' ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.513 ' HB2' ' CG1' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.481 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 90' ' ' THR . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.424 ' CB ' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.523 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.502 ' O ' ' N ' ' A' ' 126' ' ' GLN . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.523 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.524 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.555 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.521 ' CG2' ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.417 ' HA ' ' HE3' ' A' ' 136' ' ' LYS . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.509 ' CD1' HG21 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.467 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.517 HG13 ' CB ' ' A' ' 91' ' ' PHE . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.472 ' HA ' ' HB3' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.451 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.452 ' O ' HG11 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.431 ' N ' ' CG1' ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.467 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.49 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.516 ' CG1' HG23 ' A' ' 135' ' ' VAL . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 131' ' ' LYS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.42 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.432 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.521 HG21 ' CG1' ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.449 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.531 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.531 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 142' ' ' SER . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.456 ' O ' HG21 ' A' ' 94' ' ' THR . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.466 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.514 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.7 Cg_exo . . . . . 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.081 0 CA-C-O 120.849 0.357 . . . . 0.0 111.005 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.567 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.449 ' OE2' ' CB ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.517 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.517 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.511 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.436 ' OD2' HG13 ' A' ' 109' ' ' VAL . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.542 HG23 ' CE1' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.567 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.4 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.464 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.522 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.522 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.511 ' N ' ' O ' ' A' ' 124' ' ' MET . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 131' ' ' LYS . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.511 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.46 HG23 ' HB3' ' A' ' 156' ' ' GLU . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.49 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 154' ' ' VAL . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.5 HD12 ' CE2' ' A' ' 91' ' ' PHE . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 142' ' ' SER . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.57 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 88' ' ' VAL . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.401 ' HA ' HG21 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.418 ' C ' HG21 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.55 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.49 ' CG1' ' CG2' ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG1' HG21 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.46 ' HB3' HG23 ' A' ' 134' ' ' THR . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.453 HG22 HG13 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 152' ' ' LEU . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.522 ' NH1' ' HB2' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.52 ' CB ' ' CG1' ' A' ' 146' ' ' VAL . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.437 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.47 ' CA ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.562 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.496 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.526 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.528 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HD2' ' CD2' ' A' ' 102' ' ' PHE . 31.3 Cg_exo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 3.3 ptmm? . . . . . 0 CA--C 1.523 -0.06 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.552 ' CD2' ' HD2' ' A' ' 95' ' ' PRO . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.515 HG21 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.451 ' OE1' HG13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.474 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HG2' ' O ' ' A' ' 107' ' ' GLN . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.486 HG13 ' HA3' ' A' ' 133' ' ' GLY . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.547 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.528 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 90' ' ' THR . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.432 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.534 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.512 ' CE ' ' HE2' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.49 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.512 ' HE2' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.49 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.528 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.486 ' HA3' HG13 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.437 HG21 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.45 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.562 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.528 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.526 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.52 ' CG1' ' CB ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.438 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.456 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.493 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.513 ' CG1' HG23 ' A' ' 135' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.483 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.512 HG21 ' N ' ' A' ' 156' ' ' GLU . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.512 ' N ' HG21 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 N-CA-C 112.382 -0.287 . . . . 0.0 112.382 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.436 ' CD2' ' HD2' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.561 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.433 ' HA ' HD13 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.515 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CE2' ' HB3' ' A' ' 152' ' ' LEU . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.417 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.47 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.551 ' HB3' ' CE2' ' A' ' 102' ' ' PHE . 74.2 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.04 0 CA-C-O 120.773 0.32 . . . . 0.0 110.988 . . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.554 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.51 HG22 ' NZ ' ' A' ' 108' ' ' LYS . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.404 ' HG3' ' CB ' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.4 HG21 HG13 ' A' ' 138' ' ' ILE . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.531 ' CB ' ' O ' ' A' ' 107' ' ' GLN . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.402 ' CG2' ' C ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.434 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.447 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.463 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.522 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.554 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.477 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' O ' ' N ' ' A' ' 90' ' ' THR . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.404 ' HB2' ' HE3' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.404 ' HD3' ' HE1' ' A' ' 124' ' ' MET . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.522 ' O ' ' N ' ' A' ' 115' ' ' LEU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.499 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.434 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.487 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.514 ' CG2' ' HD3' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.546 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.48 HD11 ' N ' ' A' ' 139' ' ' LEU . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.468 ' N ' HG11 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.559 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.451 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 88' ' ' VAL . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.465 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.581 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.493 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 131' ' ' LYS . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.495 ' N ' HG21 ' A' ' 155' ' ' ILE . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.448 ' NE2' HD11 ' A' ' 155' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.551 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.516 ' OG ' ' CD1' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.483 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.458 HG22 ' O ' ' A' ' 93' ' ' ARG . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.567 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo . . . . . 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.823 0.344 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.448 ' HA ' HG21 ' A' ' 94' ' ' THR . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.475 ' CG2' HG22 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.406 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.455 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 118' ' ' VAL . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.482 ' N ' ' CG2' ' A' ' 117' ' ' ILE . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.454 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.454 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 124' ' ' MET . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.415 HG21 ' N ' ' A' ' 135' ' ' VAL . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.475 HG22 ' CG2' ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.406 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.577 HG23 ' CZ ' ' A' ' 91' ' ' PHE . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.531 ' CD2' ' N ' ' A' ' 139' ' ' LEU . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.581 ' O ' ' CE1' ' A' ' 91' ' ' PHE . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.575 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 91' ' ' PHE . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.524 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.467 ' CG1' ' CB ' ' A' ' 85' ' ' SER . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.449 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.449 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' CD2' ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.516 ' CD1' ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.458 HG21 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.515 HG11 ' CG2' ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.407 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.776 0.322 . . . . 0.0 110.949 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.1 pt -70.07 153.49 8.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.58 33.76 3.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.95 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.42 -129.7 9.23 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.605 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.543 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.465 HG22 ' CG1' ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG2' ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.613 ' CD1' ' CD2' ' A' ' 152' ' ' LEU . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.468 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 95' ' ' PRO . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo -56.31 -138.79 0.0 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.529 ' N ' ' H62' ' A' ' 222' ' ' BTN . 0.9 OUTLIER -29.96 105.01 0.21 Allowed Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.92 0.391 . . . . 0.0 110.669 179.845 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -31.48 -31.15 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.315 2.677 . . . . 0.0 112.942 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' SER . 12.8 m-20 -95.77 42.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.542 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.451 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -110.49 -161.81 0.77 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER -122.09 30.35 6.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.775 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.466 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.611 ' CE2' ' CG ' ' A' ' 95' ' ' PRO . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.473 HG21 ' CG2' ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.419 HG23 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.513 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.513 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.458 HG12 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.516 HG22 ' NE2' ' A' ' 126' ' ' GLN . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 126' ' ' GLN . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.532 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.464 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.513 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.532 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.442 HG21 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.506 HG12 ' CG1' ' A' ' 153' ' ' VAL . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.432 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.419 ' HA ' HG23 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.524 HG22 ' CE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.489 ' N ' HG21 ' A' ' 138' ' ' ILE . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.464 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.47 ' HB2' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.464 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.483 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.613 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.506 ' CG1' HG12 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.478 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.543 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.432 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.554 ' H4 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.829 0.347 . . . . 0.0 110.865 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 3.8 tp -145.16 122.34 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.165 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.449 ' HA ' ' OE1' ' A' ' 156' ' ' GLU . 22.7 t -126.17 44.67 2.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' SER . . . 37.45 -110.17 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.415 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.559 ' CE1' HD11 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.52 HG13 ' CG1' ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.47 ' OG ' ' HB2' ' A' ' 150' ' ' GLU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.461 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CE2' HD11 ' A' ' 138' ' ' ILE . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.577 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.465 ' N ' ' HB2' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.584 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 69.7 Cg_endo -74.37 54.19 3.26 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.3 OUTLIER 158.54 129.46 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.767 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.543 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 74.0 Cg_exo -49.52 81.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.811 2.34 . . . . 0.0 112.161 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.543 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 4.8 t0 90.16 53.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.732 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.454 ' HB1' ' HB3' ' A' ' 96' ' ' SER . . . -98.94 -155.6 0.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp -83.76 4.07 30.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.584 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 136' ' ' LYS . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.425 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.573 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.515 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 119' ' ' GLU . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.447 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.425 ' O ' ' HG3' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.454 ' HE3' ' HB3' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.454 ' HB3' ' HE3' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.493 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 115' ' ' LEU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' A' ' 128' ' ' GLU . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.512 ' CG1' HG11 ' A' ' 153' ' ' VAL . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.463 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.448 ' HB1' ' O ' ' A' ' 136' ' ' LYS . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.581 HD11 ' CE2' ' A' ' 91' ' ' PHE . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.492 ' N ' HG21 ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.525 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.465 ' HB2' ' N ' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.462 ' CG1' HG12 ' A' ' 140' ' ' VAL . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.47 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.57 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.512 HG11 ' CG1' ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.52 ' CG1' HG13 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.559 HD11 ' CE1' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.463 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.577 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 . . . . . 0 CA--C 1.527 0.061 0 CA-C-O 120.85 0.357 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.493 HG12 ' N ' ' A' ' 79' ' ' SER . 7.3 tt -138.85 155.3 27.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.493 ' N ' HG12 ' A' ' 78' ' ' ILE . 2.0 m -89.86 29.51 1.18 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.866 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -143.97 -161.69 9.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.54 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.495 ' NE2' ' HB2' ' A' ' 131' ' ' LYS . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.448 HG22 HG11 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.411 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.498 HG11 ' N ' ' A' ' 89' ' ' GLY . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.498 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.572 ' CE1' ' O ' ' A' ' 92' ' ' TYR . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.627 ' CE1' ' N2 ' ' A' ' 222' ' ' BTN . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.41 ' O ' ' H5 ' ' A' ' 222' ' ' BTN . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.572 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.2 Cg_endo -75.54 50.48 2.69 Favored 'Trans proline' 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.532 ' CB ' ' O ' ' A' ' 95' ' ' PRO . 0.5 OUTLIER 157.61 123.12 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.712 -179.878 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -49.55 -19.9 3.68 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.709 2.272 . . . . 0.0 112.283 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -134.16 58.35 1.77 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.784 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.454 ' HB1' ' HB2' ' A' ' 96' ' ' SER . . . -116.66 -162.67 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.019 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -111.11 21.84 15.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.491 ' CG2' HG11 ' A' ' 109' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.424 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.468 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.513 ' N ' ' HG3' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.538 HG23 ' CE1' ' A' ' 102' ' ' PHE . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.571 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.528 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.529 ' CE ' ' HB3' ' A' ' 125' ' ' ASN . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB3' ' CE ' ' A' ' 123' ' ' MET . 5.8 t30 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' N ' ' A' ' 115' ' ' LEU . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 130' ' ' ASP . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.495 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 109' ' ' VAL . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.48 HG12 ' CG1' ' A' ' 153' ' ' VAL . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.468 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.421 ' HB3' HG12 ' A' ' 105' ' ' VAL . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.514 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 151' ' ' PRO . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.568 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.466 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.466 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.432 ' O ' HG11 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.511 ' N ' ' OE1' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 140' ' ' VAL . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.495 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.48 ' CG1' HG12 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.486 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.424 HG21 ' N ' ' A' ' 156' ' ' GLU . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.424 ' N ' HG21 ' A' ' 155' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.627 ' N2 ' ' CE1' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.798 0.332 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.431 HD12 ' N ' ' A' ' 79' ' ' SER . 0.0 OUTLIER -142.25 132.15 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.139 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.431 ' N ' HD12 ' A' ' 78' ' ' ILE . 0.3 OUTLIER -114.77 120.16 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 179.991 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.07 168.5 40.84 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.468 HG22 ' HB3' ' A' ' 151' ' ' PRO . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.452 HG22 HD13 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.433 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.537 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.537 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CE2' HD12 ' A' ' 138' ' ' ILE . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.563 ' CE2' ' H61' ' A' ' 222' ' ' BTN . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.484 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.445 HG21 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -70.36 94.13 0.58 Allowed 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.491 ' C ' ' O ' ' A' ' 95' ' ' PRO . 0.1 OUTLIER -18.53 -60.09 0.05 OUTLIER Pre-proline 0 N--CA 1.467 0.405 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.316 -179.8 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.47 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 82.5 Cg_exo -44.04 -44.74 12.17 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.612 2.208 . . . . 0.0 112.308 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 95' ' ' PRO . 23.5 t70 -146.6 41.31 1.13 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.515 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.537 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -31.55 -91.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.503 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 50.77 22.05 1.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.51 HG22 ' CD ' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.458 ' HA ' HG13 ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.47 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.521 HG22 ' CB ' ' A' ' 113' ' ' ASP . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.434 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.521 ' CB ' HG22 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.571 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.513 HG22 ' ND2' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.525 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.429 ' CD ' ' HE1' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.526 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.526 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.503 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.45 ' N ' HG21 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.555 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.539 ' CG2' ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.507 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.412 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.579 HD12 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.528 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.484 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.444 ' O ' HG21 ' A' ' 90' ' ' THR . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.416 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB3' HG22 ' A' ' 82' ' ' ILE . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.568 HD21 ' CD1' ' A' ' 91' ' ' PHE . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 152' ' ' LEU . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.454 HG11 HG22 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.452 HD13 HG22 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.507 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.563 ' H61' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -70.46 176.21 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.192 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.3 m -112.45 36.92 3.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -139.43 -169.63 11.66 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.582 ' CD2' ' CB ' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.456 HG22 HG13 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.464 HG22 ' O ' ' A' ' 153' ' ' VAL . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.43 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.409 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.522 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.522 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.477 ' OG1' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.526 ' CD1' HD21 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.515 ' CZ ' ' H72' ' A' ' 222' ' ' BTN . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.455 ' O ' HG21 ' A' ' 94' ' ' THR . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.558 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo -54.45 -155.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 11.2 p -25.58 137.51 0.07 OUTLIER Pre-proline 0 N--CA 1.465 0.302 0 O-C-N 123.235 0.334 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.529 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 31.9 Cg_exo -59.07 61.91 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.087 2.525 . . . . 0.0 112.716 -179.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.0 m-20 156.17 39.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.777 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.516 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -99.98 -97.22 0.24 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.12 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.478 ' HB3' ' O ' ' A' ' 99' ' ' ALA . 1.5 pptp? 174.82 40.36 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.816 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.559 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.466 ' HA ' ' HG2' ' A' ' 107' ' ' GLN . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.453 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.419 ' CG2' ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.466 ' HG2' ' HA ' ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.445 ' N ' ' HD3' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.559 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.494 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.477 ' OE1' ' OG1' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.41 ' HB2' ' HE1' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' CB ' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.432 ' HA ' HG22 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.553 ' CB ' ' CE ' ' A' ' 123' ' ' MET . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.494 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 129' ' ' ALA . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.582 ' CB ' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.445 HG22 HG21 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.45 ' HD3' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.419 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.47 HG21 ' N ' ' A' ' 139' ' ' LEU . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.47 ' N ' HG21 ' A' ' 138' ' ' ILE . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.511 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 139' ' ' LEU . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.512 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.512 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 89' ' ' GLY . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.454 ' O ' HG21 ' A' ' 140' ' ' VAL . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.526 HD21 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.464 ' O ' HG22 ' A' ' 83' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.456 HG13 HG22 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.437 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.45 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.515 ' H72' ' CZ ' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.46 ' O ' HG21 ' A' ' 78' ' ' ILE . 1.1 pt-20 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.776 0.322 . . . . 0.0 110.972 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.46 ' O ' HG21 ' A' ' 78' ' ' ILE . 3.5 tp 37.26 89.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.074 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 80' ' ' GLY . 0.9 OUTLIER -96.66 10.78 37.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 79' ' ' SER . . . 36.36 -127.58 0.98 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.445 ' O ' HD11 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HD13 ' A' ' 155' ' ' ILE . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.499 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.415 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.448 HG11 ' N ' ' A' ' 89' ' ' GLY . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.519 ' CA ' HG21 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.568 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.538 ' CD2' ' H5 ' ' A' ' 222' ' ' BTN . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.468 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.476 ' HB ' ' HB2' ' A' ' 99' ' ' ALA . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.579 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.0 Cg_endo -76.61 124.22 7.47 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.6 OUTLIER -36.94 -50.08 2.08 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.838 179.955 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 96' ' ' SER . 33.3 Cg_exo -57.83 71.07 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.9 2.4 . . . . 0.0 112.385 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 96' ' ' SER . 36.6 t0 75.72 29.52 0.84 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.058 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.522 ' CA ' ' O ' ' A' ' 95' ' ' PRO . . . -35.99 95.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.132 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' N ' ' O ' ' A' ' 98' ' ' ASP . 11.2 mtpt -100.33 29.29 4.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.755 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.455 ' OE1' ' HA ' ' A' ' 104' ' ' GLU . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.47 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' A' ' 133' ' ' GLY . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.458 ' HB2' HG13 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.404 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.486 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.502 ' CG2' ' H62' ' A' ' 222' ' ' BTN . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.439 HG22 ' ND2' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.538 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.401 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 127' ' ' ILE . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.453 ' N ' ' O ' ' A' ' 128' ' ' GLU . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.415 ' CG2' ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.449 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.568 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.458 HD23 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.515 HG13 ' CB ' ' A' ' 91' ' ' PHE . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.519 HG21 ' CA ' ' A' ' 90' ' ' THR . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.458 ' HG2' HD23 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.508 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.518 HD13 ' CG2' ' A' ' 83' ' ' VAL . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.538 ' H5 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.817 0.341 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.49 -178.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.6 m -84.56 10.01 12.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.021 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.96 -128.41 47.63 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.528 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.465 ' O ' HD11 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.553 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.553 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.489 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.575 ' CZ ' HD11 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.517 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.521 ' OG1' ' CB ' ' A' ' 99' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.562 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo -65.26 -152.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.601 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -122.47 -72.79 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.083 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.601 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 23.8 Cg_endo -61.27 77.97 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.502 2.134 . . . . 0.0 112.372 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER 85.38 45.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.785 -179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.521 ' CB ' ' OG1' ' A' ' 94' ' ' THR . . . -59.59 -53.66 55.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.302 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.28 22.72 13.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.492 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 103' ' ' ILE . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.517 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.537 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' A' ' 107' ' ' GLN . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.488 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.465 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.409 HD22 ' SG ' ' A' ' 116' ' ' CYS . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.534 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.503 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 90' ' ' THR . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.461 ' HE1' ' HB2' ' A' ' 125' ' ' ASN . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.458 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 123' ' ' MET . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.503 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.437 HG23 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.437 ' N ' HG23 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.478 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 132' ' ' SER . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.491 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.534 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.537 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.422 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.453 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.575 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.49 HD13 ' CB ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.514 HG12 ' CG1' ' A' ' 146' ' ' VAL . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.473 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.459 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 3.2 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.459 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.521 HG21 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.427 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.468 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.49 ' CB ' HD13 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.511 ' O ' ' CG2' ' A' ' 153' ' ' VAL . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 152' ' ' LEU . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 137' ' ' ALA . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.528 ' CD1' ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.422 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.456 ' S1 ' ' HB3' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.816 0.341 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -149.3 124.11 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.138 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -127.51 3.62 6.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.082 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 79' ' ' SER . . . 35.52 -155.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.62 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.578 ' CD2' ' HB3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.491 HG21 ' N ' ' A' ' 83' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.491 ' N ' HG21 ' A' ' 82' ' ' ILE . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.452 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.543 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.543 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.502 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.574 ' CD2' HG13 ' A' ' 140' ' ' VAL . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.498 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 99' ' ' ALA . 89.1 Cg_endo -84.56 100.14 0.76 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.456 ' HB2' ' H4 ' ' A' ' 222' ' ' BTN . 1.0 OUTLIER -27.26 -63.2 0.17 Allowed Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.323 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.451 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 71.2 Cg_exo -36.28 -67.68 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.737 2.291 . . . . 0.0 112.447 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -118.72 43.02 2.63 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.113 0.482 . . . . 0.0 109.911 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -43.45 107.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.966 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -118.17 18.56 13.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.958 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.498 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.572 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.452 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.434 ' HA ' HG13 ' A' ' 135' ' ' VAL . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.452 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.453 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.458 HD21 ' HB ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.401 ' N ' HG21 ' A' ' 117' ' ' ILE . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.506 ' O ' ' CG ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.416 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.5 ' CE ' ' CB ' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.5 ' CB ' ' CE ' ' A' ' 123' ' ' MET . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.458 ' HB ' HD21 ' A' ' 115' ' ' LEU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.417 ' N ' ' OE1' ' A' ' 128' ' ' GLU . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.578 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.558 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.458 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.458 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.466 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 91' ' ' PHE . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.533 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.533 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.51 ' N ' ' O ' ' A' ' 89' ' ' GLY . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.438 ' HA ' HG23 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.443 ' HG3' HG21 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.518 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.436 HG21 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.508 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.55 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.527 ' C6 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' N ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.75 0.31 . . . . 0.0 110.818 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.404 HG12 ' N ' ' A' ' 79' ' ' SER . 7.4 tt -171.39 154.36 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.404 ' N ' HG12 ' A' ' 78' ' ' ILE . 54.8 p -112.57 34.14 4.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . 53.76 -149.8 14.51 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.525 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.58 ' NE2' ' CD1' ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.525 HG22 ' CG1' ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.42 HG22 HD13 ' A' ' 155' ' ' ILE . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.443 ' O ' ' HB3' ' A' ' 120' ' ' ALA . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.544 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.473 ' O ' ' O ' ' A' ' 95' ' ' PRO . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo -54.19 -149.68 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.2 OUTLIER -34.87 137.52 0.37 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.959 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.517 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 73.7 Cg_exo -49.24 79.72 0.02 OUTLIER 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 123.032 2.488 . . . . 0.0 112.597 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.5 m-20 159.24 -21.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.171 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.503 ' CB ' ' HD2' ' A' ' 95' ' ' PRO . . . -45.2 168.76 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.841 0.353 . . . . 0.0 111.087 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt -101.28 40.44 1.29 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.912 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.575 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.516 ' CG2' HG11 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.427 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.431 HG11 ' O ' ' A' ' 136' ' ' LYS . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.436 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 110' ' ' ASN . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.575 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.533 ' CG2' ' HG3' ' A' ' 119' ' ' GLU . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.527 ' N ' ' CG2' ' A' ' 117' ' ' ILE . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.533 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 88' ' ' VAL . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.499 ' CE ' ' HE2' ' A' ' 124' ' ' MET . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.496 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.499 ' HE2' ' CE ' ' A' ' 122' ' ' LYS . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.496 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.486 ' O ' ' N ' ' A' ' 115' ' ' LEU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.52 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.437 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.498 HG11 ' CG1' ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.431 ' O ' HG11 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.428 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.544 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 150' ' ' GLU . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' O ' ' A' ' 141' ' ' GLU . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.434 ' N ' ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.52 HD21 ' CD1' ' A' ' 91' ' ' PHE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.506 HG23 ' CD1' ' A' ' 138' ' ' ILE . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.525 ' CG1' HG22 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.58 ' CD1' ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.57 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.802 0.335 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.51 150.67 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.12 65.59 2.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.876 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -122.5 -147.92 7.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.525 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.565 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.518 ' OG ' ' CD2' ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.427 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.453 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.566 ' HA ' ' N ' ' A' ' 147' ' ' GLU . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.49 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CD1' HD21 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.564 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.517 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.517 HG21 ' CA ' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo -56.7 -145.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.523 ' N ' ' C3 ' ' A' ' 222' ' ' BTN . 0.5 OUTLIER -25.62 142.0 0.04 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.633 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_exo -45.71 -24.57 2.04 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.931 2.421 . . . . 0.0 112.523 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -110.25 55.4 0.65 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -118.12 -177.94 3.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.15 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp -129.47 36.36 4.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.517 ' CA ' HG21 ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.566 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.496 ' CG2' HG12 ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.496 HG12 ' CG2' ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' A' ' 110' ' ' ASN . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.565 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.482 HD13 ' CZ ' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.496 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.419 ' HB1' ' HE3' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.519 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.519 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 3.5 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.428 ' C ' HG22 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.457 ' HD3' ' HG3' ' A' ' 156' ' ' GLU . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.517 ' CD1' HG23 ' A' ' 153' ' ' VAL . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.41 HD11 ' N ' ' A' ' 139' ' ' LEU . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.489 HG21 ' CG ' ' A' ' 150' ' ' GLU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.517 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.564 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.566 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.508 ' CB ' ' CG2' ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.489 ' CG ' HG21 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.581 HD21 ' CD1' ' A' ' 91' ' ' PHE . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 138' ' ' ILE . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.49 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.457 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.523 ' C3 ' ' N ' ' A' ' 96' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 34.1 tt0 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.428 ' N ' ' CD1' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -64.67 -176.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.192 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.8 t -98.92 46.83 0.98 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.888 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -87.58 -167.33 43.44 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.542 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.578 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 152' ' ' LEU . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.486 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.486 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.487 ' CE1' ' HB3' ' A' ' 152' ' ' LEU . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.565 ' CD2' ' H2 ' ' A' ' 222' ' ' BTN . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 94' ' ' THR . 52.2 Cg_exo -54.37 -149.16 0.0 OUTLIER 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 57.9 m -33.42 154.36 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.167 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.76 -26.48 3.19 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.795 2.33 . . . . 0.0 112.426 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 98' ' ' ASP . 1.7 p30 -115.65 55.57 0.78 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.425 ' HB2' ' HD2' ' A' ' 95' ' ' PRO . . . -102.96 -167.62 1.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.72 35.02 4.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.511 HG12 ' CG1' ' A' ' 109' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.491 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.445 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.508 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.511 ' CG1' HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.576 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.52 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.481 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.459 ' HG3' ' S1 ' ' A' ' 222' ' ' BTN . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.452 ' O ' ' HG3' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.506 ' HE2' ' CA ' ' A' ' 122' ' ' LYS . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.523 ' HE2' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.479 ' CE ' ' HD3' ' A' ' 122' ' ' LYS . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.523 ' CB ' ' HE2' ' A' ' 123' ' ' MET . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.481 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.539 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.527 HG12 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.491 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.465 ' HB1' ' O ' ' A' ' 136' ' ' LYS . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.48 HG21 ' N ' ' A' ' 139' ' ' LEU . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.48 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.507 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.46 ' HA ' HG23 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.471 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.45 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.487 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.527 ' CG1' HG12 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.488 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.542 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.565 ' H2 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' A' ' 78' ' ' ILE . 79.3 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.845 0.355 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.451 HG22 ' O ' ' A' ' 78' ' ' ILE . 2.6 tp 38.97 95.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.12 8.79 9.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.981 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . -112.96 -139.37 7.43 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.535 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.513 ' CE1' ' HB2' ' A' ' 131' ' ' LYS . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.575 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.405 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.429 ' HA ' HD13 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.542 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.542 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.465 ' O ' HG21 ' A' ' 94' ' ' THR . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.477 ' O ' ' H5 ' ' A' ' 222' ' ' BTN . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.461 ' O ' ' H5 ' ' A' ' 222' ' ' BTN . 39.4 Cg_exo -59.99 -149.83 0.01 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.513 ' HA ' ' N2 ' ' A' ' 222' ' ' BTN . 85.4 p -33.49 151.65 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.023 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 28.0 Cg_endo -62.92 57.66 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.786 2.324 . . . . 0.0 112.271 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.445 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 171.57 34.24 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.892 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.422 ' HB2' ' HD2' ' A' ' 95' ' ' PRO . . . -114.2 -170.54 1.74 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.095 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.462 ' O ' HG23 ' A' ' 94' ' ' THR . 7.1 ttpt -90.19 -68.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.994 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.467 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.548 ' CE2' HD11 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.522 HG23 ' CG2' ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.458 ' OE2' ' HB2' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.475 HG12 ' HB3' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.517 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.517 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.447 HG21 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.456 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.501 ' CG2' ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.456 ' CD2' ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.456 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.548 HD11 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.507 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.534 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.448 ' HD3' ' HE2' ' A' ' 124' ' ' MET . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.51 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' HG22 ' A' ' 117' ' ' ILE . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.51 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.456 ' HB ' ' CD2' ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.49 ' N ' ' OD1' ' A' ' 130' ' ' ASP . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.513 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.461 ' N ' HG21 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.516 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.522 ' CG2' HG23 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.465 ' O ' HG11 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.475 ' HB3' HG12 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.563 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 152' ' ' LEU . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.482 ' O ' ' O ' ' A' ' 141' ' ' GLU . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.534 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 88' ' ' VAL . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.457 ' HA ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.469 ' HB3' HG23 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.46 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.462 HG23 HD13 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.492 HG13 ' CG2' ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.516 ' CG2' ' O ' ' A' ' 134' ' ' THR . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.449 ' N ' HG21 ' A' ' 155' ' ' ILE . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.513 ' N2 ' ' HA ' ' A' ' 96' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.837 0.351 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.47 HG12 ' N ' ' A' ' 79' ' ' SER . 5.0 tt -38.92 151.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.47 ' N ' HG12 ' A' ' 78' ' ' ILE . 24.7 m -98.77 36.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -132.95 -135.79 3.67 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.518 ' NE2' HD11 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.562 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.413 HG21 ' CE1' ' A' ' 81' ' ' HIS . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 149' ' ' ASP . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.519 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.519 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.465 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.582 ' O ' ' CD1' ' A' ' 92' ' ' TYR . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.455 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.584 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.1 Cg_endo -78.09 50.07 3.19 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.525 ' CB ' ' O ' ' A' ' 95' ' ' PRO . 0.3 OUTLIER 158.91 129.83 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.812 179.955 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -47.55 -21.45 2.22 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.838 2.359 . . . . 0.0 112.3 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -129.54 55.73 1.75 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.934 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.475 ' CB ' ' OG ' ' A' ' 96' ' ' SER . . . -115.41 -172.7 2.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.098 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp -109.39 19.92 18.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' A' ' 100' ' ' LYS . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.584 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.523 ' CD1' ' O ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.522 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.484 ' N ' HG11 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.535 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' A' ' 133' ' ' GLY . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.512 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.523 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.583 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.507 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.48 HG22 ' ND2' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.529 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.517 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.517 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.439 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.512 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.535 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.533 HG22 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.418 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.457 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.506 HG21 ' N ' ' A' ' 139' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.506 ' N ' HG21 ' A' ' 138' ' ' ILE . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.5 ' CG1' ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.465 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.455 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.551 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.526 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.526 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.411 ' CG2' ' HB2' ' A' ' 91' ' ' PHE . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.457 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.453 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.499 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.504 HD21 ' CD1' ' A' ' 91' ' ' PHE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 115' ' ' LEU . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.464 ' CG1' HG13 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.518 HD11 ' NE2' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' HA ' HD13 ' A' ' 78' ' ' ILE . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.588 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.842 0.353 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.7 tp -50.62 129.23 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.5 m -144.87 21.86 1.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.995 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -98.83 -134.22 8.38 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.544 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.48 ' CE1' HG21 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.48 HG21 ' CE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.472 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' ' CB ' ' A' ' 150' ' ' GLU . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.516 ' O ' ' N ' ' A' ' 148' ' ' PHE . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 146' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.617 ' CD1' ' CD2' ' A' ' 152' ' ' LEU . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.474 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.511 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.572 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.4 Cg_endo -84.81 86.8 1.12 Allowed 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.5 OUTLIER -26.8 -55.62 0.21 Allowed Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.856 -179.779 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.435 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 71.6 Cg_exo -48.47 80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.821 2.347 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.4 OUTLIER 61.01 62.87 1.35 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.76 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 95' ' ' PRO . . . -112.61 167.0 10.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.68 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.57 27.24 5.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.21 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.511 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.501 HD11 ' NE2' ' A' ' 107' ' ' GLN . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.501 ' NE2' HD11 ' A' ' 103' ' ' ILE . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.451 ' CG1' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.486 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.529 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.509 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.533 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.472 ' HG2' ' H2 ' ' A' ' 222' ' ' BTN . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.431 ' HB1' HG13 ' A' ' 118' ' ' VAL . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.545 ' CE ' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.462 ' HA ' HG21 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.545 ' OD1' ' CE ' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.481 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.493 ' O ' ' N ' ' A' ' 115' ' ' LEU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.529 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.511 ' O ' ' CG2' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.486 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.565 HD11 ' CE2' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.525 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.48 ' O ' ' HB2' ' A' ' 141' ' ' GLU . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.471 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 89' ' ' GLY . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.535 ' CB ' ' HB3' ' A' ' 85' ' ' SER . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.525 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.438 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.575 ' H4 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 tt -98.49 132.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.141 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 41.2 t -105.32 40.54 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.945 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -125.8 -150.47 7.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.508 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.592 ' CE1' ' CD1' ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.5 HD11 ' CG1' ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.427 ' HA ' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.458 HG11 ' O ' ' A' ' 146' ' ' VAL . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.485 ' N ' HG21 ' A' ' 146' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.574 ' O ' ' CG ' ' A' ' 92' ' ' TYR . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.534 ' CA ' ' HB2' ' A' ' 99' ' ' ALA . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.577 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo -62.08 113.92 2.09 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.522 ' HB3' ' CD ' ' A' ' 97' ' ' PRO . 9.9 t -29.54 -61.25 0.23 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.389 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.522 ' CD ' ' HB3' ' A' ' 96' ' ' SER . 15.1 Cg_endo -57.43 78.05 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.802 2.335 . . . . 0.0 112.067 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.458 ' N ' ' O ' ' A' ' 96' ' ' SER . 23.6 t0 62.47 47.2 5.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.703 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.534 ' HB2' ' CA ' ' A' ' 94' ' ' THR . . . -38.38 -68.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.369 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 99' ' ' ALA . 6.9 mmtm 63.54 16.65 9.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.765 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' ' HG2' ' A' ' 95' ' ' PRO . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.49 HD11 ' NE2' ' A' ' 107' ' ' GLN . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 106' ' ' GLY . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.48 ' N ' HG11 ' A' ' 105' ' ' VAL . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.49 ' NE2' HD11 ' A' ' 103' ' ' ILE . 37.1 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.439 ' HD2' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.505 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.463 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.476 HG21 ' N ' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.463 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.43 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.526 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.501 ' CD1' ' S1 ' ' A' ' 222' ' ' BTN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.522 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.454 ' SD ' ' C8 ' ' A' ' 222' ' ' BTN . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.526 ' O ' ' CG2' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.458 ' N ' HG21 ' A' ' 127' ' ' ILE . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.505 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.468 ' N ' ' OD1' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.476 ' N ' HG21 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.438 ' CG2' ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.451 HG12 ' CG1' ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.524 HG12 ' CG1' ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.474 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.458 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.524 ' CG1' HG12 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.465 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.457 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.495 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 152' ' ' LEU . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.5 ' CG1' HD11 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.592 ' CD1' ' CE1' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.56 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.867 0.365 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.4 pt -80.47 -179.14 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.455 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.3 OUTLIER -115.14 -28.14 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.921 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 79' ' ' SER . . . 32.62 -154.5 0.01 OUTLIER Glycine 0 N--CA 1.453 -0.214 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.773 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.583 ' ND1' ' CD1' ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.44 HG21 ' N ' ' A' ' 83' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 153' ' ' VAL . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.451 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.502 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.516 HG11 ' N ' ' A' ' 89' ' ' GLY . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.516 ' N ' HG11 ' A' ' 88' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.571 ' CZ ' HD11 ' A' ' 138' ' ' ILE . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.469 ' HB ' ' HB2' ' A' ' 99' ' ' ALA . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.545 ' CB ' ' S1 ' ' A' ' 222' ' ' BTN . 35.2 Cg_endo -65.67 117.59 4.75 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.528 ' OG ' ' CD ' ' A' ' 97' ' ' PRO . 0.3 OUTLIER -34.91 -59.9 0.58 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.987 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.528 ' CD ' ' OG ' ' A' ' 96' ' ' SER . 19.4 Cg_endo -58.96 69.13 0.05 OUTLIER 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.805 2.337 . . . . 0.0 112.455 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.8 t0 81.22 47.92 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.308 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -55.7 93.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.986 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.78 30.85 1.29 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.88 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.553 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.441 ' CD1' ' N ' ' A' ' 103' ' ' ILE . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.447 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.447 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.528 ' O ' ' CA ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.464 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.422 HG21 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.553 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.532 HD11 ' C6 ' ' A' ' 222' ' ' BTN . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.469 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.465 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.526 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.526 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.526 ' CE ' ' HE2' ' A' ' 122' ' ' LYS . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.526 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.424 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.424 ' HB2' ' O ' ' A' ' 130' ' ' ASP . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.465 ' OG ' HD12 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.447 HG22 ' CG2' ' A' ' 109' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.405 ' CG ' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.571 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.471 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.501 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.556 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.524 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.464 HG13 HD22 ' A' ' 152' ' ' LEU . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.451 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.459 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.473 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.473 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.461 HG21 ' O ' ' A' ' 137' ' ' ALA . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.583 ' CD1' ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.405 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.545 ' S1 ' ' CB ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -114.21 123.28 69.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.263 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.92 7.59 8.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.427 ' CA ' ' OXT' ' A' ' 156' ' ' GLU . . . -70.42 -151.67 0.73 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.476 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.522 ' HA ' ' CD1' ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.501 HG11 ' N ' ' A' ' 89' ' ' GLY . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.501 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.525 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CZ ' ' HB3' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.521 ' NE ' HD13 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.453 ' O ' ' CB ' ' A' ' 96' ' ' SER . 58.7 Cg_endo -72.08 52.23 1.81 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.508 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.0 OUTLIER 163.81 132.4 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.646 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -46.87 -22.15 1.84 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.638 2.225 . . . . 0.0 112.242 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 43.6 p30 -147.61 62.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.758 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.508 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -108.73 -155.44 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -114.65 29.95 7.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.851 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' HG23 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.616 ' CZ ' ' CG2' ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.493 ' CD1' ' N ' ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.496 HG21 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.434 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.521 HG13 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.434 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 110' ' ' ASN . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.521 ' CB ' HG13 ' A' ' 109' ' ' VAL . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.616 ' CG2' ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.461 ' O ' ' N ' ' A' ' 127' ' ' ILE . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.53 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.511 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.5 ' OE1' ' CE ' ' A' ' 124' ' ' MET . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.467 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.505 ' CE ' ' ND2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.511 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.53 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.445 ' O ' HG21 ' A' ' 155' ' ' ILE . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.45 HG22 HG23 ' A' ' 103' ' ' ILE . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.521 HD13 ' NE ' ' A' ' 93' ' ' ARG . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.497 ' N ' HG21 ' A' ' 138' ' ' ILE . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.509 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.455 ' HA ' ' HB3' ' A' ' 91' ' ' PHE . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.47 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.47 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 91' ' ' PHE . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.448 HG21 ' O ' ' A' ' 152' ' ' LEU . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.52 HG12 ' CD2' ' A' ' 81' ' ' HIS . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.427 ' OXT' ' CA ' ' A' ' 80' ' ' GLY . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.493 ' C6 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' CG ' ' O ' ' A' ' 77' ' ' GLU . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.798 0.332 . . . . 0.0 111.0 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.9 pt -56.31 173.1 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.15 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.1 t -127.75 21.52 6.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . 53.37 -118.03 7.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.433 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' N ' ' A' ' 155' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.537 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.509 ' HB2' ' CD2' ' A' ' 152' ' ' LEU . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.421 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.507 HG11 ' N ' ' A' ' 89' ' ' GLY . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.507 ' N ' HG11 ' A' ' 88' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.493 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.579 ' CE2' HD12 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.453 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.531 HG23 ' CB ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.513 ' HA ' ' N1 ' ' A' ' 222' ' ' BTN . 51.8 Cg_endo -69.57 -168.72 0.28 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.537 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER 31.58 102.05 0.02 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.609 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.558 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 57.3 Cg_exo -30.17 86.68 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.24 2.626 . . . . 0.0 112.325 179.231 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 9.2 m-20 94.55 42.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.551 -179.438 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -77.35 -148.3 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.079 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -108.63 16.69 22.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 -179.944 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.531 ' CB ' HG23 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.459 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.524 ' CG2' ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.458 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 27.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.458 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.524 ' CG1' ' CG2' ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.407 HG22 ' OG ' ' A' ' 132' ' ' SER . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.459 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.514 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.519 ' CG2' ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.429 ' O ' ' HG3' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.519 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.451 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.519 ' CE ' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.519 ' HB3' ' CG2' ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.518 ' N ' ' O ' ' A' ' 124' ' ' MET . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.598 ' N ' ' CD1' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.433 ' N ' HG21 ' A' ' 127' ' ' ILE . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.407 ' OG ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.511 ' CG1' HG11 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.43 ' N ' ' O ' ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.579 HD12 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.514 ' CG2' ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.465 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.527 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.504 ' N ' ' O ' ' A' ' 89' ' ' GLY . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.502 ' N ' HG13 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.514 ' HB3' ' CG2' ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.571 HD21 ' CD1' ' A' ' 91' ' ' PHE . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.511 HG11 ' CG1' ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.505 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.504 ' N ' ' O ' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.513 ' N1 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.787 0.327 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.0 tt -58.67 125.27 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.4 t -91.91 53.93 2.31 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . -90.41 176.76 41.97 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.483 ' ND1' ' C ' ' A' ' 80' ' ' GLY . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.565 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.503 HG11 ' N ' ' A' ' 89' ' ' GLY . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG11 ' A' ' 88' ' ' VAL . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.517 ' CB ' HG13 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.567 ' CE2' ' S1 ' ' A' ' 222' ' ' BTN . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.465 ' O ' HG22 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.527 ' CA ' ' HB2' ' A' ' 99' ' ' ALA . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.468 ' HG2' ' HA ' ' A' ' 99' ' ' ALA . 65.9 Cg_endo -74.23 115.75 4.41 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.522 ' O ' ' N ' ' A' ' 98' ' ' ASP . 2.6 t -29.16 -60.78 0.23 Allowed Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.544 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.515 ' HD2' ' N ' ' A' ' 96' ' ' SER . 12.2 Cg_endo -56.05 74.02 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.853 2.369 . . . . 0.0 112.323 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 68.46 51.36 0.66 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.076 179.843 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.527 ' HB2' ' CA ' ' A' ' 94' ' ' THR . . . -54.06 98.59 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.89 0.376 . . . . 0.0 111.005 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.59 38.9 1.02 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.428 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.444 HG23 HG22 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.496 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.576 ' N ' ' CG1' ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.513 ' HB2' ' CG1' ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.481 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 90' ' ' THR . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 119' ' ' GLU . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.424 ' CB ' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.523 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.503 ' CE ' ' H61' ' A' ' 222' ' ' BTN . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.523 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.524 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.555 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.521 ' CG2' ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.417 ' HA ' ' HE3' ' A' ' 136' ' ' LYS . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.509 ' CD1' HG21 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.467 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.517 HG13 ' CB ' ' A' ' 91' ' ' PHE . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.472 ' HA ' ' HB3' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.451 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.452 ' O ' HG11 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.431 ' N ' ' CG1' ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.467 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.49 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.516 ' CG1' HG23 ' A' ' 135' ' ' VAL . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 131' ' ' LYS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.567 ' S1 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.755 0.312 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 6.2 tt -126.61 126.57 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.14 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -98.69 7.28 46.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.061 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.42 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . 79.94 -132.36 11.29 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.449 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.432 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.521 HG21 ' CG1' ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.449 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.531 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.531 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 142' ' ' SER . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.501 ' CD2' ' H62' ' A' ' 222' ' ' BTN . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.456 ' O ' HG21 ' A' ' 94' ' ' THR . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.47 ' O ' ' H5 ' ' A' ' 222' ' ' BTN . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.514 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.7 Cg_exo -54.92 -147.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.452 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.8 p -34.18 140.49 0.26 Allowed Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.961 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.458 ' HD3' ' H2 ' ' A' ' 222' ' ' BTN . 3.0 Cg_exo -36.52 -28.98 0.08 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.241 2.627 . . . . 0.0 112.271 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.452 ' N ' ' O ' ' A' ' 96' ' ' SER . 34.0 m-20 -122.65 60.42 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.807 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.414 ' CB ' ' HB2' ' A' ' 95' ' ' PRO . . . -107.54 -153.46 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.144 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.33 31.41 5.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.005 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.567 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.449 ' OE2' ' CB ' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.517 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.517 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.511 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.436 ' OD2' HG13 ' A' ' 109' ' ' VAL . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.542 HG23 ' CE1' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.567 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.4 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.464 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.522 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.522 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.511 ' N ' ' O ' ' A' ' 124' ' ' MET . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 131' ' ' LYS . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.511 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.46 HG23 ' HB3' ' A' ' 156' ' ' GLU . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.49 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 154' ' ' VAL . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.5 HD12 ' CE2' ' A' ' 91' ' ' PHE . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.512 ' O ' ' N ' ' A' ' 142' ' ' SER . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.57 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 88' ' ' VAL . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.401 ' HA ' HG21 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.418 ' C ' HG21 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.55 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.49 ' CG1' ' CG2' ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG1' HG21 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.46 ' HB3' HG23 ' A' ' 134' ' ' THR . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.501 ' H62' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.82 0.343 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.3 tp -155.22 121.61 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.9 p -114.12 12.69 17.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 60.91 -103.27 0.5 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.453 HG22 HG13 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 152' ' ' LEU . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.522 ' NH1' ' HB2' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.52 ' CB ' ' CG1' ' A' ' 146' ' ' VAL . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.437 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.47 ' CA ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.562 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.496 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.526 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.528 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HD2' ' CD2' ' A' ' 102' ' ' PHE . 31.3 Cg_exo -60.34 64.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 94' ' ' THR . 1.1 m 156.61 107.63 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.581 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.81 -21.38 2.47 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.642 2.228 . . . . 0.0 112.274 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.51 7.6 44.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.459 ' HB1' ' HB2' ' A' ' 96' ' ' SER . . . -86.34 -148.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.932 179.91 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 3.3 ptmm? -151.94 -48.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.552 ' CD2' ' HD2' ' A' ' 95' ' ' PRO . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.515 HG21 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.451 ' OE1' HG13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.474 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HG2' ' O ' ' A' ' 107' ' ' GLN . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.486 HG13 ' HA3' ' A' ' 133' ' ' GLY . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.547 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.528 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 90' ' ' THR . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.432 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.534 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.512 ' CE ' ' HE2' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.49 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.512 ' HE2' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.49 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.528 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.486 ' HA3' HG13 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.437 HG21 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.45 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.562 HD12 ' CZ ' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.528 ' O ' ' CB ' ' A' ' 141' ' ' GLU . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.526 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.52 ' CG1' ' CB ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.438 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.456 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.493 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.513 ' CG1' HG23 ' A' ' 135' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.483 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.512 HG21 ' N ' ' A' ' 156' ' ' GLU . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.512 ' N ' HG21 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.46 ' H62' ' N ' ' A' ' 96' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' ILE . 8.3 pt-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.808 0.337 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' GLU . 0.6 OUTLIER 34.77 -158.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.643 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.44 ' N ' ' CG1' ' A' ' 78' ' ' ILE . 1.5 m -93.46 58.88 2.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.985 -179.822 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -159.03 -165.25 15.71 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.382 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.436 ' CD2' ' HD2' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.561 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.433 ' HA ' HD13 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.515 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.581 ' CE2' ' HB3' ' A' ' 152' ' ' LEU . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.417 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.47 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.551 ' HB3' ' CE2' ' A' ' 102' ' ' PHE . 74.2 Cg_endo -76.07 50.44 2.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.491 ' CB ' ' O ' ' A' ' 95' ' ' PRO . 0.4 OUTLIER 160.23 148.31 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.946 179.969 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.11 -19.75 12.63 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.771 2.314 . . . . 0.0 112.326 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -149.54 53.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -94.83 -169.43 2.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.105 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -109.49 24.79 12.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.988 -179.949 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.554 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.51 HG22 ' NZ ' ' A' ' 108' ' ' LYS . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.404 ' HG3' ' CB ' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.4 HG21 HG13 ' A' ' 138' ' ' ILE . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.531 ' CB ' ' O ' ' A' ' 107' ' ' GLN . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.402 ' CG2' ' C ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.434 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.4 HG22 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.447 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.463 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.522 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.554 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.477 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' O ' ' N ' ' A' ' 90' ' ' THR . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.404 ' HB2' ' HE3' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.404 ' HD3' ' HE1' ' A' ' 124' ' ' MET . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.522 ' O ' ' N ' ' A' ' 115' ' ' LEU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 113' ' ' ASP . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.499 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.434 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.487 ' O ' ' CG2' ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.514 ' CG2' ' HD3' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.546 HD11 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.48 HD11 ' N ' ' A' ' 139' ' ' LEU . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.468 ' N ' HG11 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.559 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.451 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.451 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 88' ' ' VAL . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.465 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.581 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.493 ' CG2' ' C ' ' A' ' 152' ' ' LEU . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 154' ' ' VAL . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 131' ' ' LYS . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.495 ' N ' HG21 ' A' ' 155' ' ' ILE . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.582 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.806 0.336 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.503 HD12 ' N ' ' A' ' 80' ' ' GLY . 0.0 OUTLIER -112.62 136.32 49.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.069 -179.898 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.64 88.63 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.503 ' N ' HD12 ' A' ' 78' ' ' ILE . . . 162.28 154.29 7.49 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.552 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.448 ' NE2' HD11 ' A' ' 155' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.551 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.516 ' OG ' ' CD1' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.483 ' CG1' ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.483 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.47 ' O ' ' H5 ' ' A' ' 222' ' ' BTN . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.567 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo -76.02 52.05 3.31 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 95' ' ' PRO . 0.1 OUTLIER 168.15 124.53 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.999 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.71 -21.35 2.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.753 2.302 . . . . 0.0 112.38 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 39.8 p30 -128.46 28.02 5.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -80.82 -170.1 2.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.185 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -95.76 -85.89 0.32 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.448 ' HA ' HG21 ' A' ' 94' ' ' THR . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.475 ' CG2' HG22 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.406 ' CG1' ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.455 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.482 ' CG2' ' N ' ' A' ' 118' ' ' VAL . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.482 ' N ' ' CG2' ' A' ' 117' ' ' ILE . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.454 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.454 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.422 ' HA ' ' HE2' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.528 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.528 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.504 ' N ' ' O ' ' A' ' 124' ' ' MET . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.415 HG21 ' N ' ' A' ' 135' ' ' VAL . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.475 HG22 ' CG2' ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.406 ' O ' ' CG1' ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.577 HG23 ' CZ ' ' A' ' 91' ' ' PHE . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.531 ' CD2' ' N ' ' A' ' 139' ' ' LEU . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.581 ' O ' ' CE1' ' A' ' 91' ' ' PHE . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.575 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 91' ' ' PHE . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.524 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.467 ' CG1' ' CB ' ' A' ' 85' ' ' SER . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.449 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.449 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' CD2' ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.516 ' CD1' ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.458 HG21 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.515 HG11 ' CG2' ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.448 HD11 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 222' ' ' BTN . . . . . 0.576 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.435 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.414 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.622 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.028 HG23 HG12 ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.444 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.99 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.444 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.417 ' O ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.833 ' HE2' HD13 ' A' ' 138' ' ' ILE . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.681 HG22 ' HA ' ' A' ' 101' ' ' ALA . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo . . . . . 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.88 0.371 . . . . 0.0 110.775 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.681 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.639 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.87 HG22 HG21 ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.489 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.5 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.5 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.525 HG11 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.639 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.569 HG23 ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.41 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.605 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.605 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.533 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.445 ' N ' HG22 ' A' ' 127' ' ' ILE . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.87 HG21 HG22 ' A' ' 103' ' ' ILE . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.429 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.53 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.833 HD13 ' HE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 91' ' ' PHE . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.498 ' H ' HG22 ' A' ' 138' ' ' ILE . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.495 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.482 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.905 ' O ' HG13 ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.99 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.464 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.501 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.676 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.76 HG12 HG13 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.028 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.622 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.429 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.415 -0.274 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.887 ' NE2' HD13 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' HD21 ' A' ' 152' ' ' LEU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.756 ' HB2' HG11 ' A' ' 140' ' ' VAL . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.893 ' HB3' HD12 ' A' ' 117' ' ' ILE . 69.7 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.707 0.289 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.743 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.738 ' HE2' HD12 ' A' ' 117' ' ' ILE . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.754 HG23 ' HG2' ' A' ' 107' ' ' GLN . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.743 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.747 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.754 ' HG2' HG23 ' A' ' 103' ' ' ILE . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.73 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 130' ' ' ASP . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.584 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.893 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.722 ' HB3' ' HE3' ' A' ' 123' ' ' MET . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.422 ' HG3' ' O ' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.722 ' HE3' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.644 ' HB2' ' HE2' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.584 HG22 ' N ' ' A' ' 128' ' ' GLU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.634 ' O ' HG22 ' A' ' 111' ' ' VAL . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.484 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.607 HG21 HG22 ' A' ' 103' ' ' ILE . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.694 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.747 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.799 ' C ' HD23 ' A' ' 139' ' ' LEU . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.799 HD23 ' C ' ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.791 HG21 HD23 ' A' ' 152' ' ' LEU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 152' ' ' LEU . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.491 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.718 ' HG2' HD12 ' A' ' 139' ' ' LEU . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.791 HD23 HG21 ' A' ' 140' ' ' VAL . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.887 HD13 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.483 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.409 ' HA3' ' C ' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.54 -0.224 . . . . 0.0 112.54 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.656 ' NE2' HD12 ' A' ' 155' ' ' ILE . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.908 HG23 HG12 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.424 ' HB2' HG11 ' A' ' 146' ' ' VAL . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.695 HG13 ' O ' ' A' ' 146' ' ' VAL . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.678 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' O ' ' CE1' ' A' ' 91' ' ' PHE . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.609 HG22 ' HA ' ' A' ' 101' ' ' ALA . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.906 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.2 Cg_endo . . . . . 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.905 HG22 HG21 ' A' ' 135' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.445 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.772 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 115' ' ' LEU . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 114' ' ' THR . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.906 HD12 ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.477 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.712 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.444 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.712 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.822 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.8 t-20 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.488 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.616 HD11 HG21 ' A' ' 118' ' ' VAL . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB2' HG11 ' A' ' 109' ' ' VAL . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.511 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.905 HG21 HG22 ' A' ' 103' ' ' ILE . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.62 ' HB2' HG23 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 152' ' ' LEU . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.66 HD22 ' N ' ' A' ' 139' ' ' LEU . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.619 HG11 ' HB2' ' A' ' 91' ' ' PHE . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' HB2' ' A' ' 144' ' ' GLN . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.562 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.476 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.695 ' O ' HG13 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.558 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 139' ' ' LEU . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.689 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.545 HG12 HG13 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.908 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.656 HD12 ' NE2' ' A' ' 81' ' ' HIS . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.423 ' HG3' ' CG ' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.565 -0.214 . . . . 0.0 112.565 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.436 ' ND1' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.739 HG23 HD11 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.661 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.591 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.591 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.721 ' HB2' HG11 ' A' ' 140' ' ' VAL . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 91' ' ' PHE . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.51 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.764 ' HB3' HD12 ' A' ' 117' ' ' ILE . 54.0 Cg_endo . . . . . 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.58 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.671 HG21 ' HE2' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.466 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.915 ' O ' HG13 ' A' ' 109' ' ' VAL . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 132' ' ' SER . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.764 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.455 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.696 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.428 ' CD ' ' HE3' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.696 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.719 ' C ' HG22 ' A' ' 111' ' ' VAL . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.549 ' HE3' HG22 ' A' ' 83' ' ' VAL . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.787 ' HB3' HG23 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.57 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.814 HG23 ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.454 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.641 HD13 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.468 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.823 HG21 HD23 ' A' ' 152' ' ' LEU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.51 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.423 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.823 HD23 HG21 ' A' ' 140' ' ' VAL . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.576 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.739 HD11 HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.519 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB2' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.757 HG23 HG12 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.552 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.476 ' CB ' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.814 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.435 ' C ' ' HB2' ' A' ' 142' ' ' SER . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.458 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.55 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo . . . . . 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.5 pptp? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.709 0.29 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.61 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.655 HG22 HG21 ' A' ' 135' ' ' VAL . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.475 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.889 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.619 ' HG2' HG23 ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.57 ' HA ' ' CE2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.61 HD12 ' HE2' ' A' ' 102' ' ' PHE . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.476 ' OE1' ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.407 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.563 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.415 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.572 ' HE2' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.441 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.515 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.435 ' N ' HG22 ' A' ' 127' ' ' ILE . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.655 HG21 HG22 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.798 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.889 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.796 HD13 ' HE2' ' A' ' 91' ' ' PHE . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.713 HD23 ' N ' ' A' ' 139' ' ' LEU . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.79 HG21 HD23 ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.57 ' H ' HG22 ' A' ' 138' ' ' ILE . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.505 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 21.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.607 HG12 HG11 ' A' ' 140' ' ' VAL . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HG22 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.597 ' HG2' HD12 ' A' ' 139' ' ' LEU . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.814 HD22 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' HG13 ' A' ' 135' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.757 HG12 HG23 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.454 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.485 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.555 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.357 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.555 ' CD2' ' C ' ' A' ' 80' ' ' GLY . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.753 HG23 HG12 ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.805 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.43 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 146' ' ' VAL . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.603 ' N ' HG23 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.772 ' HB2' HG11 ' A' ' 140' ' ' VAL . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.0 Cg_endo . . . . . 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 11.2 mtpt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.612 HD13 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.538 ' OE1' HD12 ' A' ' 138' ' ' ILE . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.467 HG22 ' HA ' ' A' ' 137' ' ' ALA . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.462 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.59 HG11 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' HA ' ' A' ' 130' ' ' ASP . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.59 ' CB ' HG11 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.416 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.489 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.763 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.763 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.439 ' O ' ' N ' ' A' ' 126' ' ' GLN . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.859 ' O ' HG23 ' A' ' 118' ' ' VAL . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.453 ' O ' ' N ' ' A' ' 130' ' ' ASP . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.641 ' HA ' HG13 ' A' ' 111' ' ' VAL . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.47 HG22 ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.939 HG13 HG12 ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.547 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.663 HG12 HG13 ' A' ' 153' ' ' VAL . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.546 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.804 HG21 HD23 ' A' ' 152' ' ' LEU . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 3.6 pt20 -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 88' ' ' VAL . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.487 ' HB3' HG22 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.546 ' HG2' HD22 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.805 HD11 ' HA ' ' A' ' 85' ' ' SER . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.939 HG12 HG13 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.753 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 81' ' ' HIS . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.845 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.745 HG23 HG12 ' A' ' 154' ' ' VAL . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.478 ' O ' HD12 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.545 ' HA ' HD21 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.588 HG22 ' HA ' ' A' ' 147' ' ' GLU . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.581 ' N ' HG23 ' A' ' 146' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.457 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CZ ' HD13 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.537 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.46 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo . . . . . 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.882 0.372 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.733 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.527 HG21 ' HD3' ' A' ' 108' ' ' LYS . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.537 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.555 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.903 ' CG ' HG23 ' A' ' 135' ' ' VAL . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.502 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.481 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.545 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.733 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 125' ' ' ASN . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.473 ' H ' HG22 ' A' ' 117' ' ' ILE . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.614 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.614 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.509 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.467 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.517 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.662 ' O ' HD13 ' A' ' 155' ' ' ILE . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.502 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.541 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.903 HG23 ' CG ' ' A' ' 108' ' ' LYS . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.44 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.49 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.642 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 1.003 HD12 ' CG ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.512 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 23.3 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.581 HG23 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.588 ' HA ' HG22 ' A' ' 88' ' ' VAL . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.478 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 1.003 ' CG ' HD12 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.545 HD21 ' HA ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 HG13 ' A' ' 135' ' ' VAL . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.745 HG12 HG23 ' A' ' 82' ' ' ILE . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.845 HD12 ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.44 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.62 -0.192 . . . . 0.0 112.62 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.529 ' CD2' ' C ' ' A' ' 80' ' ' GLY . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.837 HG23 HG12 ' A' ' 154' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.443 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.502 ' CB ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.637 HG22 ' HA ' ' A' ' 147' ' ' GLU . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.571 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.835 ' CD1' HD22 ' A' ' 152' ' ' LEU . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.494 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.472 ' HD2' ' OG1' ' A' ' 94' ' ' THR . 89.1 Cg_endo . . . . . 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm . . . . . 0 N--CA 1.456 -0.158 0 CA-C-O 121.067 0.46 . . . . 0.0 109.958 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.494 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 1.018 ' CG2' HG12 ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.667 HG13 ' HA ' ' A' ' 137' ' ' ALA . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 1.018 HG12 ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.658 ' O ' HD11 ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.443 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.514 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.506 ' CG ' ' O ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.436 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.555 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.89 ' O ' HG23 ' A' ' 118' ' ' VAL . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.512 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.512 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.864 HG23 ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.659 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.749 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 152' ' ' LEU . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.796 HG21 HD23 ' A' ' 152' ' ' LEU . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.582 HG22 ' N ' ' A' ' 147' ' ' GLU . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.637 ' HA ' HG22 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.449 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.835 HD22 ' CD1' ' A' ' 91' ' ' PHE . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.468 HG22 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.837 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.438 HD12 ' O ' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.404 ' HG2' ' OXT' ' A' ' 156' ' ' GLU . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.929 ' NE2' HD13 ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.06 HG23 HG12 ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.749 HG22 ' HA ' ' A' ' 147' ' ' GLU . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.539 ' CD1' HD22 ' A' ' 152' ' ' LEU . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.65 HG22 ' HA ' ' A' ' 101' ' ' ALA . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo . . . . . 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.863 0.363 . . . . 0.0 110.912 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.885 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.599 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 1.033 HG21 HG13 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.885 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.743 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.578 ' HG2' HG23 ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 1.033 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.803 HG23 ' OG ' ' A' ' 132' ' ' SER . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.587 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.55 HG13 ' HB3' ' A' ' 126' ' ' GLN . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.526 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.762 ' HB3' ' HE2' ' A' ' 123' ' ' MET . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.431 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.762 ' HE2' ' HB3' ' A' ' 120' ' ' ALA . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.486 ' SD ' ' HG2' ' A' ' 119' ' ' GLU . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.723 ' O ' HG23 ' A' ' 118' ' ' VAL . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.55 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.562 HG22 ' N ' ' A' ' 128' ' ' GLU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.562 ' N ' HG22 ' A' ' 127' ' ' ILE . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.803 ' OG ' HG23 ' A' ' 111' ' ' VAL . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.61 ' C ' HG23 ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.663 HG13 HG12 ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' HG13 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.743 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.576 HG23 ' O ' ' A' ' 152' ' ' LEU . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.579 HG23 ' C ' ' A' ' 151' ' ' PRO . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 140' ' ' VAL . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.789 HG22 ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.749 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.574 ' OE1' HG22 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.579 ' C ' HG23 ' A' ' 140' ' ' VAL . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.576 ' O ' HG23 ' A' ' 138' ' ' ILE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.663 HG12 HG13 ' A' ' 135' ' ' VAL . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.06 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.929 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.544 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.979 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.554 ' OG ' HD21 ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.446 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.471 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.899 HG23 ' HB2' ' A' ' 148' ' ' PHE . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.834 ' CD1' HD22 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.576 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.533 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.55 ' CG2' ' HB2' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo . . . . . 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.842 0.353 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB2' ' CG2' ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.762 ' HE2' HD12 ' A' ' 117' ' ' ILE . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.688 HG21 ' CG1' ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.688 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.475 HG23 ' OG ' ' A' ' 132' ' ' SER . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.527 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.762 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.496 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.462 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.54 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.54 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 9.7 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 109' ' ' VAL . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.475 ' OG ' HG23 ' A' ' 111' ' ' VAL . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.475 ' C ' HG23 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.685 HG13 HG12 ' A' ' 153' ' ' VAL . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.639 ' HB3' HG23 ' A' ' 154' ' ' VAL . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.683 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 152' ' ' LEU . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.906 HG21 HD23 ' A' ' 152' ' ' LEU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.533 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.661 ' HA ' HG13 ' A' ' 88' ' ' VAL . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.576 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.899 ' HB2' HG23 ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.746 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 140' ' ' VAL . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.906 HD23 HG21 ' A' ' 140' ' ' VAL . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.685 HG12 HG13 ' A' ' 135' ' ' VAL . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.979 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.456 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.508 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.562 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 151' ' ' PRO . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.539 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.518 ' HA ' HG23 ' A' ' 146' ' ' VAL . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.742 ' HE2' HD13 ' A' ' 138' ' ' ILE . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.787 ' HD2' HD12 ' A' ' 138' ' ' ILE . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.471 ' HG3' ' CD2' ' A' ' 102' ' ' PHE . 52.2 Cg_exo . . . . . 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.643 ' HB1' ' CD ' ' A' ' 104' ' ' GLU . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.716 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 135' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.643 ' CD ' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.514 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.527 HG11 HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 1.0 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.716 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.645 ' H ' HG22 ' A' ' 114' ' ' THR . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 124' ' ' MET . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.962 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.424 ' C ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.454 ' HG3' ' O ' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.501 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.489 ' HE3' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.562 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.962 ' O ' HG23 ' A' ' 118' ' ' VAL . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.501 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.552 HG13 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.717 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.77 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.787 HD12 ' HD2' ' A' ' 93' ' ' ARG . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.493 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.799 HG22 ' CG ' ' A' ' 150' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.518 HG23 ' HA ' ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.799 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.714 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.539 HD11 ' HA ' ' A' ' 85' ' ' SER . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.8 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.511 HD12 ' O ' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.535 -0.226 . . . . 0.0 112.535 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.765 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.869 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.555 ' OG ' HG21 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.58 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.726 HG23 ' N ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.797 ' CD1' HD22 ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.702 HG22 ' HA ' ' A' ' 101' ' ' ALA . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 94' ' ' THR . 39.4 Cg_exo . . . . . 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 7.1 ttpt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.842 0.353 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.702 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.91 HG22 HG21 ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.768 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.537 ' NE2' ' H ' ' A' ' 108' ' ' LYS . 0.4 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.537 ' H ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.894 HG23 ' HB2' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.488 ' HB3' HG23 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.77 HG23 ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.713 HD23 ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.511 ' N ' HG22 ' A' ' 117' ' ' ILE . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.534 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.408 ' CA ' ' HE2' ' A' ' 122' ' ' LYS . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.606 ' HE3' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.606 ' ND2' ' HE3' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.77 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.713 ' HB ' HD23 ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.465 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.651 ' HA ' HG13 ' A' ' 111' ' ' VAL . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.716 ' N ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.894 ' HB2' HG23 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.748 ' O ' HG23 ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.91 HG21 HG22 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.635 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.768 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.639 HG23 ' O ' ' A' ' 152' ' ' LEU . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.747 HG23 ' C ' ' A' ' 151' ' ' PRO . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 140' ' ' VAL . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.611 ' C ' HG23 ' A' ' 90' ' ' THR . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.726 ' N ' HG23 ' A' ' 90' ' ' THR . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.555 HG21 ' OG ' ' A' ' 85' ' ' SER . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.439 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.519 ' HG3' HG22 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.747 ' C ' HG23 ' A' ' 140' ' ' VAL . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.797 HD22 ' CD1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.621 HG22 HD11 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.869 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.765 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.41 ' HA ' ' HA3' ' A' ' 80' ' ' GLY . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 1.001 ' CE1' HD12 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.839 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.503 ' CB ' HG11 ' A' ' 146' ' ' VAL . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.562 HG12 ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.562 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.968 ' HB3' HG11 ' A' ' 140' ' ' VAL . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.478 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.874 HG22 ' HB2' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.589 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.1 Cg_endo . . . . . 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.844 0.354 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.874 ' HB2' HG22 ' A' ' 94' ' ' THR . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.605 ' C ' HD12 ' A' ' 103' ' ' ILE . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.731 HD13 ' C ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.529 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.446 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.54 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 110' ' ' ASN . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.523 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.731 ' C ' HD13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.527 HD21 ' CG2' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.594 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.589 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.672 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.672 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.945 ' O ' HG23 ' A' ' 118' ' ' VAL . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.447 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB2' ' HE3' ' A' ' 108' ' ' LYS . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.523 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.54 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.532 HG23 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.531 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.61 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.893 HG23 ' O ' ' A' ' 152' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.528 ' CG ' ' HB2' ' A' ' 151' ' ' PRO . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.968 HG11 ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.478 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.565 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.53 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.503 HG11 ' CB ' ' A' ' 85' ' ' SER . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.528 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.893 ' O ' HG23 ' A' ' 138' ' ' ILE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.878 HG13 ' CG1' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.839 HG12 HG23 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 1.001 HD12 ' CE1' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.544 -0.223 . . . . 0.0 112.544 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.743 ' HE1' HG22 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.046 HG23 HG12 ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.743 HG22 ' HE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.704 ' OG ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.614 ' O ' HG23 ' A' ' 88' ' ' VAL . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 89' ' ' GLY . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.683 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.823 ' HB2' HG11 ' A' ' 146' ' ' VAL . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.492 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.489 ' CB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.585 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.4 Cg_endo . . . . . 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.059 0.457 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.572 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.411 HG22 ' HA ' ' A' ' 137' ' ' ALA . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.479 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.492 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 1.022 HG22 ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.538 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.52 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.54 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.555 HG13 ' CG1' ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.401 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.661 ' HE3' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.511 ' HA ' HG23 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.661 ' OD1' ' HE3' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.506 ' HB3' HG13 ' A' ' 117' ' ' ILE . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.579 HG22 ' N ' ' A' ' 128' ' ' GLU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.579 ' N ' HG22 ' A' ' 127' ' ' ILE . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 1.022 ' O ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.492 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.654 HG13 HG12 ' A' ' 153' ' ' VAL . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.713 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.544 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.608 HG11 ' CB ' ' A' ' 91' ' ' PHE . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.48 ' OG ' ' HA ' ' A' ' 92' ' ' TYR . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.471 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.869 HG23 ' CB ' ' A' ' 150' ' ' GLU . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.869 ' CB ' HG23 ' A' ' 146' ' ' VAL . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.544 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.654 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.046 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 1.005 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.78 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.585 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 147' ' ' GLU . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.457 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.612 ' CE2' HD13 ' A' ' 138' ' ' ILE . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.611 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo . . . . . 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.9 mmtm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.905 0.383 . . . . 0.0 110.765 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.899 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.899 HD13 ' O ' ' A' ' 102' ' ' PHE . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 135' ' ' VAL . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.871 ' O ' HG23 ' A' ' 134' ' ' THR . 11.0 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.45 ' HD2' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.451 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.615 HG23 ' HB2' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.501 HG13 ' HB3' ' A' ' 126' ' ' GLN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.927 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.652 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.652 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.927 ' O ' HG23 ' A' ' 118' ' ' VAL . 0.2 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.513 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.615 ' HB2' HG23 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.871 HG23 ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.708 HG13 HG12 ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.483 ' HA ' HG11 ' A' ' 105' ' ' VAL . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.612 HD13 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.855 HG11 HG12 ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.855 HG12 HG11 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.472 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.585 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.708 HG12 HG13 ' A' ' 135' ' ' VAL . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.78 HG12 HG23 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 1.005 HD13 ' NE2' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.214 0 N-CA-C 112.773 -0.131 . . . . 0.0 112.773 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 1.088 ' ND1' HD12 ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 154' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.828 HG22 ' HE1' ' A' ' 81' ' ' HIS . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.516 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.871 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.621 ' H ' HG13 ' A' ' 146' ' ' VAL . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.486 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 35.2 Cg_endo . . . . . 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.901 0.381 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG21 HG21 ' A' ' 109' ' ' VAL . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.504 HG22 ' HA ' ' A' ' 137' ' ' ALA . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.461 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.48 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.81 HG21 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.753 HG22 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.562 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.57 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.981 HG23 ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.469 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.457 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.475 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HE2' ' HE1' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.57 ' HA ' HG23 ' A' ' 117' ' ' ILE . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.981 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.495 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.753 ' HA ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.778 ' HA ' HD13 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.683 HG13 HG12 ' A' ' 153' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.553 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.551 ' O ' HD13 ' A' ' 139' ' ' LEU . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.617 HG11 ' CB ' ' A' ' 91' ' ' PHE . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.553 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.621 HG13 ' H ' ' A' ' 91' ' ' PHE . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.469 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.483 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.582 HD23 HG21 ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.683 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 1.088 HD12 ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.424 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.441 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.74 HG23 HG12 ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.705 ' OG ' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 146' ' ' VAL . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.492 ' HA3' ' HA ' ' A' ' 120' ' ' ALA . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.819 ' HE2' HD13 ' A' ' 138' ' ' ILE . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.627 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.566 HG22 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.412 ' HB3' ' CZ ' ' A' ' 102' ' ' PHE . 58.7 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.566 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 1.05 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.759 ' O ' HG22 ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.509 HG23 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.435 ' C ' ' HG2' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.538 ' HD3' HG23 ' A' ' 134' ' ' THR . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.506 ' H ' HG12 ' A' ' 109' ' ' VAL . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' A' ' 130' ' ' ASP . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 114' ' ' THR . . . . . 1.05 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.543 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.559 HG23 ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.507 ' H ' HG22 ' A' ' 117' ' ' ILE . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.492 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.549 ' HE2' ' OD1' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.559 ' HB3' HG23 ' A' ' 118' ' ' VAL . 2.1 t30 -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.543 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' HA ' HG13 ' A' ' 111' ' ' VAL . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.457 ' HG ' HG21 ' A' ' 155' ' ' ILE . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.538 HG23 ' HD3' ' A' ' 108' ' ' LYS . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.422 HG13 HG12 ' A' ' 153' ' ' VAL . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.819 HD13 ' HE2' ' A' ' 91' ' ' PHE . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.496 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.929 HG21 HD23 ' A' ' 152' ' ' LEU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.495 ' HB2' ' HD3' ' A' ' 93' ' ' ARG . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 4.3 mt-30 -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.736 HG12 HG11 ' A' ' 140' ' ' VAL . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.611 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.929 HD23 HG21 ' A' ' 140' ' ' VAL . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.422 HG12 HG13 ' A' ' 135' ' ' VAL . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.74 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 156' ' ' GLU . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.552 ' N ' HG22 ' A' ' 155' ' ' ILE . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.933 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 81' ' ' HIS . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' ' CG1' ' A' ' 146' ' ' VAL . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.909 HG13 ' O ' ' A' ' 146' ' ' VAL . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.679 ' CE2' HD13 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.46 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.723 HG22 ' HA ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.41 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 51.8 Cg_endo . . . . . 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.723 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.526 ' CE2' HD12 ' A' ' 117' ' ' ILE . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.94 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 106' ' ' GLY . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 37.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.473 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.94 ' CG1' HG21 ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.706 HD22 HG21 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.527 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.401 ' N ' HG22 ' A' ' 117' ' ' ILE . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.535 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.439 ' HG3' ' O ' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.655 ' HE2' ' HE3' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.535 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.655 ' HE3' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.56 ' HB3' HG23 ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.527 ' CB ' HG13 ' A' ' 117' ' ' ILE . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.706 HG21 HD22 ' A' ' 115' ' ' LEU . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.564 ' C ' HG23 ' A' ' 155' ' ' ILE . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.546 ' HB3' HG23 ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.679 HD13 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.528 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.909 ' O ' HG13 ' A' ' 88' ' ' VAL . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.565 ' N ' HG12 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.883 ' HB3' HG22 ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.652 ' O ' HG23 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.731 HD23 HG21 ' A' ' 140' ' ' VAL . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.906 HD12 ' HB2' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 136' ' ' LYS . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.699 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.821 HD13 ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.803 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 146' ' ' VAL . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.503 ' HA ' HG23 ' A' ' 146' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.732 ' HB2' HG11 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.451 ' O ' ' SG ' ' A' ' 116' ' ' CYS . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' O ' HG23 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 93' ' ' ARG . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo . . . . . 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.788 0.328 . . . . 0.0 110.886 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.439 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.52 HG22 HG21 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.573 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.514 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 1.016 ' HG2' HG23 ' A' ' 135' ' ' VAL . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.836 HG13 ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.836 ' N ' HG13 ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.616 ' HB2' HG11 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 125' ' ' ASN . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.446 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.537 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.517 ' HA ' HG23 ' A' ' 117' ' ' ILE . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.537 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.545 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.569 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 1.016 HG23 ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.625 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.617 ' CD1' HG22 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.755 HG21 HD23 ' A' ' 152' ' ' LEU . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 1.8 mt-30 -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.872 ' O ' HG13 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.803 HD11 ' HA ' ' A' ' 85' ' ' SER . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.617 HG22 ' CD1' ' A' ' 138' ' ' ILE . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.699 HD12 ' HB2' ' A' ' 81' ' ' HIS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.441 ' N ' HG22 ' A' ' 155' ' ' ILE . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.439 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.667 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.144 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.655 ' HB2' HD11 ' A' ' 152' ' ' LEU . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 147' ' ' GLU . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.6 ' C ' HG22 ' A' ' 146' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.692 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.638 HG22 ' HA ' ' A' ' 101' ' ' ALA . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.521 ' HG3' ' CZ ' ' A' ' 102' ' ' PHE . 52.7 Cg_exo . . . . . 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.081 0 CA-C-O 120.849 0.357 . . . . 0.0 111.005 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.763 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.578 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.555 HG23 ' HG2' ' A' ' 107' ' ' GLN . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.763 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 137' ' ' ALA . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.448 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.555 ' HG2' HG23 ' A' ' 103' ' ' ILE . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.504 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.518 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.519 HG23 ' OE1' ' A' ' 126' ' ' GLN . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.578 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.507 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.472 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.767 ' O ' HG23 ' A' ' 118' ' ' VAL . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.519 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.592 ' O ' HG21 ' A' ' 155' ' ' ILE . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.518 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.651 HG22 ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.75 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.617 HD11 HG22 ' A' ' 153' ' ' VAL . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 139' ' ' LEU . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.645 HG21 HD23 ' A' ' 152' ' ' LEU . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.586 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 4.2 mt-30 -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.6 HG22 ' C ' ' A' ' 89' ' ' GLY . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.672 ' HA ' HG22 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.618 ' C ' HG23 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.692 HD22 ' CD1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.651 ' CG1' HG22 ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.144 HG12 HG23 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OXT' ' HA3' ' A' ' 80' ' ' GLY . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.568 ' NE2' HD12 ' A' ' 155' ' ' ILE . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.011 HG23 HG12 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.615 HG23 ' O ' ' A' ' 153' ' ' VAL . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.529 ' HB2' ' NH1' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.885 ' HA ' HD11 ' A' ' 152' ' ' LEU . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.453 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.461 ' CA ' HG23 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 140' ' ' VAL . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.513 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.527 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.535 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.758 ' HB2' HD12 ' A' ' 117' ' ' ILE . 31.3 Cg_exo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.668 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 3.3 ptmm? . . . . . 0 CA--C 1.523 -0.06 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.558 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG22 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.728 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.481 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.641 ' HD3' HG23 ' A' ' 134' ' ' THR . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 110' ' ' ASN . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.69 ' H ' HG22 ' A' ' 109' ' ' VAL . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.776 HG22 ' H ' ' A' ' 132' ' ' SER . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.558 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 95' ' ' PRO . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.433 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.677 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.593 ' CE ' ' HE1' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.677 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.593 ' HE1' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.524 ' O ' HG23 ' A' ' 118' ' ' VAL . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.548 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.776 ' H ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.618 ' HA3' HG12 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.641 HG23 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.81 ' CG2' HG22 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.518 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.728 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.667 HD13 ' CE2' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.575 HD22 ' HG2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 91' ' ' PHE . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.527 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 2.8 mt-30 -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.407 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.745 HG11 ' OG ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.575 ' HG2' HD22 ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.885 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.615 ' O ' HG23 ' A' ' 83' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.011 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.568 HD12 ' NE2' ' A' ' 81' ' ' HIS . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.421 ' N ' HG22 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 N-CA-C 112.382 -0.287 . . . . 0.0 112.382 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.606 ' CE1' ' HB3' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.041 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 153' ' ' VAL . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.027 ' HB3' HG11 ' A' ' 140' ' ' VAL . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.759 ' HB3' HD12 ' A' ' 117' ' ' ILE . 74.2 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.04 0 CA-C-O 120.773 0.32 . . . . 0.0 110.988 . . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.522 ' HB1' ' CG ' ' A' ' 104' ' ' GLU . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.851 ' CE1' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 103' ' ' ILE . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.522 ' CG ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.927 ' HE2' HG22 ' A' ' 135' ' ' VAL . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.851 HG21 ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.65 HD23 ' SG ' ' A' ' 116' ' ' CYS . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.65 ' SG ' HD23 ' A' ' 115' ' ' LEU . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 95' ' ' PRO . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.731 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.731 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.542 HG22 ' N ' ' A' ' 128' ' ' GLU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.542 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.716 ' C ' HG22 ' A' ' 111' ' ' VAL . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.715 ' HB2' HD13 ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.771 ' HB2' HG23 ' A' ' 111' ' ' VAL . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.9 ' O ' HG23 ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.927 HG22 ' HE2' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.576 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.566 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.842 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.027 HG11 ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 142' ' ' SER . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.457 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.497 HG13 ' HB2' ' A' ' 150' ' ' GLU . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.497 ' HB2' HG13 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.842 ' HG2' HD22 ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.622 HD22 ' CD2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.747 HG12 HG13 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.041 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.9 HG23 ' O ' ' A' ' 134' ' ' THR . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.775 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.995 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 153' ' ' VAL . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' SER . . . . . 1.006 ' OG ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.555 HG22 ' HA2' ' A' ' 143' ' ' GLY . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.587 HG23 ' O ' ' A' ' 93' ' ' ARG . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo . . . . . 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.823 0.344 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.876 HG22 HG21 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.639 ' NE2' HD13 ' A' ' 103' ' ' ILE . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.628 HG13 HD12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.504 HG13 ' HB3' ' A' ' 126' ' ' GLN . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.494 HG12 ' HA3' ' A' ' 89' ' ' GLY . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.628 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.452 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.413 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.554 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.504 ' HB3' HG13 ' A' ' 117' ' ' ILE . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.508 ' C ' HG23 ' A' ' 155' ' ' ILE . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.876 HG21 HG22 ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.425 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CD1' HG22 ' A' ' 153' ' ' VAL . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.64 HD23 ' HB2' ' A' ' 151' ' ' PRO . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.712 HG11 HG22 ' A' ' 146' ' ' VAL . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.59 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.555 ' HA2' HG22 ' A' ' 90' ' ' THR . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.546 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.712 HG22 HG11 ' A' ' 140' ' ' VAL . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.448 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.552 ' CD ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.64 ' HB2' HD23 ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.006 HD11 ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.637 HG22 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.995 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.508 HG23 ' C ' ' A' ' 134' ' ' THR . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.416 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.776 0.322 . . . . 0.0 110.949 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.1 pt -70.07 153.49 8.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.58 33.76 3.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.95 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.435 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . 82.42 -129.7 9.23 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.605 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.622 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.028 HG23 HG12 ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.444 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.99 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.444 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.417 ' O ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.833 ' HE2' HD13 ' A' ' 138' ' ' ILE . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.681 HG22 ' HA ' ' A' ' 101' ' ' ALA . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo -56.31 -138.79 0.0 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.539 ' N ' ' H62' ' A' ' 222' ' ' BTN . 0.9 OUTLIER -29.96 105.01 0.21 Allowed Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.92 0.391 . . . . 0.0 110.669 179.845 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -31.48 -31.15 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.315 2.677 . . . . 0.0 112.942 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' SER . 12.8 m-20 -95.77 42.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.542 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.451 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -110.49 -161.81 0.77 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER -122.09 30.35 6.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.775 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.681 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.639 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.87 HG22 HG21 ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.489 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.5 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.5 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.525 HG11 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.639 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.569 HG23 ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.41 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.605 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.605 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.533 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.445 ' N ' HG22 ' A' ' 127' ' ' ILE . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.87 HG21 HG22 ' A' ' 103' ' ' ILE . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.429 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.53 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.833 HD13 ' HE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 91' ' ' PHE . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.498 ' H ' HG22 ' A' ' 138' ' ' ILE . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.495 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.482 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.905 ' O ' HG13 ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.99 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.464 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.501 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.676 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.76 HG12 HG13 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.028 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.622 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.429 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.603 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.829 0.347 . . . . 0.0 110.865 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 3.8 tp -145.16 122.34 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.165 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.461 ' HA ' ' OE1' ' A' ' 156' ' ' GLU . 22.7 t -126.17 44.67 2.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' SER . . . 37.45 -110.17 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.415 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.887 ' NE2' HD13 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' HD21 ' A' ' 152' ' ' LEU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.756 ' HB2' HG11 ' A' ' 140' ' ' VAL . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.893 ' HB3' HD12 ' A' ' 117' ' ' ILE . 69.7 Cg_endo -74.37 54.19 3.26 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.723 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER 158.54 129.46 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.767 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.543 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 74.0 Cg_exo -49.52 81.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.811 2.34 . . . . 0.0 112.161 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.543 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 4.8 t0 90.16 53.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.732 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.723 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -98.94 -155.6 0.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp -83.76 4.07 30.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.743 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.738 ' HE2' HD12 ' A' ' 117' ' ' ILE . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.754 HG23 ' HG2' ' A' ' 107' ' ' GLN . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.743 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.747 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.754 ' HG2' HG23 ' A' ' 103' ' ' ILE . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.73 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 130' ' ' ASP . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.584 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.893 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.722 ' HB3' ' HE3' ' A' ' 123' ' ' MET . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.422 ' HG3' ' O ' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.722 ' HE3' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.644 ' HB2' ' HE2' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.584 HG22 ' N ' ' A' ' 128' ' ' GLU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.634 ' O ' HG22 ' A' ' 111' ' ' VAL . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.484 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.607 HG21 HG22 ' A' ' 103' ' ' ILE . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.694 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.747 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.799 ' C ' HD23 ' A' ' 139' ' ' LEU . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.799 HD23 ' C ' ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.791 HG21 HD23 ' A' ' 152' ' ' LEU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 152' ' ' LEU . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.491 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.718 ' HG2' HD12 ' A' ' 139' ' ' LEU . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.791 HD23 HG21 ' A' ' 140' ' ' VAL . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.887 HD13 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.483 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.619 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 . . . . . 0 CA--C 1.527 0.061 0 CA-C-O 120.85 0.357 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.52 HG12 ' N ' ' A' ' 79' ' ' SER . 7.3 tt -138.85 155.3 27.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.52 ' N ' HG12 ' A' ' 78' ' ' ILE . 2.0 m -89.86 29.51 1.18 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.866 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.409 ' HA3' ' C ' ' A' ' 156' ' ' GLU . . . -143.97 -161.69 9.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.54 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.656 ' NE2' HD12 ' A' ' 155' ' ' ILE . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.908 HG23 HG12 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.424 ' HB2' HG11 ' A' ' 146' ' ' VAL . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.695 HG13 ' O ' ' A' ' 146' ' ' VAL . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.678 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.627 ' CE1' ' N2 ' ' A' ' 222' ' ' BTN . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.609 HG22 ' HA ' ' A' ' 101' ' ' ALA . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.906 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.2 Cg_endo -75.54 50.48 2.69 Favored 'Trans proline' 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.669 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.5 OUTLIER 157.61 123.12 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.712 -179.878 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -49.55 -19.9 3.68 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.709 2.272 . . . . 0.0 112.283 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -134.16 58.35 1.77 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.784 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.669 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -116.66 -162.67 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.019 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -111.11 21.84 15.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.905 HG22 HG21 ' A' ' 135' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.445 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.772 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 115' ' ' LEU . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 114' ' ' THR . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.906 HD12 ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.477 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.712 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.444 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.712 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.822 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.8 t-20 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.488 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.616 HD11 HG21 ' A' ' 118' ' ' VAL . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB2' HG11 ' A' ' 109' ' ' VAL . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.511 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.905 HG21 HG22 ' A' ' 103' ' ' ILE . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.62 ' HB2' HG23 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 152' ' ' LEU . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.66 HD22 ' N ' ' A' ' 139' ' ' LEU . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.619 HG11 ' HB2' ' A' ' 91' ' ' PHE . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' HB2' ' A' ' 144' ' ' GLN . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.562 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.476 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.695 ' O ' HG13 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.558 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 139' ' ' LEU . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.689 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.545 HG12 HG13 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.908 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.656 HD12 ' NE2' ' A' ' 81' ' ' HIS . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.423 ' HG3' ' CG ' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.627 ' N2 ' ' CE1' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.798 0.332 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.503 ' C ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -142.25 132.15 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.139 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.431 ' N ' HD13 ' A' ' 78' ' ' ILE . 0.3 OUTLIER -114.77 120.16 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 179.991 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.07 168.5 40.84 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.436 ' ND1' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.739 HG23 HD11 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.661 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.591 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.591 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.721 ' HB2' HG11 ' A' ' 140' ' ' VAL . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.571 ' CE2' ' H61' ' A' ' 222' ' ' BTN . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.51 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.764 ' HB3' HD12 ' A' ' 117' ' ' ILE . 54.0 Cg_endo -70.36 94.13 0.58 Allowed 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.491 ' C ' ' O ' ' A' ' 95' ' ' PRO . 0.1 OUTLIER -18.53 -60.09 0.05 OUTLIER Pre-proline 0 N--CA 1.467 0.405 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.316 -179.8 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 82.5 Cg_exo -44.04 -44.74 12.17 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.612 2.208 . . . . 0.0 112.308 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 95' ' ' PRO . 23.5 t70 -146.6 41.31 1.13 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.515 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.537 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -31.55 -91.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.503 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 50.77 22.05 1.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.58 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.671 HG21 ' HE2' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.466 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.915 ' O ' HG13 ' A' ' 109' ' ' VAL . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 132' ' ' SER . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.764 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.455 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.696 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.425 ' CD ' ' HE3' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.696 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.719 ' C ' HG22 ' A' ' 111' ' ' VAL . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.549 ' HE3' HG22 ' A' ' 83' ' ' VAL . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.787 ' HB3' HG23 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.57 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.814 HG23 ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.454 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.641 HD13 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.468 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.823 HG21 HD23 ' A' ' 152' ' ' LEU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.51 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.423 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.823 HD23 HG21 ' A' ' 140' ' ' VAL . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.576 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.739 HD11 HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.519 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.571 ' H61' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -70.46 176.21 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.192 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.3 m -112.45 36.92 3.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -139.43 -169.63 11.66 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB2' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.757 HG23 HG12 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.552 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.476 ' CB ' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.814 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.508 ' CZ ' ' H72' ' A' ' 222' ' ' BTN . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.458 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.55 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo -54.45 -155.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 11.2 p -25.58 137.51 0.07 OUTLIER Pre-proline 0 N--CA 1.465 0.302 0 O-C-N 123.235 0.334 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.529 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 31.9 Cg_exo -59.07 61.91 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.087 2.525 . . . . 0.0 112.716 -179.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.0 m-20 156.17 39.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.777 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.527 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -99.98 -97.22 0.24 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.12 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 99' ' ' ALA . 1.5 pptp? 174.82 40.36 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.816 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.61 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.655 HG22 HG21 ' A' ' 135' ' ' VAL . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.475 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.889 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.619 ' HG2' HG23 ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.57 ' HA ' ' CE2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.61 HD12 ' HE2' ' A' ' 102' ' ' PHE . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.476 ' OE1' ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.407 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.563 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.415 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.572 ' HE2' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.441 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.515 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.435 ' N ' HG22 ' A' ' 127' ' ' ILE . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.655 HG21 HG22 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.798 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.889 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.796 HD13 ' HE2' ' A' ' 91' ' ' PHE . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.713 HD23 ' N ' ' A' ' 139' ' ' LEU . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.79 HG21 HD23 ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.57 ' H ' HG22 ' A' ' 138' ' ' ILE . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.505 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 21.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.607 HG12 HG11 ' A' ' 140' ' ' VAL . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HG22 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.597 ' HG2' HD12 ' A' ' 139' ' ' LEU . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.814 HD22 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' HG13 ' A' ' 135' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.757 HG12 HG23 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.454 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.485 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.508 ' H72' ' CZ ' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 78' ' ' ILE . 1.1 pt-20 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.776 0.322 . . . . 0.0 110.972 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.623 HD11 ' OXT' ' A' ' 156' ' ' GLU . 3.5 tp 37.26 89.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.074 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 80' ' ' GLY . 0.9 OUTLIER -96.66 10.78 37.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.555 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . 36.36 -127.58 0.98 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.555 ' CD2' ' C ' ' A' ' 80' ' ' GLY . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.753 HG23 HG12 ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.805 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.43 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 146' ' ' VAL . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.603 ' N ' HG23 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.772 ' HB2' HG11 ' A' ' 140' ' ' VAL . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.546 ' CD2' ' H5 ' ' A' ' 222' ' ' BTN . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.737 ' HB ' ' HB1' ' A' ' 99' ' ' ALA . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.707 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 72.0 Cg_endo -76.61 124.22 7.47 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.6 OUTLIER -36.94 -50.08 2.08 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.838 179.955 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 96' ' ' SER . 33.3 Cg_exo -57.83 71.07 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.9 2.4 . . . . 0.0 112.385 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 96' ' ' SER . 36.6 t0 75.72 29.52 0.84 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.058 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.737 ' HB1' ' HB ' ' A' ' 94' ' ' THR . . . -35.99 95.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.132 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' N ' ' O ' ' A' ' 98' ' ' ASP . 11.2 mtpt -100.33 29.29 4.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.755 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.612 HD13 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.538 ' OE1' HD12 ' A' ' 138' ' ' ILE . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.467 HG22 ' HA ' ' A' ' 137' ' ' ALA . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.462 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.59 HG11 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' HA ' ' A' ' 130' ' ' ASP . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.59 ' CB ' HG11 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.416 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.489 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.65 HD13 ' S1 ' ' A' ' 222' ' ' BTN . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.763 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.763 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.467 ' HE1' ' H81' ' A' ' 222' ' ' BTN . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.859 ' O ' HG23 ' A' ' 118' ' ' VAL . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.453 ' O ' ' N ' ' A' ' 130' ' ' ASP . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.641 ' HA ' HG13 ' A' ' 111' ' ' VAL . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.47 HG22 ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.939 HG13 HG12 ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.547 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.663 HG12 HG13 ' A' ' 153' ' ' VAL . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.546 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.804 HG21 HD23 ' A' ' 152' ' ' LEU . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 3.6 pt20 -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 88' ' ' VAL . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.487 ' HB3' HG22 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.546 ' HG2' HD22 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.805 HD11 ' HA ' ' A' ' 85' ' ' SER . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.939 HG12 HG13 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.753 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 81' ' ' HIS . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.623 ' OXT' HD11 ' A' ' 78' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.65 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.817 0.341 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.49 -178.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.6 m -84.56 10.01 12.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.021 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.96 -128.41 47.63 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.845 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.745 HG23 HG12 ' A' ' 154' ' ' VAL . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.478 ' O ' HD12 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.545 ' HA ' HD21 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.588 HG22 ' HA ' ' A' ' 147' ' ' GLU . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.581 ' N ' HG23 ' A' ' 146' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.457 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CZ ' HD13 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.537 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' THR . . . . . 1.025 ' OG1' ' HB1' ' A' ' 99' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo -65.26 -152.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.601 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -122.47 -72.79 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.083 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.601 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 23.8 Cg_endo -61.27 77.97 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.502 2.134 . . . . 0.0 112.372 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER 85.38 45.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.785 -179.956 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 1.025 ' HB1' ' OG1' ' A' ' 94' ' ' THR . . . -59.59 -53.66 55.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.302 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.28 22.72 13.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.733 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.527 HG21 ' HD3' ' A' ' 108' ' ' LYS . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.537 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.555 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.903 ' CG ' HG23 ' A' ' 135' ' ' VAL . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.502 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.481 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.545 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.733 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 125' ' ' ASN . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.473 ' H ' HG22 ' A' ' 117' ' ' ILE . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.614 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.614 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.509 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.467 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.517 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.662 ' O ' HD13 ' A' ' 155' ' ' ILE . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.502 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.541 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.903 HG23 ' CG ' ' A' ' 108' ' ' LYS . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.44 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.49 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.642 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 1.003 HD12 ' CG ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.512 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 23.3 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.581 HG23 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.588 ' HA ' HG22 ' A' ' 88' ' ' VAL . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.478 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 1.003 ' CG ' HD12 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.545 HD21 ' HA ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 HG13 ' A' ' 135' ' ' VAL . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.745 HG12 HG23 ' A' ' 82' ' ' ILE . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.845 HD12 ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.44 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.568 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.816 0.341 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -149.3 124.11 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.138 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -127.51 3.62 6.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.082 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . 35.52 -155.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.62 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.529 ' CD2' ' C ' ' A' ' 80' ' ' GLY . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.837 HG23 HG12 ' A' ' 154' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.443 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.502 ' CB ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.637 HG22 ' HA ' ' A' ' 147' ' ' GLU . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.571 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.835 ' CD1' HD22 ' A' ' 152' ' ' LEU . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.494 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 99' ' ' ALA . 89.1 Cg_endo -84.56 100.14 0.76 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.451 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 1.0 OUTLIER -27.26 -63.2 0.17 Allowed Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.323 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.451 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 71.2 Cg_exo -36.28 -67.68 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.737 2.291 . . . . 0.0 112.447 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.413 ' OD1' ' HG2' ' A' ' 95' ' ' PRO . 10.1 p30 -118.72 43.02 2.63 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.113 0.482 . . . . 0.0 109.911 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -43.45 107.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.966 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -118.17 18.56 13.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.958 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.494 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 1.018 ' CG2' HG12 ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.667 HG13 ' HA ' ' A' ' 137' ' ' ALA . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 1.018 HG12 ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.658 ' O ' HD11 ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.443 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.514 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.506 ' CG ' ' O ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.436 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.555 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.89 ' O ' HG23 ' A' ' 118' ' ' VAL . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.512 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.512 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.864 HG23 ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.659 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.749 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 152' ' ' LEU . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.796 HG21 HD23 ' A' ' 152' ' ' LEU . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.582 HG22 ' N ' ' A' ' 147' ' ' GLU . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.637 ' HA ' HG22 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.449 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.835 HD22 ' CD1' ' A' ' 91' ' ' PHE . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.468 HG22 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.837 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.438 HD12 ' O ' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.404 ' HG2' ' OXT' ' A' ' 156' ' ' GLU . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.527 ' C6 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' N ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.75 0.31 . . . . 0.0 110.818 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.426 HG12 ' N ' ' A' ' 79' ' ' SER . 7.4 tt -171.39 154.36 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.426 ' N ' HG12 ' A' ' 78' ' ' ILE . 54.8 p -112.57 34.14 4.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . 53.76 -149.8 14.51 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.525 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.929 ' NE2' HD13 ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.06 HG23 HG12 ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.749 HG22 ' HA ' ' A' ' 147' ' ' GLU . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.539 ' CD1' HD22 ' A' ' 152' ' ' LEU . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.65 HG22 ' HA ' ' A' ' 101' ' ' ALA . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo -54.19 -149.68 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.2 OUTLIER -34.87 137.52 0.37 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.959 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.517 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 73.7 Cg_exo -49.24 79.72 0.02 OUTLIER 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 123.032 2.488 . . . . 0.0 112.597 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.5 m-20 159.24 -21.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.171 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.491 ' CB ' ' HD2' ' A' ' 95' ' ' PRO . . . -45.2 168.76 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.841 0.353 . . . . 0.0 111.087 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt -101.28 40.44 1.29 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.912 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.885 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.599 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 1.033 HG21 HG13 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.885 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.743 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.578 ' HG2' HG23 ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 1.033 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.803 HG23 ' OG ' ' A' ' 132' ' ' SER . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.587 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.55 HG13 ' HB3' ' A' ' 126' ' ' GLN . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.526 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.762 ' HB3' ' HE2' ' A' ' 123' ' ' MET . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.431 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.762 ' HE2' ' HB3' ' A' ' 120' ' ' ALA . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.486 ' SD ' ' HG2' ' A' ' 119' ' ' GLU . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.723 ' O ' HG23 ' A' ' 118' ' ' VAL . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.55 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.562 HG22 ' N ' ' A' ' 128' ' ' GLU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.562 ' N ' HG22 ' A' ' 127' ' ' ILE . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.803 ' OG ' HG23 ' A' ' 111' ' ' VAL . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.61 ' C ' HG23 ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.663 HG13 HG12 ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' HG13 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.743 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.576 HG23 ' O ' ' A' ' 152' ' ' LEU . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.579 HG23 ' C ' ' A' ' 151' ' ' PRO . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 140' ' ' VAL . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.789 HG22 ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.749 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.574 ' OE1' HG22 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.579 ' C ' HG23 ' A' ' 140' ' ' VAL . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.576 ' O ' HG23 ' A' ' 138' ' ' ILE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.663 HG12 HG13 ' A' ' 135' ' ' VAL . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.06 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.929 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.57 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.802 0.335 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.51 150.67 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.12 65.59 2.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.876 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -122.5 -147.92 7.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.525 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.544 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.979 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.554 ' OG ' HD21 ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.446 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.471 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.899 HG23 ' HB2' ' A' ' 148' ' ' PHE . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.834 ' CD1' HD22 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.576 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.533 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.55 ' CG2' ' HB2' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo -56.7 -145.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.523 ' N ' ' C3 ' ' A' ' 222' ' ' BTN . 0.5 OUTLIER -25.62 142.0 0.04 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.633 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_exo -45.71 -24.57 2.04 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.931 2.421 . . . . 0.0 112.523 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -110.25 55.4 0.65 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -118.12 -177.94 3.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.15 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp -129.47 36.36 4.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB2' ' CG2' ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.762 ' HE2' HD12 ' A' ' 117' ' ' ILE . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.688 HG21 ' CG1' ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.688 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.475 HG23 ' OG ' ' A' ' 132' ' ' SER . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.527 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.762 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.496 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.462 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.54 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.54 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 9.7 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 109' ' ' VAL . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.475 ' OG ' HG23 ' A' ' 111' ' ' VAL . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.475 ' C ' HG23 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.685 HG13 HG12 ' A' ' 153' ' ' VAL . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.639 ' HB3' HG23 ' A' ' 154' ' ' VAL . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.683 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 152' ' ' LEU . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.906 HG21 HD23 ' A' ' 152' ' ' LEU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.533 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.661 ' HA ' HG13 ' A' ' 88' ' ' VAL . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.576 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.899 ' HB2' HG23 ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.746 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 140' ' ' VAL . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.906 HD23 HG21 ' A' ' 140' ' ' VAL . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.685 HG12 HG13 ' A' ' 135' ' ' VAL . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.979 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.456 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.525 ' S1 ' ' HB3' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.458 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 34.1 tt0 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.428 ' N ' ' CD1' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -64.67 -176.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.192 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.8 t -98.92 46.83 0.98 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.888 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.508 ' C ' ' CD2' ' A' ' 81' ' ' HIS . . . -87.58 -167.33 43.44 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.58 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.562 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 151' ' ' PRO . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.539 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.518 ' HA ' HG23 ' A' ' 146' ' ' VAL . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.742 ' HE2' HD13 ' A' ' 138' ' ' ILE . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD2' ' H2 ' ' A' ' 222' ' ' BTN . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.787 ' HD2' HD12 ' A' ' 138' ' ' ILE . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.471 ' HG3' ' CD2' ' A' ' 102' ' ' PHE . 52.2 Cg_exo -54.37 -149.16 0.0 OUTLIER 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 57.9 m -33.42 154.36 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.167 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.76 -26.48 3.19 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.795 2.33 . . . . 0.0 112.426 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' A' ' 98' ' ' ASP . 1.7 p30 -115.65 55.57 0.78 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.409 ' HB1' ' HD2' ' A' ' 95' ' ' PRO . . . -102.96 -167.62 1.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.72 35.02 4.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.643 ' HB1' ' CD ' ' A' ' 104' ' ' GLU . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.716 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 135' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.643 ' CD ' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.514 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.527 HG11 HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 1.0 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.716 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.645 ' H ' HG22 ' A' ' 114' ' ' THR . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 124' ' ' MET . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.962 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.468 ' HG3' ' S1 ' ' A' ' 222' ' ' BTN . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.454 ' HG3' ' O ' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.501 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.489 ' HE3' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.562 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.962 ' O ' HG23 ' A' ' 118' ' ' VAL . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.501 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.552 HG13 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.717 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.77 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.787 HD12 ' HD2' ' A' ' 93' ' ' ARG . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.493 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.799 HG22 ' CG ' ' A' ' 150' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.518 HG23 ' HA ' ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.799 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.714 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.539 HD11 ' HA ' ' A' ' 85' ' ' SER . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.8 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.511 HD12 ' O ' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.544 ' H2 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' A' ' 78' ' ' ILE . 79.3 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.845 0.355 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.471 HG23 ' O ' ' A' ' 78' ' ' ILE . 2.6 tp 38.97 95.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.12 8.79 9.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.981 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . -112.96 -139.37 7.43 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.535 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.765 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.869 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.555 ' OG ' HG21 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.58 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.726 HG23 ' N ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.797 ' CD1' HD22 ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.702 HG22 ' HA ' ' A' ' 101' ' ' ALA . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 99' ' ' ALA . 39.4 Cg_exo -59.99 -149.83 0.01 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.524 ' HA ' ' N2 ' ' A' ' 222' ' ' BTN . 85.4 p -33.49 151.65 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.023 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.429 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 28.0 Cg_endo -62.92 57.66 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.786 2.324 . . . . 0.0 112.271 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 171.57 34.24 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.892 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.457 ' HB3' ' HD2' ' A' ' 95' ' ' PRO . . . -114.2 -170.54 1.74 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.095 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 7.1 ttpt -90.19 -68.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.994 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.702 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.91 HG22 HG21 ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.768 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.537 ' NE2' ' H ' ' A' ' 108' ' ' LYS . 0.4 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.537 ' H ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.894 HG23 ' HB2' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.488 ' HB3' HG23 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.77 HG23 ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.713 HD23 ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.511 ' N ' HG22 ' A' ' 117' ' ' ILE . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.534 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.408 ' CA ' ' HE2' ' A' ' 122' ' ' LYS . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.606 ' HE3' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.606 ' ND2' ' HE3' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.77 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.713 ' HB ' HD23 ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.465 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.651 ' HA ' HG13 ' A' ' 111' ' ' VAL . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.716 ' N ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.894 ' HB2' HG23 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.748 ' O ' HG23 ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.91 HG21 HG22 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.635 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.768 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.639 HG23 ' O ' ' A' ' 152' ' ' LEU . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.747 HG23 ' C ' ' A' ' 151' ' ' PRO . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 140' ' ' VAL . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.611 ' C ' HG23 ' A' ' 90' ' ' THR . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.726 ' N ' HG23 ' A' ' 90' ' ' THR . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.555 HG21 ' OG ' ' A' ' 85' ' ' SER . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.439 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.519 ' HG3' HG22 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.747 ' C ' HG23 ' A' ' 140' ' ' VAL . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.797 HD22 ' CD1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.621 HG22 HD11 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.869 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.765 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.41 ' HA ' ' HA3' ' A' ' 80' ' ' GLY . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.524 ' N2 ' ' HA ' ' A' ' 96' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.837 0.351 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.793 HD11 ' HA ' ' A' ' 156' ' ' GLU . 5.0 tt -38.92 151.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.492 ' N ' HG12 ' A' ' 78' ' ' ILE . 24.7 m -98.77 36.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -132.95 -135.79 3.67 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 1.001 ' CE1' HD12 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.839 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.503 ' CB ' HG11 ' A' ' 146' ' ' VAL . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.562 HG12 ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.562 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.968 ' HB3' HG11 ' A' ' 140' ' ' VAL . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.597 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.478 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.874 HG22 ' HB2' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.616 ' HA ' ' H5 ' ' A' ' 222' ' ' BTN . 72.1 Cg_endo -78.09 50.07 3.19 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.964 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER 158.91 129.83 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.812 179.955 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -47.55 -21.45 2.22 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.838 2.359 . . . . 0.0 112.3 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -129.54 55.73 1.75 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.934 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.964 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -115.41 -172.7 2.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.098 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp -109.39 19.92 18.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.874 ' HB2' HG22 ' A' ' 94' ' ' THR . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.605 ' C ' HD12 ' A' ' 103' ' ' ILE . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.731 HD13 ' C ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.529 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.446 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.54 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 110' ' ' ASN . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.523 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.731 ' C ' HD13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.527 HD21 ' CG2' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.594 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.589 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.672 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.672 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.945 ' O ' HG23 ' A' ' 118' ' ' VAL . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.447 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB2' ' HE3' ' A' ' 108' ' ' LYS . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.523 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.54 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.532 HG23 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.531 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.61 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.893 HG23 ' O ' ' A' ' 152' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.528 ' CG ' ' HB2' ' A' ' 151' ' ' PRO . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.968 HG11 ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.478 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.565 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.53 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.503 HG11 ' CB ' ' A' ' 85' ' ' SER . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.528 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.893 ' O ' HG23 ' A' ' 138' ' ' ILE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.878 HG13 ' CG1' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.839 HG12 HG23 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 1.001 HD12 ' CE1' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.793 ' HA ' HD11 ' A' ' 78' ' ' ILE . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.616 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.842 0.353 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.7 tp -50.62 129.23 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.5 m -144.87 21.86 1.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.995 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -98.83 -134.22 8.38 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.544 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.743 ' HE1' HG22 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.046 HG23 HG12 ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.743 HG22 ' HE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.704 ' OG ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.614 ' O ' HG23 ' A' ' 88' ' ' VAL . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 89' ' ' GLY . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.683 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.823 ' HB2' HG11 ' A' ' 146' ' ' VAL . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.492 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.489 ' CB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.969 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 72.4 Cg_endo -84.81 86.8 1.12 Allowed 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.5 OUTLIER -26.8 -55.62 0.21 Allowed Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.856 -179.779 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.445 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 71.6 Cg_exo -48.47 80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.821 2.347 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.4 OUTLIER 61.01 62.87 1.35 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.76 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.969 ' HB2' ' O ' ' A' ' 95' ' ' PRO . . . -112.61 167.0 10.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.68 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.57 27.24 5.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.21 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.572 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.411 HG22 ' HA ' ' A' ' 137' ' ' ALA . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.479 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.492 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 1.022 HG22 ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.538 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.52 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.54 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.555 HG13 ' CG1' ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.553 ' HG2' ' H2 ' ' A' ' 222' ' ' BTN . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.401 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.661 ' HE3' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.511 ' HA ' HG23 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.661 ' OD1' ' HE3' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.506 ' HB3' HG13 ' A' ' 117' ' ' ILE . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.579 HG22 ' N ' ' A' ' 128' ' ' GLU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.579 ' N ' HG22 ' A' ' 127' ' ' ILE . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 1.022 ' O ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.492 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.654 HG13 HG12 ' A' ' 153' ' ' VAL . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.713 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.544 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.608 HG11 ' CB ' ' A' ' 91' ' ' PHE . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.48 ' OG ' ' HA ' ' A' ' 92' ' ' TYR . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.471 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.869 HG23 ' CB ' ' A' ' 150' ' ' GLU . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.869 ' CB ' HG23 ' A' ' 146' ' ' VAL . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.544 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.654 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.046 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.557 ' H4 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 tt -98.49 132.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.141 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 41.2 t -105.32 40.54 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.945 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -125.8 -150.47 7.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.508 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 1.005 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.78 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.585 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 147' ' ' GLU . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.457 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.612 ' CE2' HD13 ' A' ' 138' ' ' ILE . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.627 ' CA ' ' HB1' ' A' ' 99' ' ' ALA . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.611 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo -62.08 113.92 2.09 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.509 ' HB3' ' CD ' ' A' ' 97' ' ' PRO . 9.9 t -29.54 -61.25 0.23 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.389 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.509 ' CD ' ' HB3' ' A' ' 96' ' ' SER . 15.1 Cg_endo -57.43 78.05 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.802 2.335 . . . . 0.0 112.067 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.458 ' N ' ' O ' ' A' ' 96' ' ' SER . 23.6 t0 62.47 47.2 5.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.703 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.627 ' HB1' ' CA ' ' A' ' 94' ' ' THR . . . -38.38 -68.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.369 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 99' ' ' ALA . 6.9 mmtm 63.54 16.65 9.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.765 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.899 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.899 HD13 ' O ' ' A' ' 102' ' ' PHE . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 135' ' ' VAL . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.871 ' O ' HG23 ' A' ' 134' ' ' THR . 11.0 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.45 ' HD2' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.451 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.615 HG23 ' HB2' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.501 HG13 ' HB3' ' A' ' 126' ' ' GLN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.927 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.652 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.652 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.55 ' SD ' ' H2 ' ' A' ' 222' ' ' BTN . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.927 ' O ' HG23 ' A' ' 118' ' ' VAL . 0.2 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.513 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.615 ' HB2' HG23 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.871 HG23 ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.708 HG13 HG12 ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.483 ' HA ' HG11 ' A' ' 105' ' ' VAL . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.612 HD13 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.855 HG11 HG12 ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.855 HG12 HG11 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.472 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.585 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.708 HG12 HG13 ' A' ' 135' ' ' VAL . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.78 HG12 HG23 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 1.005 HD13 ' NE2' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.55 ' H2 ' ' SD ' ' A' ' 124' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.867 0.365 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.4 pt -80.47 -179.14 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.455 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.3 OUTLIER -115.14 -28.14 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.921 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 79' ' ' SER . . . 32.62 -154.5 0.01 OUTLIER Glycine 0 N--CA 1.453 -0.214 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.773 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 1.088 ' ND1' HD12 ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 154' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.828 HG22 ' HE1' ' A' ' 81' ' ' HIS . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.516 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.871 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.621 ' H ' HG13 ' A' ' 146' ' ' VAL . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.561 ' HB ' ' HB1' ' A' ' 99' ' ' ALA . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.545 ' CB ' ' S1 ' ' A' ' 222' ' ' BTN . 35.2 Cg_endo -65.67 117.59 4.75 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.528 ' OG ' ' CD ' ' A' ' 97' ' ' PRO . 0.3 OUTLIER -34.91 -59.9 0.58 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.987 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.528 ' CD ' ' OG ' ' A' ' 96' ' ' SER . 19.4 Cg_endo -58.96 69.13 0.05 OUTLIER 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.805 2.337 . . . . 0.0 112.455 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.8 t0 81.22 47.92 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.308 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.561 ' HB1' ' HB ' ' A' ' 94' ' ' THR . . . -55.7 93.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.986 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.78 30.85 1.29 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.88 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG21 HG21 ' A' ' 109' ' ' VAL . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.504 HG22 ' HA ' ' A' ' 137' ' ' ALA . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.461 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.48 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.81 HG21 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.753 HG22 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.562 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.761 HD13 ' S1 ' ' A' ' 222' ' ' BTN . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.981 HG23 ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.469 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.457 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.475 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.533 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.57 ' HA ' HG23 ' A' ' 117' ' ' ILE . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.981 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.495 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.753 ' HA ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.778 ' HA ' HD13 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.683 HG13 HG12 ' A' ' 153' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.553 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.551 ' O ' HD13 ' A' ' 139' ' ' LEU . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.617 HG11 ' CB ' ' A' ' 91' ' ' PHE . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.553 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.621 HG13 ' H ' ' A' ' 91' ' ' PHE . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.469 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.483 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.582 HD23 HG21 ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.683 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 1.088 HD12 ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.424 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.761 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.528 HG23 ' O ' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -114.21 123.28 69.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.263 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.92 7.59 8.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.441 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . -70.42 -151.67 0.73 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.476 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.74 HG23 HG12 ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.705 ' OG ' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 146' ' ' VAL . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.492 ' HA3' ' HA ' ' A' ' 120' ' ' ALA . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.819 ' HE2' HD13 ' A' ' 138' ' ' ILE . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.627 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.566 HG22 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 96' ' ' SER . 58.7 Cg_endo -72.08 52.23 1.81 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.644 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER 163.81 132.4 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.646 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -46.87 -22.15 1.84 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.638 2.225 . . . . 0.0 112.242 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 43.6 p30 -147.61 62.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.758 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.644 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -108.73 -155.44 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -114.65 29.95 7.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.851 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.566 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 1.05 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.759 ' O ' HG22 ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.509 HG23 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.435 ' C ' ' HG2' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.538 ' HD3' HG23 ' A' ' 134' ' ' THR . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.506 ' H ' HG12 ' A' ' 109' ' ' VAL . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' A' ' 130' ' ' ASP . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 114' ' ' THR . . . . . 1.05 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.543 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.559 HG23 ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.507 ' H ' HG22 ' A' ' 117' ' ' ILE . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.492 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.549 ' HE2' ' OD1' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.559 ' HB3' HG23 ' A' ' 118' ' ' VAL . 2.1 t30 -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.543 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' HA ' HG13 ' A' ' 111' ' ' VAL . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.457 ' HG ' HG21 ' A' ' 155' ' ' ILE . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.538 HG23 ' HD3' ' A' ' 108' ' ' LYS . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.422 HG13 HG12 ' A' ' 153' ' ' VAL . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.819 HD13 ' HE2' ' A' ' 91' ' ' PHE . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.496 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.929 HG21 HD23 ' A' ' 152' ' ' LEU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.495 ' HB2' ' HD3' ' A' ' 93' ' ' ARG . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 4.3 mt-30 -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.736 HG12 HG11 ' A' ' 140' ' ' VAL . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.611 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.929 HD23 HG21 ' A' ' 140' ' ' VAL . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.422 HG12 HG13 ' A' ' 135' ' ' VAL . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.74 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 156' ' ' GLU . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.552 ' N ' HG22 ' A' ' 155' ' ' ILE . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.504 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.798 0.332 . . . . 0.0 111.0 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.9 pt -56.31 173.1 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.15 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.1 t -127.75 21.52 6.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . 53.37 -118.03 7.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.433 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.933 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 81' ' ' HIS . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' ' CG1' ' A' ' 146' ' ' VAL . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.909 HG13 ' O ' ' A' ' 146' ' ' VAL . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.679 ' CE2' HD13 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.46 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.723 HG22 ' HA ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.509 ' HA ' ' C3 ' ' A' ' 222' ' ' BTN . 51.8 Cg_endo -69.57 -168.72 0.28 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.537 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER 31.58 102.05 0.02 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.609 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.558 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 57.3 Cg_exo -30.17 86.68 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.24 2.626 . . . . 0.0 112.325 179.231 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 9.2 m-20 94.55 42.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.551 -179.438 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -77.35 -148.3 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.079 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -108.63 16.69 22.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 -179.944 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.723 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.526 ' CE2' HD12 ' A' ' 117' ' ' ILE . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.94 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 106' ' ' GLY . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 37.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.473 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.94 ' CG1' HG21 ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.706 HD22 HG21 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.527 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.401 ' N ' HG22 ' A' ' 117' ' ' ILE . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.535 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.439 ' HG3' ' O ' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.655 ' HE2' ' HE3' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.535 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.655 ' HE3' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.56 ' HB3' HG23 ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.527 ' CB ' HG13 ' A' ' 117' ' ' ILE . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.706 HG21 HD22 ' A' ' 115' ' ' LEU . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.564 ' C ' HG23 ' A' ' 155' ' ' ILE . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.546 ' HB3' HG23 ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.679 HD13 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.528 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.909 ' O ' HG13 ' A' ' 88' ' ' VAL . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.565 ' N ' HG12 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.883 ' HB3' HG22 ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.652 ' O ' HG23 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.731 HD23 HG21 ' A' ' 140' ' ' VAL . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.906 HD12 ' HB2' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 136' ' ' LYS . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.509 ' C3 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.787 0.327 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.0 tt -58.67 125.27 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.4 t -91.91 53.93 2.31 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . -90.41 176.76 41.97 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.699 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.821 HD13 ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.803 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 146' ' ' VAL . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.503 ' HA ' HG23 ' A' ' 146' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.732 ' HB2' HG11 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.567 ' CE2' ' S1 ' ' A' ' 222' ' ' BTN . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' O ' HG23 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 93' ' ' ARG . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.467 ' HG2' ' HA ' ' A' ' 99' ' ' ALA . 65.9 Cg_endo -74.23 115.75 4.41 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.522 ' O ' ' N ' ' A' ' 98' ' ' ASP . 2.6 t -29.16 -60.78 0.23 Allowed Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.544 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 96' ' ' SER . 12.2 Cg_endo -56.05 74.02 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.853 2.369 . . . . 0.0 112.323 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 68.46 51.36 0.66 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.076 179.843 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.54 ' HB1' ' CA ' ' A' ' 94' ' ' THR . . . -54.06 98.59 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.89 0.376 . . . . 0.0 111.005 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.59 38.9 1.02 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.439 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.52 HG22 HG21 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.573 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.514 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 1.016 ' HG2' HG23 ' A' ' 135' ' ' VAL . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.836 HG13 ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.836 ' N ' HG13 ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.616 ' HB2' HG11 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 125' ' ' ASN . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.456 ' OE1' ' S1 ' ' A' ' 222' ' ' BTN . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.537 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.517 ' CE ' ' H62' ' A' ' 222' ' ' BTN . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.537 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.545 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.569 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 1.016 HG23 ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.625 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.617 ' CD1' HG22 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.755 HG21 HD23 ' A' ' 152' ' ' LEU . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 1.8 mt-30 -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.872 ' O ' HG13 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.803 HD11 ' HA ' ' A' ' 85' ' ' SER . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.617 HG22 ' CD1' ' A' ' 138' ' ' ILE . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.699 HD12 ' HB2' ' A' ' 81' ' ' HIS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.441 ' N ' HG22 ' A' ' 155' ' ' ILE . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.567 ' S1 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.755 0.312 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.415 ' CG1' ' H ' ' A' ' 80' ' ' GLY . 6.2 tt -126.61 126.57 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.14 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -98.69 7.28 46.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.061 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.439 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . 79.94 -132.36 11.29 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.449 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.667 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.144 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.655 ' HB2' HD11 ' A' ' 152' ' ' LEU . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 147' ' ' GLU . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.6 ' C ' HG22 ' A' ' 146' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.692 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.524 ' CD2' ' H61' ' A' ' 222' ' ' BTN . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.638 HG22 ' HA ' ' A' ' 101' ' ' ALA . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.521 ' HG3' ' CZ ' ' A' ' 102' ' ' PHE . 52.7 Cg_exo -54.92 -147.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.452 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.8 p -34.18 140.49 0.26 Allowed Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.961 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD3' ' H2 ' ' A' ' 222' ' ' BTN . 3.0 Cg_exo -36.52 -28.98 0.08 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.241 2.627 . . . . 0.0 112.271 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.452 ' N ' ' O ' ' A' ' 96' ' ' SER . 34.0 m-20 -122.65 60.42 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.807 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.406 ' CB ' ' HB2' ' A' ' 95' ' ' PRO . . . -107.54 -153.46 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.144 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.33 31.41 5.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.005 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.763 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.578 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.555 HG23 ' HG2' ' A' ' 107' ' ' GLN . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.763 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 137' ' ' ALA . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.448 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.555 ' HG2' HG23 ' A' ' 103' ' ' ILE . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.504 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.518 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.519 HG23 ' OE1' ' A' ' 126' ' ' GLN . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.578 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.507 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.472 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.767 ' O ' HG23 ' A' ' 118' ' ' VAL . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.519 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.592 ' O ' HG21 ' A' ' 155' ' ' ILE . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.518 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.651 HG22 ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.75 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.617 HD11 HG22 ' A' ' 153' ' ' VAL . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 139' ' ' LEU . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.645 HG21 HD23 ' A' ' 152' ' ' LEU . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.586 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 4.2 mt-30 -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.6 HG22 ' C ' ' A' ' 89' ' ' GLY . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.672 ' HA ' HG22 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.618 ' C ' HG23 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.692 HD22 ' CD1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.651 ' CG1' HG22 ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.144 HG12 HG23 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OXT' ' HA3' ' A' ' 80' ' ' GLY . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.524 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.82 0.343 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.3 tp -155.22 121.61 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.9 p -114.12 12.69 17.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 60.91 -103.27 0.5 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.568 ' NE2' HD12 ' A' ' 155' ' ' ILE . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.011 HG23 HG12 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.615 HG23 ' O ' ' A' ' 153' ' ' VAL . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.529 ' HB2' ' NH1' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.885 ' HA ' HD11 ' A' ' 152' ' ' LEU . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.453 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.461 ' CA ' HG23 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 140' ' ' VAL . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.513 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.527 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.535 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.758 ' HB2' HD12 ' A' ' 117' ' ' ILE . 31.3 Cg_exo -60.34 64.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 94' ' ' THR . 1.1 m 156.61 107.63 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.581 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.81 -21.38 2.47 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.642 2.228 . . . . 0.0 112.274 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.51 7.6 44.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.45 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -86.34 -148.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.932 179.91 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.668 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 3.3 ptmm? -151.94 -48.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.558 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG22 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.728 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.481 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.641 ' HD3' HG23 ' A' ' 134' ' ' THR . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 110' ' ' ASN . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.69 ' H ' HG22 ' A' ' 109' ' ' VAL . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.776 HG22 ' H ' ' A' ' 132' ' ' SER . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.558 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 95' ' ' PRO . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.433 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.677 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.593 ' CE ' ' HE1' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.677 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.593 ' HE1' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.524 ' O ' HG23 ' A' ' 118' ' ' VAL . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.548 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.776 ' H ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.618 ' HA3' HG12 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.641 HG23 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.81 ' CG2' HG22 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.518 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.728 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.667 HD13 ' CE2' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.575 HD22 ' HG2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 91' ' ' PHE . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.527 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 2.8 mt-30 -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.407 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.745 HG11 ' OG ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.575 ' HG2' HD22 ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.885 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.615 ' O ' HG23 ' A' ' 83' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.011 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.568 HD12 ' NE2' ' A' ' 81' ' ' HIS . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.421 ' N ' HG22 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.552 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' ILE . 8.3 pt-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.808 0.337 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 79' ' ' SER . 0.6 OUTLIER 34.77 -158.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.643 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.667 ' N ' HD12 ' A' ' 78' ' ' ILE . 1.5 m -93.46 58.88 2.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.985 -179.822 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -159.03 -165.25 15.71 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.382 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.606 ' CE1' ' HB3' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.041 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 153' ' ' VAL . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.027 ' HB3' HG11 ' A' ' 140' ' ' VAL . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.63 ' CE2' ' H2 ' ' A' ' 222' ' ' BTN . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.759 ' HB3' HD12 ' A' ' 117' ' ' ILE . 74.2 Cg_endo -76.07 50.44 2.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.867 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER 160.23 148.31 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.946 179.969 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.11 -19.75 12.63 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.771 2.314 . . . . 0.0 112.326 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -149.54 53.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.867 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -94.83 -169.43 2.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -109.49 24.79 12.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.988 -179.949 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.522 ' HB1' ' CG ' ' A' ' 104' ' ' GLU . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.851 ' CE1' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 103' ' ' ILE . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.522 ' CG ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.927 ' HE2' HG22 ' A' ' 135' ' ' VAL . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.851 HG21 ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.65 HD23 ' SG ' ' A' ' 116' ' ' CYS . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.65 ' SG ' HD23 ' A' ' 115' ' ' LEU . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 95' ' ' PRO . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.731 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.731 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.542 HG22 ' N ' ' A' ' 128' ' ' GLU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.542 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.716 ' C ' HG22 ' A' ' 111' ' ' VAL . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.715 ' HB2' HD13 ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.771 ' HB2' HG23 ' A' ' 111' ' ' VAL . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.9 ' O ' HG23 ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.927 HG22 ' HE2' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.576 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.566 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.842 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.027 HG11 ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 142' ' ' SER . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.457 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.497 HG13 ' HB2' ' A' ' 150' ' ' GLU . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.497 ' HB2' HG13 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.842 ' HG2' HD22 ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.622 HD22 ' CD2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.747 HG12 HG13 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.041 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.9 HG23 ' O ' ' A' ' 134' ' ' THR . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.63 ' H2 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.806 0.336 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.571 ' C ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -112.62 136.32 49.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.069 -179.898 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.64 88.63 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 162.28 154.29 7.49 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.552 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.775 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.995 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 153' ' ' VAL . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' SER . . . . . 1.006 ' OG ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.555 HG22 ' HA2' ' A' ' 143' ' ' GLY . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.587 HG23 ' O ' ' A' ' 93' ' ' ARG . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo -76.02 52.05 3.31 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.771 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER 168.15 124.53 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.999 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.71 -21.35 2.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.753 2.302 . . . . 0.0 112.38 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 39.8 p30 -128.46 28.02 5.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.771 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -80.82 -170.1 2.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.185 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -95.76 -85.89 0.32 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.876 HG22 HG21 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.639 ' NE2' HD13 ' A' ' 103' ' ' ILE . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.628 HG13 HD12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.549 HD13 ' HN1' ' A' ' 222' ' ' BTN . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.494 HG12 ' HA3' ' A' ' 89' ' ' GLY . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.628 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.452 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.413 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.554 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.504 ' HB3' HG13 ' A' ' 117' ' ' ILE . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.508 ' C ' HG23 ' A' ' 155' ' ' ILE . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.876 HG21 HG22 ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.425 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CD1' HG22 ' A' ' 153' ' ' VAL . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.64 HD23 ' HB2' ' A' ' 151' ' ' PRO . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.712 HG11 HG22 ' A' ' 146' ' ' VAL . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.59 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.555 ' HA2' HG22 ' A' ' 90' ' ' THR . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.546 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.712 HG22 HG11 ' A' ' 140' ' ' VAL . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.448 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.552 ' CD ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.64 ' HB2' HD23 ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.006 HD11 ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.637 HG22 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.995 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.508 HG23 ' C ' ' A' ' 134' ' ' THR . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 222' ' ' BTN . . . . . 0.593 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.414 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.624 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.028 HG23 HG12 ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.444 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.99 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.444 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.417 ' O ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.833 ' HE2' HD13 ' A' ' 138' ' ' ILE . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.681 HG22 ' HA ' ' A' ' 101' ' ' ALA . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo . . . . . 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.88 0.371 . . . . 0.0 110.775 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.681 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.639 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.87 HG22 HG21 ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.489 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.5 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.5 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.525 HG11 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.526 HG23 ' NE2' ' A' ' 126' ' ' GLN . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.639 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.569 HG23 ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.41 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.605 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.605 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.533 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.445 ' N ' HG22 ' A' ' 127' ' ' ILE . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.87 HG21 HG22 ' A' ' 103' ' ' ILE . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.429 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.53 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.833 HD13 ' HE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 91' ' ' PHE . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.498 ' H ' HG22 ' A' ' 138' ' ' ILE . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.495 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.482 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.905 ' O ' HG13 ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.99 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.464 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.501 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.676 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.76 HG12 HG13 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.028 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.624 HD13 ' HD2' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.429 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.415 -0.274 . . . . 0.0 112.415 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.887 ' NE2' HD13 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' HD21 ' A' ' 152' ' ' LEU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.756 ' HB2' HG11 ' A' ' 140' ' ' VAL . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.893 ' HB3' HD12 ' A' ' 117' ' ' ILE . 69.7 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.707 0.289 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.743 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.738 ' HE2' HD12 ' A' ' 117' ' ' ILE . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.754 HG23 ' HG2' ' A' ' 107' ' ' GLN . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.743 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.747 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.754 ' HG2' HG23 ' A' ' 103' ' ' ILE . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.73 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 130' ' ' ASP . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.584 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.893 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.722 ' HB3' ' HE3' ' A' ' 123' ' ' MET . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.422 ' HG3' ' O ' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.722 ' HE3' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.644 ' HB2' ' HE2' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.584 HG22 ' N ' ' A' ' 128' ' ' GLU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.634 ' O ' HG22 ' A' ' 111' ' ' VAL . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.484 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.607 HG21 HG22 ' A' ' 103' ' ' ILE . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.694 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.747 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.799 ' C ' HD23 ' A' ' 139' ' ' LEU . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.799 HD23 ' C ' ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.791 HG21 HD23 ' A' ' 152' ' ' LEU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 152' ' ' LEU . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.491 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.718 ' HG2' HD12 ' A' ' 139' ' ' LEU . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.791 HD23 HG21 ' A' ' 140' ' ' VAL . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.887 HD13 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.483 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.409 ' HA3' ' C ' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.54 -0.224 . . . . 0.0 112.54 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.656 ' NE2' HD12 ' A' ' 155' ' ' ILE . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.908 HG23 HG12 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.424 ' HB2' HG11 ' A' ' 146' ' ' VAL . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.695 HG13 ' O ' ' A' ' 146' ' ' VAL . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.678 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' O ' ' CE1' ' A' ' 91' ' ' PHE . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.609 HG22 ' HA ' ' A' ' 101' ' ' ALA . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.906 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.2 Cg_endo . . . . . 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.859 0.361 . . . . 0.0 110.902 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.905 HG22 HG21 ' A' ' 135' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.445 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.772 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 115' ' ' LEU . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 114' ' ' THR . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.906 HD12 ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.477 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.836 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.444 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.836 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.822 ' O ' HG23 ' A' ' 118' ' ' VAL . 5.8 t30 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.488 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.616 HD11 HG21 ' A' ' 118' ' ' VAL . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB2' HG11 ' A' ' 109' ' ' VAL . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.511 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.905 HG21 HG22 ' A' ' 103' ' ' ILE . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.62 ' HB2' HG23 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 152' ' ' LEU . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.66 HD22 ' N ' ' A' ' 139' ' ' LEU . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.619 HG11 ' HB2' ' A' ' 91' ' ' PHE . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' HB2' ' A' ' 144' ' ' GLN . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.562 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.476 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.695 ' O ' HG13 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.558 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 139' ' ' LEU . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.689 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.545 HG12 HG13 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.908 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.656 HD12 ' NE2' ' A' ' 81' ' ' HIS . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.423 ' HG3' ' CG ' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.565 -0.214 . . . . 0.0 112.565 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.739 HG23 HD11 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.661 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.591 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.591 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.721 ' HB2' HG11 ' A' ' 140' ' ' VAL . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 91' ' ' PHE . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.51 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.764 ' HB3' HD12 ' A' ' 117' ' ' ILE . 54.0 Cg_endo . . . . . 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.58 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.671 HG21 ' HE2' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.466 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.915 ' O ' HG13 ' A' ' 109' ' ' VAL . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 132' ' ' SER . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.764 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.455 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.696 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.428 ' CD ' ' HE3' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.696 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.719 ' C ' HG22 ' A' ' 111' ' ' VAL . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.549 ' HE3' HG22 ' A' ' 83' ' ' VAL . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.787 ' HB3' HG23 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.57 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.814 HG23 ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.454 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.641 HD13 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.468 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.823 HG21 HD23 ' A' ' 152' ' ' LEU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.51 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.423 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.823 HD23 HG21 ' A' ' 140' ' ' VAL . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.576 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.739 HD11 HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.519 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB2' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.757 HG23 HG12 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.552 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.476 ' CB ' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.814 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.435 ' C ' ' HB2' ' A' ' 142' ' ' SER . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.458 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.55 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo . . . . . 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.5 pptp? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.709 0.29 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.61 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.655 HG22 HG21 ' A' ' 135' ' ' VAL . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.475 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.889 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.619 ' HG2' HG23 ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.57 ' HA ' ' CE2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.61 HD12 ' HE2' ' A' ' 102' ' ' PHE . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.476 ' OE1' ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.407 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.563 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.415 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.572 ' HE2' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.441 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.515 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.435 ' N ' HG22 ' A' ' 127' ' ' ILE . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.655 HG21 HG22 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.798 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.889 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.796 HD13 ' HE2' ' A' ' 91' ' ' PHE . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.713 HD23 ' N ' ' A' ' 139' ' ' LEU . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.79 HG21 HD23 ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.57 ' H ' HG22 ' A' ' 138' ' ' ILE . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.505 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.607 HG12 HG11 ' A' ' 140' ' ' VAL . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HG22 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.597 ' HG2' HD12 ' A' ' 139' ' ' LEU . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.814 HD22 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' HG13 ' A' ' 135' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.757 HG12 HG23 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.454 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.485 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.357 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.558 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.753 HG23 HG12 ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.805 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.43 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 146' ' ' VAL . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.603 ' N ' HG23 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.772 ' HB2' HG11 ' A' ' 140' ' ' VAL . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 72.0 Cg_endo . . . . . 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 11.2 mtpt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.875 0.369 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.612 HD13 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.538 ' OE1' HD12 ' A' ' 138' ' ' ILE . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.467 HG22 ' HA ' ' A' ' 137' ' ' ALA . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.462 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.59 HG11 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' HA ' ' A' ' 130' ' ' ASP . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.59 ' CB ' HG11 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.416 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.489 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.763 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.763 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.439 ' O ' ' N ' ' A' ' 126' ' ' GLN . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.859 ' O ' HG23 ' A' ' 118' ' ' VAL . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.453 ' O ' ' N ' ' A' ' 130' ' ' ASP . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.641 ' HA ' HG13 ' A' ' 111' ' ' VAL . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.47 HG22 ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.939 HG13 HG12 ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.547 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.663 HG12 HG13 ' A' ' 153' ' ' VAL . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.546 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.804 HG21 HD23 ' A' ' 152' ' ' LEU . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 88' ' ' VAL . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.487 ' HB3' HG22 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.546 ' HG2' HD22 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.805 HD11 ' HA ' ' A' ' 85' ' ' SER . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.939 HG12 HG13 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.753 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.558 HD13 ' HD2' ' A' ' 81' ' ' HIS . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.845 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.745 HG23 HG12 ' A' ' 154' ' ' VAL . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.478 ' O ' HD12 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.545 ' HA ' HD21 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.588 HG22 ' HA ' ' A' ' 147' ' ' GLU . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.581 ' N ' HG23 ' A' ' 146' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.457 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CZ ' HD13 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.537 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.46 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo . . . . . 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.882 0.372 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.733 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.527 HG21 ' HD3' ' A' ' 108' ' ' LYS . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.537 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.555 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.903 ' CG ' HG23 ' A' ' 135' ' ' VAL . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.502 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.481 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.545 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.733 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 125' ' ' ASN . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.473 ' H ' HG22 ' A' ' 117' ' ' ILE . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.614 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.614 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.509 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.467 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.517 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.662 ' O ' HD13 ' A' ' 155' ' ' ILE . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.502 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.541 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.903 HG23 ' CG ' ' A' ' 108' ' ' LYS . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.44 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.49 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.642 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 1.003 HD12 ' CG ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.512 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 3.2 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.581 HG23 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.588 ' HA ' HG22 ' A' ' 88' ' ' VAL . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.478 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 1.003 ' CG ' HD12 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.545 HD21 ' HA ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 HG13 ' A' ' 135' ' ' VAL . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.745 HG12 HG23 ' A' ' 82' ' ' ILE . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.845 HD12 ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.44 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.62 -0.192 . . . . 0.0 112.62 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.837 HG23 HG12 ' A' ' 154' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.443 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.502 ' CB ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.637 HG22 ' HA ' ' A' ' 147' ' ' GLU . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.571 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.835 ' CD1' HD22 ' A' ' 152' ' ' LEU . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.494 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.472 ' HD2' ' OG1' ' A' ' 94' ' ' THR . 89.1 Cg_endo . . . . . 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm . . . . . 0 N--CA 1.456 -0.158 0 CA-C-O 121.067 0.46 . . . . 0.0 109.958 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.494 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 1.018 ' CG2' HG12 ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.667 HG13 ' HA ' ' A' ' 137' ' ' ALA . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 1.018 HG12 ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.658 ' O ' HD11 ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.443 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.514 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.506 ' CG ' ' O ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.436 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.555 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.89 ' O ' HG23 ' A' ' 118' ' ' VAL . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.512 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.512 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.864 HG23 ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.659 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.749 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 152' ' ' LEU . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.796 HG21 HD23 ' A' ' 152' ' ' LEU . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.582 HG22 ' N ' ' A' ' 147' ' ' GLU . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.637 ' HA ' HG22 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.449 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.835 HD22 ' CD1' ' A' ' 91' ' ' PHE . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.468 HG22 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.837 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.557 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.404 ' HG2' ' OXT' ' A' ' 156' ' ' GLU . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.929 ' NE2' HD13 ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.06 HG23 HG12 ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.749 HG22 ' HA ' ' A' ' 147' ' ' GLU . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.539 ' CD1' HD22 ' A' ' 152' ' ' LEU . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.65 HG22 ' HA ' ' A' ' 101' ' ' ALA . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo . . . . . 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.863 0.363 . . . . 0.0 110.912 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.885 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.599 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 1.033 HG21 HG13 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.885 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.743 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.578 ' HG2' HG23 ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 1.033 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.803 HG23 ' OG ' ' A' ' 132' ' ' SER . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.587 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.55 HG13 ' HB3' ' A' ' 126' ' ' GLN . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.526 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.762 ' HB3' ' HE2' ' A' ' 123' ' ' MET . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.431 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.762 ' HE2' ' HB3' ' A' ' 120' ' ' ALA . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.486 ' SD ' ' HG2' ' A' ' 119' ' ' GLU . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.723 ' O ' HG23 ' A' ' 118' ' ' VAL . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.55 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.562 HG22 ' N ' ' A' ' 128' ' ' GLU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.562 ' N ' HG22 ' A' ' 127' ' ' ILE . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.803 ' OG ' HG23 ' A' ' 111' ' ' VAL . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.61 ' C ' HG23 ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.663 HG13 HG12 ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' HG13 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.743 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.576 HG23 ' O ' ' A' ' 152' ' ' LEU . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.579 HG23 ' C ' ' A' ' 151' ' ' PRO . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 140' ' ' VAL . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.789 HG22 ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.749 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.574 ' OE1' HG22 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.579 ' C ' HG23 ' A' ' 140' ' ' VAL . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.576 ' O ' HG23 ' A' ' 138' ' ' ILE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.663 HG12 HG13 ' A' ' 135' ' ' VAL . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.06 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.929 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.544 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.979 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.554 ' OG ' HD21 ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.446 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.471 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.899 HG23 ' HB2' ' A' ' 148' ' ' PHE . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.834 ' CD1' HD22 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.576 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.533 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.55 ' CG2' ' HB2' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo . . . . . 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.842 0.353 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB2' ' CG2' ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.762 ' HE2' HD12 ' A' ' 117' ' ' ILE . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.688 HG21 ' CG1' ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.688 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.475 HG23 ' OG ' ' A' ' 132' ' ' SER . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.527 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.762 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.496 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.462 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.54 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.54 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 3.5 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 109' ' ' VAL . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.475 ' OG ' HG23 ' A' ' 111' ' ' VAL . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.475 ' C ' HG23 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.685 HG13 HG12 ' A' ' 153' ' ' VAL . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.639 ' HB3' HG23 ' A' ' 154' ' ' VAL . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.683 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 152' ' ' LEU . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.906 HG21 HD23 ' A' ' 152' ' ' LEU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.533 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.661 ' HA ' HG13 ' A' ' 88' ' ' VAL . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.576 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.899 ' HB2' HG23 ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.746 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 140' ' ' VAL . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.906 HD23 HG21 ' A' ' 140' ' ' VAL . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.685 HG12 HG13 ' A' ' 135' ' ' VAL . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.979 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.456 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.562 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 151' ' ' PRO . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.539 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.518 ' HA ' HG23 ' A' ' 146' ' ' VAL . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.742 ' HE2' HD13 ' A' ' 138' ' ' ILE . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.787 ' HD2' HD12 ' A' ' 138' ' ' ILE . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.471 ' HG3' ' CD2' ' A' ' 102' ' ' PHE . 52.2 Cg_exo . . . . . 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.643 ' HB1' ' CD ' ' A' ' 104' ' ' GLU . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.716 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 135' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.643 ' CD ' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.514 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.527 HG11 HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.2 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.716 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.645 ' H ' HG22 ' A' ' 114' ' ' THR . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 124' ' ' MET . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.962 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.424 ' C ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.454 ' HG3' ' O ' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.501 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.489 ' HE3' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.562 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.962 ' O ' HG23 ' A' ' 118' ' ' VAL . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.501 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.544 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.552 HG13 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.717 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.77 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.787 HD12 ' HD2' ' A' ' 93' ' ' ARG . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.493 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.799 HG22 ' CG ' ' A' ' 150' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.518 HG23 ' HA ' ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.799 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.714 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.539 HD11 ' HA ' ' A' ' 85' ' ' SER . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.8 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.553 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.535 -0.226 . . . . 0.0 112.535 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.765 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.869 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.555 ' OG ' HG21 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.58 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.726 HG23 ' N ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.797 ' CD1' HD22 ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.702 HG22 ' HA ' ' A' ' 101' ' ' ALA . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 94' ' ' THR . 39.4 Cg_exo . . . . . 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 7.1 ttpt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.842 0.353 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.702 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.91 HG22 HG21 ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.768 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.72 HE21 HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.517 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.894 HG23 ' HB2' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.488 ' HB3' HG23 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.77 HG23 ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.713 HD23 ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.511 ' N ' HG22 ' A' ' 117' ' ' ILE . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.534 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.408 ' CA ' ' HE2' ' A' ' 122' ' ' LYS . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.606 ' HE3' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.606 ' ND2' ' HE3' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.77 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.713 ' HB ' HD23 ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.465 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.651 ' HA ' HG13 ' A' ' 111' ' ' VAL . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.716 ' N ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.894 ' HB2' HG23 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.748 ' O ' HG23 ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.91 HG21 HG22 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.635 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.768 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.639 HG23 ' O ' ' A' ' 152' ' ' LEU . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.747 HG23 ' C ' ' A' ' 151' ' ' PRO . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 140' ' ' VAL . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.611 ' C ' HG23 ' A' ' 90' ' ' THR . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.726 ' N ' HG23 ' A' ' 90' ' ' THR . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.555 HG21 ' OG ' ' A' ' 85' ' ' SER . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.439 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.519 ' HG3' HG22 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.747 ' C ' HG23 ' A' ' 140' ' ' VAL . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.797 HD22 ' CD1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.621 HG22 HD11 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.869 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.765 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.41 ' HA ' ' HA3' ' A' ' 80' ' ' GLY . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 1.001 ' CE1' HD12 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.839 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.503 ' CB ' HG11 ' A' ' 146' ' ' VAL . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.562 HG12 ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.562 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.968 ' HB3' HG11 ' A' ' 140' ' ' VAL . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.478 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.874 HG22 ' HB2' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.589 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.1 Cg_endo . . . . . 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.844 0.354 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.874 ' HB2' HG22 ' A' ' 94' ' ' THR . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.605 ' C ' HD12 ' A' ' 103' ' ' ILE . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.731 HD13 ' C ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.529 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.446 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.54 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 110' ' ' ASN . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.523 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.731 ' C ' HD13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.527 HD21 ' CG2' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.594 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.589 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.672 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.672 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.945 ' O ' HG23 ' A' ' 118' ' ' VAL . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.447 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB2' ' HE3' ' A' ' 108' ' ' LYS . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.523 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.54 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.532 HG23 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.531 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.61 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.893 HG23 ' O ' ' A' ' 152' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.528 ' CG ' ' HB2' ' A' ' 151' ' ' PRO . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.968 HG11 ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.478 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.565 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.53 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.503 HG11 ' CB ' ' A' ' 85' ' ' SER . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.528 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.893 ' O ' HG23 ' A' ' 138' ' ' ILE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.878 HG13 ' CG1' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.839 HG12 HG23 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 1.001 HD12 ' CE1' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.544 -0.223 . . . . 0.0 112.544 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.743 ' HE1' HG22 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.046 HG23 HG12 ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.743 HG22 ' HE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.704 ' OG ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.614 ' O ' HG23 ' A' ' 88' ' ' VAL . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 89' ' ' GLY . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.683 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.823 ' HB2' HG11 ' A' ' 146' ' ' VAL . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.492 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.489 ' CB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.585 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 72.4 Cg_endo . . . . . 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.059 0.457 . . . . 0.0 110.21 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.572 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.411 HG22 ' HA ' ' A' ' 137' ' ' ALA . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.479 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.492 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 1.022 HG22 ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.538 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.52 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.54 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.555 HG13 ' CG1' ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.401 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.661 ' HE3' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.511 ' HA ' HG23 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.661 ' OD1' ' HE3' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.506 ' HB3' HG13 ' A' ' 117' ' ' ILE . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.579 HG22 ' N ' ' A' ' 128' ' ' GLU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.579 ' N ' HG22 ' A' ' 127' ' ' ILE . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 1.022 ' O ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.492 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.654 HG13 HG12 ' A' ' 153' ' ' VAL . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.713 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.544 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.608 HG11 ' CB ' ' A' ' 91' ' ' PHE . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.48 ' OG ' ' HA ' ' A' ' 92' ' ' TYR . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.471 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.869 HG23 ' CB ' ' A' ' 150' ' ' GLU . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.869 ' CB ' HG23 ' A' ' 146' ' ' VAL . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.544 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.654 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.046 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 1.005 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.78 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.585 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 147' ' ' GLU . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.457 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.612 ' CE2' HD13 ' A' ' 138' ' ' ILE . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.611 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo . . . . . 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.9 mmtm . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.905 0.383 . . . . 0.0 110.765 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.899 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.899 HD13 ' O ' ' A' ' 102' ' ' PHE . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 135' ' ' VAL . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.871 ' O ' HG23 ' A' ' 134' ' ' THR . 37.1 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.45 ' HD2' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.451 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.615 HG23 ' HB2' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.501 HG13 ' HB3' ' A' ' 126' ' ' GLN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.927 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.812 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.812 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.927 ' O ' HG23 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.513 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.615 ' HB2' HG23 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.871 HG23 ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.708 HG13 HG12 ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.483 ' HA ' HG11 ' A' ' 105' ' ' VAL . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.612 HD13 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.855 HG11 HG12 ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.855 HG12 HG11 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.472 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.585 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.708 HG12 HG13 ' A' ' 135' ' ' VAL . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.78 HG12 HG23 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 1.005 HD13 ' NE2' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.214 0 N-CA-C 112.773 -0.131 . . . . 0.0 112.773 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 1.088 ' ND1' HD12 ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 154' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.828 HG22 ' HE1' ' A' ' 81' ' ' HIS . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.516 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.871 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.621 ' H ' HG13 ' A' ' 146' ' ' VAL . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.486 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 35.2 Cg_endo . . . . . 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.901 0.381 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG21 HG21 ' A' ' 109' ' ' VAL . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.504 HG22 ' HA ' ' A' ' 137' ' ' ALA . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.461 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.48 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.81 HG21 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.753 HG22 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.562 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.57 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.981 HG23 ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.469 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.457 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.475 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HE2' ' HE1' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.57 ' HA ' HG23 ' A' ' 117' ' ' ILE . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.981 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.495 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.753 ' HA ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.778 ' HA ' HD13 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.683 HG13 HG12 ' A' ' 153' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.553 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.551 ' O ' HD13 ' A' ' 139' ' ' LEU . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.617 HG11 ' CB ' ' A' ' 91' ' ' PHE . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.553 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.621 HG13 ' H ' ' A' ' 91' ' ' PHE . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.469 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.483 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.582 HD23 HG21 ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.683 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 1.088 HD12 ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.424 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.441 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.74 HG23 HG12 ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.705 ' OG ' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 146' ' ' VAL . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.492 ' HA3' ' HA ' ' A' ' 120' ' ' ALA . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.819 ' HE2' HD13 ' A' ' 138' ' ' ILE . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.627 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.566 HG22 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.412 ' HB3' ' CZ ' ' A' ' 102' ' ' PHE . 58.7 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.85 0.357 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.566 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 1.05 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.759 ' O ' HG22 ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.509 HG23 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.435 ' C ' ' HG2' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.538 ' HD3' HG23 ' A' ' 134' ' ' THR . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.506 ' H ' HG12 ' A' ' 109' ' ' VAL . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' A' ' 130' ' ' ASP . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 1.05 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.543 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.559 HG23 ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.507 ' H ' HG22 ' A' ' 117' ' ' ILE . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.492 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.699 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.699 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 0.8 OUTLIER -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.543 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' HA ' HG13 ' A' ' 111' ' ' VAL . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.457 ' HG ' HG21 ' A' ' 155' ' ' ILE . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.538 HG23 ' HD3' ' A' ' 108' ' ' LYS . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.422 HG13 HG12 ' A' ' 153' ' ' VAL . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.819 HD13 ' HE2' ' A' ' 91' ' ' PHE . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.496 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.929 HG21 HD23 ' A' ' 152' ' ' LEU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.495 ' HB2' ' HD3' ' A' ' 93' ' ' ARG . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.736 HG12 HG11 ' A' ' 140' ' ' VAL . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.611 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.929 HD23 HG21 ' A' ' 140' ' ' VAL . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.422 HG12 HG13 ' A' ' 135' ' ' VAL . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.74 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 156' ' ' GLU . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.552 ' N ' HG22 ' A' ' 155' ' ' ILE . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.933 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 81' ' ' HIS . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' ' CG1' ' A' ' 146' ' ' VAL . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.909 HG13 ' O ' ' A' ' 146' ' ' VAL . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.679 ' CE2' HD13 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.46 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.723 HG22 ' HA ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.41 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 51.8 Cg_endo . . . . . 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.723 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.526 ' CE2' HD12 ' A' ' 117' ' ' ILE . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.94 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 106' ' ' GLY . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 27.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.473 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.94 ' CG1' HG21 ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.706 HD22 HG21 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.527 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.401 ' N ' HG22 ' A' ' 117' ' ' ILE . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.535 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.439 ' HG3' ' O ' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.655 ' HE2' ' HE3' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.535 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.655 ' HE3' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.56 ' HB3' HG23 ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.527 ' CB ' HG13 ' A' ' 117' ' ' ILE . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.706 HG21 HD22 ' A' ' 115' ' ' LEU . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.564 ' C ' HG23 ' A' ' 155' ' ' ILE . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.546 ' HB3' HG23 ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.679 HD13 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.528 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.909 ' O ' HG13 ' A' ' 88' ' ' VAL . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.565 ' N ' HG12 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.883 ' HB3' HG22 ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.652 ' O ' HG23 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.731 HD23 HG21 ' A' ' 140' ' ' VAL . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.906 HD12 ' HB2' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 136' ' ' LYS . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.699 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.821 HD13 ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.803 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 146' ' ' VAL . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.503 ' HA ' HG23 ' A' ' 146' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.732 ' HB2' HG11 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.451 ' O ' ' SG ' ' A' ' 116' ' ' CYS . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' O ' HG23 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 93' ' ' ARG . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo . . . . . 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.788 0.328 . . . . 0.0 110.886 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.439 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.52 HG22 HG21 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.573 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.514 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 1.016 ' HG2' HG23 ' A' ' 135' ' ' VAL . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.836 HG13 ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.836 ' N ' HG13 ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.616 ' HB2' HG11 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 125' ' ' ASN . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.446 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.537 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.517 ' HA ' HG23 ' A' ' 117' ' ' ILE . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.537 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.545 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.569 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 1.016 HG23 ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.625 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.617 ' CD1' HG22 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.755 HG21 HD23 ' A' ' 152' ' ' LEU . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.872 ' O ' HG13 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.803 HD11 ' HA ' ' A' ' 85' ' ' SER . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.617 HG22 ' CD1' ' A' ' 138' ' ' ILE . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.699 HD12 ' HB2' ' A' ' 81' ' ' HIS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.441 ' N ' HG22 ' A' ' 155' ' ' ILE . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.439 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.667 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.144 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.655 ' HB2' HD11 ' A' ' 152' ' ' LEU . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 147' ' ' GLU . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.6 ' C ' HG22 ' A' ' 146' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.692 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.638 HG22 ' HA ' ' A' ' 101' ' ' ALA . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.521 ' HG3' ' CZ ' ' A' ' 102' ' ' PHE . 52.7 Cg_exo . . . . . 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.081 0 CA-C-O 120.849 0.357 . . . . 0.0 111.005 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.763 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.578 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.555 HG23 ' HG2' ' A' ' 107' ' ' GLN . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.763 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 137' ' ' ALA . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.448 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.555 ' HG2' HG23 ' A' ' 103' ' ' ILE . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.504 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.518 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.519 HG23 ' OE1' ' A' ' 126' ' ' GLN . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.578 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.507 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.472 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.767 ' O ' HG23 ' A' ' 118' ' ' VAL . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.519 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.592 ' O ' HG21 ' A' ' 155' ' ' ILE . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.518 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.651 HG22 ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.75 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.617 HD11 HG22 ' A' ' 153' ' ' VAL . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 139' ' ' LEU . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.645 HG21 HD23 ' A' ' 152' ' ' LEU . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.586 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.6 HG22 ' C ' ' A' ' 89' ' ' GLY . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.672 ' HA ' HG22 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.618 ' C ' HG23 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.692 HD22 ' CD1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.651 ' CG1' HG22 ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.144 HG12 HG23 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OXT' ' HA3' ' A' ' 80' ' ' GLY . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.568 ' NE2' HD12 ' A' ' 155' ' ' ILE . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.011 HG23 HG12 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.615 HG23 ' O ' ' A' ' 153' ' ' VAL . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.529 ' HB2' ' NH1' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.885 ' HA ' HD11 ' A' ' 152' ' ' LEU . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.453 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.461 ' CA ' HG23 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 140' ' ' VAL . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.513 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.527 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.535 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.758 ' HB2' HD12 ' A' ' 117' ' ' ILE . 31.3 Cg_exo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.668 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 3.3 ptmm? . . . . . 0 CA--C 1.523 -0.06 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.558 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.81 HG22 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.728 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.481 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.641 ' HD3' HG23 ' A' ' 134' ' ' THR . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 110' ' ' ASN . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.69 ' H ' HG22 ' A' ' 109' ' ' VAL . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.776 HG22 ' H ' ' A' ' 132' ' ' SER . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.558 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 95' ' ' PRO . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.433 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.677 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.593 ' CE ' ' HE1' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.677 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.593 ' HE1' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.524 ' O ' HG23 ' A' ' 118' ' ' VAL . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.548 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.776 ' H ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.618 ' HA3' HG12 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.641 HG23 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.81 ' CG2' HG22 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.518 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.728 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.667 HD13 ' CE2' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.575 HD22 ' HG2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 91' ' ' PHE . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.527 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.407 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.745 HG11 ' OG ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.575 ' HG2' HD22 ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.885 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.615 ' O ' HG23 ' A' ' 83' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.011 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.568 HD12 ' NE2' ' A' ' 81' ' ' HIS . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.421 ' N ' HG22 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.452 0 N-CA-C 112.382 -0.287 . . . . 0.0 112.382 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.565 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.041 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 153' ' ' VAL . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.027 ' HB3' HG11 ' A' ' 140' ' ' VAL . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.759 ' HB3' HD12 ' A' ' 117' ' ' ILE . 74.2 Cg_endo . . . . . 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.04 0 CA-C-O 120.773 0.32 . . . . 0.0 110.988 . . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.522 ' HB1' ' CG ' ' A' ' 104' ' ' GLU . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.851 ' CE1' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 103' ' ' ILE . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.522 ' CG ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.927 ' HE2' HG22 ' A' ' 135' ' ' VAL . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.851 HG21 ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.65 HD23 ' SG ' ' A' ' 116' ' ' CYS . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.65 ' SG ' HD23 ' A' ' 115' ' ' LEU . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 95' ' ' PRO . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.731 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.731 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.542 HG22 ' N ' ' A' ' 128' ' ' GLU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.542 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.716 ' C ' HG22 ' A' ' 111' ' ' VAL . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.715 ' HB2' HD13 ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.771 ' HB2' HG23 ' A' ' 111' ' ' VAL . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.9 ' O ' HG23 ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.927 HG22 ' HE2' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.576 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.566 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.842 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.027 HG11 ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 142' ' ' SER . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.457 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.497 HG13 ' HB2' ' A' ' 150' ' ' GLU . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.497 ' HB2' HG13 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.842 ' HG2' HD22 ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.622 HD22 ' CD2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.747 HG12 HG13 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.041 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.9 HG23 ' O ' ' A' ' 134' ' ' THR . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.775 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.995 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 153' ' ' VAL . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 1.006 ' OG ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.555 HG22 ' HA2' ' A' ' 143' ' ' GLY . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.587 HG23 ' O ' ' A' ' 93' ' ' ARG . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo . . . . . 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.823 0.344 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.876 HG22 HG21 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.639 ' NE2' HD13 ' A' ' 103' ' ' ILE . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.628 HG13 HD12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.504 HG13 ' HB3' ' A' ' 126' ' ' GLN . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.494 HG12 ' HA3' ' A' ' 89' ' ' GLY . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.628 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.452 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.413 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.554 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.504 ' HB3' HG13 ' A' ' 117' ' ' ILE . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.508 ' C ' HG23 ' A' ' 155' ' ' ILE . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.876 HG21 HG22 ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.425 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CD1' HG22 ' A' ' 153' ' ' VAL . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.64 HD23 ' HB2' ' A' ' 151' ' ' PRO . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.712 HG11 HG22 ' A' ' 146' ' ' VAL . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.59 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.555 ' HA2' HG22 ' A' ' 90' ' ' THR . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.546 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.712 HG22 HG11 ' A' ' 140' ' ' VAL . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.448 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.552 ' CD ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.64 ' HB2' HD23 ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.006 HD11 ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.637 HG22 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.995 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.508 HG23 ' C ' ' A' ' 134' ' ' THR . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.416 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.776 0.322 . . . . 0.0 110.949 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.1 pt -70.07 153.49 8.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.196 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.58 33.76 3.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.95 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.42 -129.7 9.23 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.605 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.624 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -136.83 135.29 37.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.028 HG23 HG12 ' A' ' 154' ' ' VAL . 2.4 mt -115.85 130.27 70.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 6.6 t -100.74 110.31 27.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.063 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -95.73 132.5 40.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.961 -179.962 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.444 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -52.12 128.84 39.67 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.918 -179.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.67 -23.81 10.81 Favored 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.829 2.352 . . . . 0.0 112.303 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.15 -166.58 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.116 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.99 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.8 t -108.12 141.63 22.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.135 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.444 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . -173.7 -121.99 0.65 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.495 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.417 ' O ' ' O ' ' A' ' 118' ' ' VAL . 32.6 m -151.75 108.57 3.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.77 0.319 . . . . 0.0 110.85 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.833 ' HE2' HD13 ' A' ' 138' ' ' ILE . 13.1 t80 -65.15 167.38 8.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.569 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 6.3 m-85 -167.53 161.22 13.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 0.1 OUTLIER -120.36 -25.37 5.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.916 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.681 HG22 ' HA ' ' A' ' 101' ' ' ALA . 2.7 p -136.59 92.51 14.98 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.025 -179.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.611 ' CG ' ' CE2' ' A' ' 102' ' ' PHE . 36.3 Cg_exo -56.31 -138.79 0.0 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.531 2.154 . . . . 0.0 111.376 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.539 ' N ' ' H62' ' A' ' 222' ' ' BTN . 0.9 OUTLIER -29.96 105.01 0.21 Allowed Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.92 0.391 . . . . 0.0 110.669 179.845 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -31.48 -31.15 0.03 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.315 2.677 . . . . 0.0 112.942 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' SER . 12.8 m-20 -95.77 42.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.542 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.451 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -110.49 -161.81 0.77 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.3 OUTLIER -122.09 30.35 6.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.775 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.681 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 59.31 137.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.176 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.639 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.4 OUTLIER -73.67 -167.68 0.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.807 179.937 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.87 HG22 HG21 ' A' ' 135' ' ' VAL . 8.9 mm -68.37 91.98 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -88.79 -176.06 5.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.951 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 137' ' ' ALA . 41.0 t -57.73 157.79 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.489 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 55.74 16.89 12.94 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.454 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.5 ' HG3' ' N ' ' A' ' 108' ' ' LYS . 35.6 tp60 -92.93 162.33 14.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 0.0 110.656 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.5 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 125.39 52.5 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.8 0.333 . . . . 0.0 110.913 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.525 HG11 HG13 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -130.61 141.24 46.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.046 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.407 ' O ' ' C ' ' A' ' 111' ' ' VAL . 4.0 p-10 -123.2 142.38 50.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 78.3 t -37.31 104.89 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.134 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.71 -5.0 9.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -92.71 157.62 16.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.85 0.357 . . . . 0.0 110.976 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.526 HG23 ' NE2' ' A' ' 126' ' ' GLN . 0.2 OUTLIER -66.8 169.43 8.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.859 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -135.52 -72.79 0.46 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -176.16 164.99 2.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.998 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.639 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.2 mt -102.76 148.75 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.179 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.569 HG23 ' HB3' ' A' ' 125' ' ' ASN . 91.0 t -91.11 -36.36 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.782 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.41 ' OE1' ' HB ' ' A' ' 90' ' ' THR . 23.2 tt0 68.3 56.81 0.48 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.937 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CE ' ' A' ' 121' ' ' MET . . . -102.76 100.71 10.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.041 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CE ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 65.56 25.45 11.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.873 -179.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 70.37 56.86 0.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.0 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.605 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 6.3 tmm? -115.72 -10.28 11.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.495 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 54.86 57.5 5.6 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.605 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 10.2 t-20 -65.65 60.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.729 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.533 ' HB2' ' CG1' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -72.22 98.31 2.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 115' ' ' LEU . 20.2 mm -73.95 158.49 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.154 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.445 ' N ' HG22 ' A' ' 127' ' ' ILE . 14.0 mt-10 -131.26 117.98 19.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -47.22 122.89 4.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.075 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 16.9 p-10 -126.09 20.02 7.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.906 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' A' ' 132' ' ' SER . 4.1 mmtp -127.2 0.0 6.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.106 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER 53.42 164.53 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.91 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.26 -170.5 16.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.631 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 107' ' ' GLN . 5.0 m -121.61 114.26 20.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.791 0.329 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.87 HG21 HG22 ' A' ' 103' ' ' ILE . 17.7 t -41.29 135.54 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.161 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.429 ' HG2' ' HB2' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -98.1 -45.41 6.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.918 179.985 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.53 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . -177.86 -176.03 0.54 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.259 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.833 HD13 ' HE2' ' A' ' 91' ' ' PHE . 61.3 mt -131.05 139.42 51.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.022 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.6 mp -109.12 -26.84 9.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.143 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 91' ' ' PHE . 42.7 t -65.69 -29.69 47.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.093 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.498 ' H ' HG22 ' A' ' 138' ' ' ILE . 25.5 mt-10 66.32 90.78 0.09 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.013 0.435 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.495 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -40.65 164.42 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.702 179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 68.37 4.52 37.9 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.41 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.482 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -124.94 138.59 31.78 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 120.9 0.381 . . . . 0.0 110.953 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 85.8 Cg_exo -46.82 143.65 9.01 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.741 2.294 . . . . 0.0 112.41 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.905 ' O ' HG13 ' A' ' 88' ' ' VAL . 3.2 t -100.5 149.34 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.99 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -125.61 158.11 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.826 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.464 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 38.2 t80 -53.95 125.12 17.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.834 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 3.6 m-20 66.34 65.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.715 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.501 ' CG ' ' HG2' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -124.46 121.75 25.91 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.717 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.481 ' CD ' ' OE1' ' A' ' 150' ' ' GLU . 10.9 Cg_endo -54.57 80.83 0.03 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.188 0 C-N-CA 122.631 2.22 . . . . 0.0 112.123 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.676 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.7 mt -58.81 -45.47 89.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.76 HG12 HG13 ' A' ' 135' ' ' VAL . 1.6 t -158.78 130.33 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.028 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -103.95 118.74 51.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.075 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.624 HD13 ' HD2' ' A' ' 81' ' ' HIS . 0.9 OUTLIER -86.01 150.08 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.236 -179.843 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.429 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 1.2 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.155 -0.926 . . . . 0.0 110.85 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.603 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.829 0.347 . . . . 0.0 110.865 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 3.8 tp -145.16 122.34 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.165 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.461 ' HA ' ' OE1' ' A' ' 156' ' ' GLU . 22.7 t -126.17 44.67 2.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.913 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' SER . . . 37.45 -110.17 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.415 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.887 ' NE2' HD13 ' A' ' 155' ' ' ILE . 7.4 p80 -166.42 143.2 4.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.863 0.363 . . . . 0.0 110.893 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 154' ' ' VAL . 1.3 mp -104.59 114.49 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 152' ' ' LEU . 22.7 t -79.8 92.26 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 2.3 ptt180 -102.17 124.01 47.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.831 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.535 ' HB3' HD21 ' A' ' 152' ' ' LEU . 20.9 p -51.59 125.16 27.5 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.07 -23.24 46.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.299 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.8 ptm -143.92 177.79 8.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.897 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 70.0 t -59.53 158.6 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.13 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.47 -167.95 40.94 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.456 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -128.61 102.28 6.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.931 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.756 ' HB2' HG11 ' A' ' 140' ' ' VAL . 70.4 t80 -66.11 167.97 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.743 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 3.7 m-85 -161.89 158.05 24.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.885 0.374 . . . . 0.0 111.247 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 10.7 mtp85 -116.18 -23.51 8.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.612 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 101' ' ' ALA . 61.9 p -137.22 106.63 8.65 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.57 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.893 ' HB3' HD12 ' A' ' 117' ' ' ILE . 69.7 Cg_endo -74.37 54.19 3.26 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.797 2.332 . . . . 0.0 112.39 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.723 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER 158.54 129.46 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.767 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.543 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 74.0 Cg_exo -49.52 81.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 122.811 2.34 . . . . 0.0 112.161 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.543 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 4.8 t0 90.16 53.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.732 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.723 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -98.94 -155.6 0.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ALA . 4.3 mmtp -83.76 4.07 30.55 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.743 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 56.83 124.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.26 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.738 ' HE2' HD12 ' A' ' 117' ' ' ILE . 1.5 m-85 -56.98 -169.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.754 HG23 ' HG2' ' A' ' 107' ' ' GLN . 5.2 mm -68.73 105.79 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.047 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.743 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -102.49 -174.12 2.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.747 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.3 t -60.24 147.58 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.202 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 67.47 16.46 67.43 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.586 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.754 ' HG2' HG23 ' A' ' 103' ' ' ILE . 13.0 tt0 -102.62 157.07 17.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.567 0.222 . . . . 0.0 110.544 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.42 150.6 23.68 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.73 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.97 153.3 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.433 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -152.29 140.64 20.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.942 -179.964 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 130' ' ' ASP . 41.3 t -37.09 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.289 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.43 -31.03 5.39 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.448 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.513 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -61.41 121.47 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 0.0 110.871 -179.946 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -33.83 154.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.204 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -117.44 -76.05 0.58 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.815 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.584 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 10.9 p -177.09 159.52 1.66 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.979 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.893 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.4 mt -82.73 143.31 12.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.243 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -102.34 -18.63 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.866 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 3.2 tt0 36.02 57.98 0.97 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.722 ' HB3' ' HE3' ' A' ' 123' ' ' MET . . . -85.87 -6.93 59.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.2 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.422 ' HG3' ' O ' ' A' ' 121' ' ' MET . 13.9 ptt? -170.65 30.03 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.903 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? 71.18 13.03 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.868 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.722 ' HE3' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -89.92 5.24 47.21 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.133 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.49 ' O ' ' N ' ' A' ' 126' ' ' GLN . 20.4 mmt 40.68 39.37 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.908 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.644 ' HB2' ' HE2' ' A' ' 123' ' ' MET . 48.3 t30 -59.05 80.11 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.422 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.5 pt20 -84.13 117.01 23.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.359 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.584 HG22 ' N ' ' A' ' 128' ' ' GLU . 24.5 mm -78.57 166.79 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.707 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 pt-20 -128.18 131.38 48.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.864 0.364 . . . . 0.0 110.778 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.04 105.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.174 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.634 ' O ' HG22 ' A' ' 111' ' ' VAL . 5.0 p-10 -76.72 -32.97 58.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.809 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.484 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -118.51 129.05 55.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.903 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 14.0 m -60.51 -175.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.02 -142.68 17.7 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.9 m -144.87 123.95 12.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.835 0.35 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.607 HG21 HG22 ' A' ' 103' ' ' ILE . 60.1 t -49.28 115.1 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.065 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.694 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.1 -46.88 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.897 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.747 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.08 -174.77 0.2 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.271 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.799 ' C ' HD23 ' A' ' 139' ' ' LEU . 15.7 mt -130.17 152.77 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.799 HD23 ' C ' ' A' ' 138' ' ' ILE . 4.2 mt -120.31 -41.45 2.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.961 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.791 HG21 HD23 ' A' ' 152' ' ' LEU . 53.9 t -51.31 -55.07 9.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 2.0 mm-40 85.07 98.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.66 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 1.9 t -37.22 159.94 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.8 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 72.32 1.27 50.24 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.357 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.437 ' OE1' ' O ' ' A' ' 145' ' ' PRO . 1.1 tm0? -120.37 129.73 25.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.353 . . . . 0.0 110.706 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 60.1 Cg_endo -72.88 120.43 6.65 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.759 2.306 . . . . 0.0 112.465 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 152' ' ' LEU . 32.9 m -66.68 168.31 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.941 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 148' ' ' PHE . 3.7 pt-20 -155.93 89.28 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.134 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.459 ' O ' ' O ' ' A' ' 147' ' ' GLU . 1.9 t80 57.7 129.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.148 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 148' ' ' PHE . 75.3 m-20 34.75 78.98 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.022 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.491 ' HB2' ' OG ' ' A' ' 85' ' ' SER . 0.3 OUTLIER -122.77 104.3 36.42 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.718 ' HG2' HD12 ' A' ' 139' ' ' LEU . 73.1 Cg_exo -48.49 88.5 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.736 2.291 . . . . 0.0 112.444 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.791 HD23 HG21 ' A' ' 140' ' ' VAL . 6.9 mt -68.07 -48.65 64.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.873 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 135' ' ' VAL . 56.5 t -157.49 109.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.074 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 82' ' ' ILE . 5.2 m -87.85 135.14 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.167 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.887 HD13 ' NE2' ' A' ' 81' ' ' HIS . 3.0 mp -110.01 141.32 25.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.057 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.483 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.1 tp10 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.275 -0.869 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.619 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 . . . . . 0 CA--C 1.527 0.061 0 CA-C-O 120.85 0.357 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.52 HG12 ' N ' ' A' ' 79' ' ' SER . 7.3 tt -138.85 155.3 27.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.52 ' N ' HG12 ' A' ' 78' ' ' ILE . 2.0 m -89.86 29.51 1.18 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.866 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.409 ' HA3' ' C ' ' A' ' 156' ' ' GLU . . . -143.97 -161.69 9.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.54 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.656 ' NE2' HD12 ' A' ' 155' ' ' ILE . 1.5 p80 -171.81 -167.16 0.48 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.361 . . . . 0.0 110.838 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.908 HG23 HG12 ' A' ' 154' ' ' VAL . 3.5 mt -138.84 117.96 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.179 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.0 t -88.21 90.46 3.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.91 169.49 16.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.424 ' HB2' HG11 ' A' ' 146' ' ' VAL . 0.8 OUTLIER -86.58 128.32 57.22 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.914 179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.63 -38.78 2.25 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.707 2.272 . . . . 0.0 112.254 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.2 ptm -144.67 -164.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.695 HG13 ' O ' ' A' ' 146' ' ' VAL . 54.7 t -96.24 145.43 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.164 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -174.08 -131.95 1.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.387 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -147.66 101.13 3.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.837 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.678 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 23.9 t80 -67.43 156.19 37.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.01 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.627 ' CE1' ' N2 ' ' A' ' 222' ' ' BTN . 1.6 m-85 -149.41 179.83 7.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.966 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -133.35 -44.72 0.83 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.786 179.771 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.609 HG22 ' HA ' ' A' ' 101' ' ' ALA . 36.2 p -116.44 102.72 53.37 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.858 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.906 ' HB3' HD12 ' A' ' 117' ' ' ILE . 72.2 Cg_endo -75.54 50.48 2.69 Favored 'Trans proline' 0 N--CA 1.465 -0.201 0 C-N-CA 122.879 2.386 . . . . 0.0 112.272 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.669 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.5 OUTLIER 157.61 123.12 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.712 -179.878 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -49.55 -19.9 3.68 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.709 2.272 . . . . 0.0 112.283 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -134.16 58.35 1.77 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.784 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.669 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -116.66 -162.67 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.019 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -111.11 21.84 15.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.01 125.64 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.194 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.582 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.01 -164.59 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.863 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.905 HG22 HG21 ' A' ' 135' ' ' VAL . 5.4 mm -69.09 66.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.136 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.445 ' OE2' ' HB3' ' A' ' 93' ' ' ARG . 29.5 mt-10 -68.38 -172.35 0.32 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.2 t -64.95 145.97 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.24 -12.46 44.58 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.577 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -86.6 150.8 23.96 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 10.4 tptt -104.24 146.3 28.98 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.854 0.359 . . . . 0.0 111.014 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.772 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -125.46 173.04 12.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -151.56 145.5 25.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.9 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 92.9 t -47.2 94.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.09 -18.05 4.51 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.507 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.441 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.4 OUTLIER -80.83 155.76 26.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.811 0.338 . . . . 0.0 111.038 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 115' ' ' LEU . 1.3 m -65.38 178.4 0.94 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.987 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 114' ' ' THR . 4.6 tp -134.87 -72.94 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.893 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.582 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -174.5 153.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.906 HD12 ' HB3' ' A' ' 95' ' ' PRO . 8.6 mt -70.86 122.8 23.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.003 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.1 t -79.94 -15.99 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.656 179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.477 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 36.2 tt0 38.52 38.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.838 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.836 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.44 85.57 4.53 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.777 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.528 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.2 ptt? 87.79 28.02 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.568 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.444 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.19 49.4 7.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.51 -179.681 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.836 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 4.8 ptt? -115.77 9.98 15.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.998 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.424 ' C ' ' O ' ' A' ' 123' ' ' MET . 36.0 mmt 36.88 38.49 0.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.832 0.349 . . . . 0.0 110.817 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.822 ' O ' HG23 ' A' ' 118' ' ' VAL . 5.8 t30 -80.2 71.43 6.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.601 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.488 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 4.8 pt20 -70.91 132.61 45.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.14 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.616 HD11 HG21 ' A' ' 118' ' ' VAL . 12.0 mm -78.81 155.96 4.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.124 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.1 mt-10 -116.17 118.77 33.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.817 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB2' HG11 ' A' ' 109' ' ' VAL . . . -38.3 95.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.084 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 128' ' ' GLU . 1.8 p-10 -69.88 -13.21 62.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.817 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.511 ' HB2' ' NE2' ' A' ' 81' ' ' HIS . 2.9 mtmm -137.64 140.25 40.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.834 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.0 t -73.29 -175.97 2.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 120.46 167.0 13.3 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.408 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 135' ' ' VAL . 54.5 m -94.0 101.65 13.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.834 0.35 . . . . 0.0 110.864 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.905 HG21 HG22 ' A' ' 103' ' ' ILE . 33.3 t -36.17 126.27 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.62 ' HB2' HG23 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -80.39 -47.13 14.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.911 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.14 169.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.267 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 152' ' ' LEU . 61.9 mt -119.08 151.45 21.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.872 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.66 HD22 ' N ' ' A' ' 139' ' ' LEU . 1.8 mm? -120.83 -33.09 3.85 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.335 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.619 HG11 ' HB2' ' A' ' 91' ' ' PHE . 47.9 t -39.93 -30.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' HB2' ' A' ' 144' ' ' GLN . 15.4 mt-10 68.87 99.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.0 0.428 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.562 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -48.55 164.14 0.06 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.72 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 67.64 5.05 35.58 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.454 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -119.85 142.12 32.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.85 0.357 . . . . 0.0 110.842 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.476 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.9 Cg_endo -64.89 121.43 8.94 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.71 2.273 . . . . 0.0 112.249 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.695 ' O ' HG13 ' A' ' 88' ' ' VAL . 61.5 t -61.3 146.81 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.207 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.558 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.39 137.32 53.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.881 179.919 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.523 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 23.4 t80 -39.66 113.21 0.32 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.012 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.523 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 34.6 t0 86.04 54.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.048 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.511 ' OE1' ' N ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -121.28 122.23 28.23 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.684 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 139' ' ' LEU . 18.2 Cg_endo -59.73 85.42 0.07 OUTLIER 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.719 2.279 . . . . 0.0 112.271 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.689 ' O ' HG23 ' A' ' 138' ' ' ILE . 9.8 mt -59.14 -51.65 69.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.976 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.545 HG12 HG13 ' A' ' 135' ' ' VAL . 3.1 t -153.95 128.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.117 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.908 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -108.5 118.74 56.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.656 HD12 ' NE2' ' A' ' 81' ' ' HIS . 23.0 mt -100.94 139.56 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.21 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.423 ' HG3' ' CG ' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.897 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.627 ' N2 ' ' CE1' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.798 0.332 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.503 ' C ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -142.25 132.15 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.139 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.431 ' N ' HD13 ' A' ' 78' ' ' ILE . 0.3 OUTLIER -114.77 120.16 39.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 179.991 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -168.07 168.5 40.84 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -168.11 -175.65 2.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.826 0.346 . . . . 0.0 110.774 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -141.62 126.6 17.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.739 HG23 HD11 ' A' ' 155' ' ' ILE . 8.8 t -87.07 94.3 4.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -84.6 136.12 33.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.932 -179.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.661 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -61.28 107.95 1.31 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.54 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 44.6 Cg_endo -68.46 -53.27 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.678 2.252 . . . . 0.0 112.275 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.11 134.61 47.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.888 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.591 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.2 t -56.12 162.78 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.14 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.591 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 158.58 -115.43 0.66 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.445 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.6 OUTLIER -162.05 138.03 7.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 110.921 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.721 ' HB2' HG11 ' A' ' 140' ' ' VAL . 26.2 t80 -85.75 168.0 14.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.974 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.571 ' CE2' ' H61' ' A' ' 222' ' ' BTN . 1.6 m-85 -168.99 158.88 8.92 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.043 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.51 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 3.6 mtp180 -139.91 9.84 2.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.979 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 93' ' ' ARG . 17.7 p -157.2 83.39 3.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.025 0.441 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.764 ' HB3' HD12 ' A' ' 117' ' ' ILE . 54.0 Cg_endo -70.36 94.13 0.58 Allowed 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.623 2.215 . . . . 0.0 112.283 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.491 ' C ' ' O ' ' A' ' 95' ' ' PRO . 0.1 OUTLIER -18.53 -60.09 0.05 OUTLIER Pre-proline 0 N--CA 1.467 0.405 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.316 -179.8 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 82.5 Cg_exo -44.04 -44.74 12.17 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.612 2.208 . . . . 0.0 112.308 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 95' ' ' PRO . 23.5 t70 -146.6 41.31 1.13 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.515 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.537 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -31.55 -91.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.503 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 50.77 22.05 1.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.977 0.418 . . . . 0.0 110.522 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 59.55 97.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.309 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.58 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.1 OUTLIER -55.7 -159.09 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.813 179.886 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.671 HG21 ' HE2' ' A' ' 108' ' ' LYS . 15.7 mm -66.46 97.75 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.036 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -107.84 -171.45 1.87 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 1.7 t -67.13 150.8 10.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.119 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 69.38 4.32 43.84 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.385 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.466 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 0.1 OUTLIER -132.46 151.75 51.78 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.915 ' O ' HG13 ' A' ' 109' ' ' VAL . 2.3 tptp 174.23 -158.15 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.801 0.334 . . . . 0.0 110.886 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 177.64 -172.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.0 p30 -86.5 159.26 19.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.907 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 132' ' ' SER . 56.2 t -49.89 115.5 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.139 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.18 -30.52 1.47 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.637 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -77.86 -176.6 4.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.844 0.354 . . . . 0.0 111.221 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -83.96 174.4 10.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.995 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.506 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.2 OUTLIER -131.33 -70.1 0.6 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.968 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.58 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 7.7 p 178.27 153.97 0.34 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.764 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.2 mt -81.63 128.08 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.184 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 12.5 t -81.6 -18.33 11.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.494 179.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.455 ' O ' ' HG2' ' A' ' 119' ' ' GLU . 4.8 tt0 47.47 39.62 9.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.264 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.696 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -84.69 120.51 26.48 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.651 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 3.9 ptm 52.34 34.13 14.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.596 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.425 ' CD ' ' HE3' ' A' ' 124' ' ' MET . 3.1 tppt? 54.52 57.29 5.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.696 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 6.2 ptt? -124.79 13.44 8.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.307 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.497 ' O ' ' N ' ' A' ' 126' ' ' GLN . 29.8 mmt 35.73 39.04 0.06 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.79 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.5 t30 -62.03 73.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.664 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -81.97 122.09 27.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.186 -179.773 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.1 mm -80.19 155.3 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.941 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 25.2 mt-10 -112.86 115.73 28.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.7 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.82 102.49 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.883 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.719 ' C ' HG22 ' A' ' 111' ' ' VAL . 8.8 p-10 -121.4 26.53 8.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.549 ' HE3' HG22 ' A' ' 83' ' ' VAL . 60.2 mmtt -105.9 -14.32 15.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.765 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.787 ' HB3' HG23 ' A' ' 111' ' ' VAL . 14.8 p 50.22 69.08 0.66 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.855 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.525 ' O ' ' CG ' ' A' ' 108' ' ' LYS . . . -168.05 -165.53 25.6 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.626 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.57 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 39.7 m -114.3 141.45 47.57 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.728 0.299 . . . . 0.0 111.005 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.814 HG23 ' HD3' ' A' ' 108' ' ' LYS . 55.6 t -73.06 138.51 21.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.146 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 0.0 OUTLIER -104.84 -38.53 6.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.454 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -179.88 171.6 1.13 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.224 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.641 HD13 ' CE2' ' A' ' 91' ' ' PHE . 3.8 mt -123.78 144.45 33.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.069 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.468 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.4 mm? -109.69 -42.33 4.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.986 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.823 HG21 HD23 ' A' ' 152' ' ' LEU . 69.8 t -53.03 -54.93 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.2 mt-10 85.12 97.75 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.751 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.51 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 2.1 t -38.25 161.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.721 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 77.4 -4.74 54.5 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.367 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -117.77 157.71 47.42 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.952 0.406 . . . . 0.0 110.83 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.3 Cg_endo -71.88 145.49 45.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.748 2.299 . . . . 0.0 112.261 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 89' ' ' GLY . 17.0 m -99.66 143.02 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.029 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 1.4 tm-20 -122.75 138.86 54.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.015 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.54 ' CD1' ' O ' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -37.38 122.7 0.92 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.803 179.957 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.423 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 0.7 OUTLIER 73.57 52.52 0.12 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.813 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.513 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.4 mt-10 -120.75 111.61 34.34 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.834 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 71.9 Cg_exo -48.84 82.21 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.673 2.248 . . . . 0.0 112.402 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.823 HD23 HG21 ' A' ' 140' ' ' VAL . 12.0 mt -62.15 -47.16 85.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.907 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.7 t -153.97 113.9 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.576 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -82.65 124.98 39.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.739 HD11 HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -98.57 145.74 9.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.122 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.519 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 1.0 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.901 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.571 ' H61' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.2 tt0 . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.824 0.345 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -70.46 176.21 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.192 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.3 m -112.45 36.92 3.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -139.43 -169.63 11.66 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB2' ' A' ' 131' ' ' LYS . 7.6 p80 -167.94 -172.97 1.95 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.881 0.372 . . . . 0.0 110.941 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.757 HG23 HG12 ' A' ' 154' ' ' VAL . 3.8 mt -137.32 111.73 9.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.113 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.4 t -85.47 109.67 18.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.18 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -97.78 139.5 33.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.799 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 150' ' ' GLU . 1.3 t -63.08 109.12 2.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.84 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.529 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 55.7 Cg_endo -70.44 -40.01 4.65 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.703 2.269 . . . . 0.0 112.359 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.18 51.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.552 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -49.7 161.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.552 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.75 -126.83 1.43 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.396 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.476 ' CB ' ' OE1' ' A' ' 119' ' ' GLU . 4.3 m -158.89 111.68 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.825 0.345 . . . . 0.0 110.942 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.814 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.2 t80 -71.41 167.71 19.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.508 ' CZ ' ' H72' ' A' ' 222' ' ' BTN . 9.7 m-85 -161.15 168.89 23.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.042 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.458 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 16.6 mtp180 -140.09 8.96 2.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.289 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 95' ' ' PRO . 12.2 p -149.84 94.07 3.87 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 120.764 0.316 . . . . 0.0 111.439 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.55 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 10.6 Cg_endo -54.45 -155.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.561 2.174 . . . . 0.0 111.737 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 11.2 p -25.58 137.51 0.07 OUTLIER Pre-proline 0 N--CA 1.465 0.302 0 O-C-N 123.235 0.334 . . . . 0.0 111.493 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.529 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 31.9 Cg_exo -59.07 61.91 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.087 2.525 . . . . 0.0 112.716 -179.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.0 m-20 156.17 39.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.777 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.527 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -99.98 -97.22 0.24 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.12 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 99' ' ' ALA . 1.5 pptp? 174.82 40.36 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.816 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . 57.11 117.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.069 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.61 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -51.16 -169.75 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.973 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.655 HG22 HG21 ' A' ' 135' ' ' VAL . 3.2 mm -76.55 106.06 6.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.092 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.475 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -119.81 -166.5 1.3 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.889 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.6 t -49.74 148.49 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.348 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 57.25 28.12 58.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.543 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.619 ' HG2' HG23 ' A' ' 103' ' ' ILE . 14.0 tp60 -119.16 88.96 3.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.539 0.209 . . . . 0.0 111.022 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -44.83 159.47 0.05 OUTLIER 'General case' 0 C--O 1.232 0.137 0 CA-C-O 120.764 0.316 . . . . 0.0 110.646 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -157.47 151.4 8.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.119 179.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -133.86 145.8 50.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -44.14 116.91 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.56 10.81 20.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.493 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.503 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -109.39 156.02 20.53 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.885 0.374 . . . . 0.0 111.045 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.13 169.66 2.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.928 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -130.88 -70.02 0.62 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.007 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.57 ' HA ' ' CE2' ' A' ' 102' ' ' PHE . 0.5 OUTLIER 175.25 153.09 0.14 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.029 179.965 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.61 HD12 ' HE2' ' A' ' 102' ' ' PHE . 6.1 mt -80.25 138.94 18.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.364 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.909 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.5 t -89.82 -24.08 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.663 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.476 ' OE1' ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER 46.59 39.32 6.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.262 179.801 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.407 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -58.16 -77.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.387 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.563 ' CG ' ' HG3' ' A' ' 123' ' ' MET . 3.1 ptt? -104.69 37.96 2.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.042 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.415 ' HD3' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 58.32 37.8 25.96 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.3 -179.152 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.572 ' HE2' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -110.61 14.75 22.34 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.754 -179.717 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.441 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 39.95 58.88 2.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.254 179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.909 ' O ' HG23 ' A' ' 118' ' ' VAL . 7.3 t30 -81.44 72.59 8.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.92 0.391 . . . . 0.0 110.281 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.515 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.4 OUTLIER -76.8 131.48 38.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.393 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 26.5 mm -89.98 156.37 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.885 179.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.435 ' N ' HG22 ' A' ' 127' ' ' ILE . 88.3 mt-10 -117.54 122.47 43.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.894 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.503 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -37.64 111.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.09 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 18.6 p30 -93.48 -21.69 19.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.867 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -122.74 113.92 19.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.411 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 t -51.14 -173.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.933 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 116.22 -138.18 14.27 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.9 m -151.78 129.97 11.95 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.761 0.315 . . . . 0.0 110.824 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.655 HG21 HG22 ' A' ' 103' ' ' ILE . 93.7 t -56.22 110.13 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.033 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.798 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.0 OUTLIER -70.77 -46.17 63.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.889 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 178.49 174.54 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.394 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.796 HD13 ' HE2' ' A' ' 91' ' ' PHE . 48.2 mt -122.65 136.65 58.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.985 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.713 HD23 ' N ' ' A' ' 139' ' ' LEU . 1.3 mt -104.25 -28.36 11.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.19 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.79 HG21 HD23 ' A' ' 152' ' ' LEU . 41.4 t -63.53 -36.49 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.114 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.57 ' H ' HG22 ' A' ' 138' ' ' ILE . 31.6 mm-40 72.24 90.03 0.09 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.789 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.79 162.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.74 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 75.93 -3.9 48.68 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.584 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.505 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.0 tt0 -120.04 144.49 37.75 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.845 0.355 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 29.4 Cg_endo -63.45 127.7 20.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.816 2.344 . . . . 0.0 112.296 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.607 HG12 HG11 ' A' ' 140' ' ' VAL . 4.3 m -79.23 152.5 4.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.132 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.0 OUTLIER -128.61 143.67 51.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 179.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.529 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.6 t80 -35.74 127.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.986 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.7 64.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HB3' HG22 ' A' ' 140' ' ' VAL . 0.4 OUTLIER -132.67 116.88 15.05 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.597 ' HG2' HD12 ' A' ' 139' ' ' LEU . 50.3 Cg_exo -53.09 90.88 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.7 2.267 . . . . 0.0 112.281 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.814 HD22 ' CD1' ' A' ' 91' ' ' PHE . 45.6 mt -64.27 -57.77 8.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.922 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' HG13 ' A' ' 135' ' ' VAL . 41.8 t -149.74 118.1 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.183 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.757 HG12 HG23 ' A' ' 82' ' ' ILE . 4.2 m -92.0 121.39 42.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.454 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 6.4 mm -94.38 145.84 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.233 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.485 ' HB3' ' HD3' ' A' ' 136' ' ' LYS . 2.2 mm-40 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.922 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.508 ' H72' ' CZ ' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 78' ' ' ILE . 1.1 pt-20 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.776 0.322 . . . . 0.0 110.972 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.623 HD11 ' OXT' ' A' ' 156' ' ' GLU . 3.5 tp 37.26 89.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.074 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 80' ' ' GLY . 0.9 OUTLIER -96.66 10.78 37.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.965 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 79' ' ' SER . . . 36.36 -127.58 0.98 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.472 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.558 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -152.7 98.22 2.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.753 0.311 . . . . 0.0 110.872 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.753 HG23 HG12 ' A' ' 154' ' ' VAL . 4.2 mt -73.19 119.48 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 t -88.18 96.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.07 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -76.55 152.89 35.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.805 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -67.23 124.34 88.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.974 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 -50.3 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.703 2.269 . . . . 0.0 112.198 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.43 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 34.9 ttm -139.11 162.49 34.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.831 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 146' ' ' VAL . 79.8 t -65.91 144.04 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -173.98 -112.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.438 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.603 ' N ' HG23 ' A' ' 146' ' ' VAL . 9.5 m -169.03 107.32 0.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.924 0.392 . . . . 0.0 110.86 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.772 ' HB2' HG11 ' A' ' 140' ' ' VAL . 40.8 t80 -67.16 171.77 5.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.747 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.546 ' CD2' ' H5 ' ' A' ' 222' ' ' BTN . 4.1 m-85 -171.57 158.04 4.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.147 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.493 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.0 mtm-85 -116.52 -23.53 8.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.737 ' HB ' ' HB1' ' A' ' 99' ' ' ALA . 2.2 p -143.35 101.98 5.14 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.977 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.707 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 72.0 Cg_endo -76.61 124.22 7.47 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.625 2.216 . . . . 0.0 112.359 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.6 OUTLIER -36.94 -50.08 2.08 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.838 179.955 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 96' ' ' SER . 33.3 Cg_exo -57.83 71.07 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.9 2.4 . . . . 0.0 112.385 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 96' ' ' SER . 36.6 t0 75.72 29.52 0.84 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.058 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.737 ' HB1' ' HB ' ' A' ' 94' ' ' THR . . . -35.99 95.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.132 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' N ' ' O ' ' A' ' 98' ' ' ASP . 11.2 mtpt -100.33 29.29 4.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.755 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 58.65 88.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 4.8 m-85 -48.78 -176.52 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.769 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.612 HD13 ' N ' ' A' ' 103' ' ' ILE . 2.5 mm -69.52 85.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.914 0.388 . . . . 0.0 111.16 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.538 ' OE1' HD12 ' A' ' 138' ' ' ILE . 0.9 OUTLIER -84.29 -173.86 4.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.903 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.467 HG22 ' HA ' ' A' ' 137' ' ' ALA . 16.6 t -61.45 144.63 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.176 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.19 2.99 90.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.581 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 108' ' ' LYS . 1.2 tp-100 -95.93 160.0 14.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.629 0.252 . . . . 0.0 110.78 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.462 ' HG3' ' O ' ' A' ' 107' ' ' GLN . 0.8 OUTLIER -150.75 101.99 2.97 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.59 HG11 ' CB ' ' A' ' 113' ' ' ASP . 0.2 OUTLIER -111.32 161.59 9.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.139 179.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -102.39 148.22 25.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' HA ' ' A' ' 130' ' ' ASP . 23.6 t -40.37 120.41 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.189 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.12 -11.44 6.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.59 ' CB ' HG11 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -100.16 158.87 15.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.83 0.347 . . . . 0.0 111.02 -179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.416 ' HA ' ' HG2' ' A' ' 128' ' ' GLU . 0.2 OUTLIER -66.49 -178.76 0.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.9 tp -138.51 -60.41 0.61 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.915 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.489 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 31.3 p 179.55 146.88 0.22 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.014 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.65 HD13 ' S1 ' ' A' ' 222' ' ' BTN . 4.2 mt -82.37 125.7 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.183 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 125' ' ' ASN . 10.7 t -77.46 -28.72 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.588 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 46.18 60.37 3.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.03 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.763 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -94.45 73.77 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.538 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptm 87.71 30.24 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.796 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HB3' ' O ' ' A' ' 121' ' ' MET . 8.9 tppt? 74.03 49.46 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.681 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.763 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.4 ttp -110.48 -8.48 14.65 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.05 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.467 ' HE1' ' H81' ' A' ' 222' ' ' BTN . 9.1 mmt 46.92 37.4 4.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.727 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.859 ' O ' HG23 ' A' ' 118' ' ' VAL . 19.9 t30 -67.83 63.02 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.686 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 6.1 pt20 -73.49 114.04 11.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.114 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' A' ' 115' ' ' LEU . 40.1 mm -71.23 146.43 11.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.881 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.453 ' O ' ' N ' ' A' ' 130' ' ' ASP . 75.0 mt-10 -116.38 109.87 17.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.89 94.35 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.251 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.641 ' HA ' HG13 ' A' ' 111' ' ' VAL . 32.3 p-10 -92.24 -6.67 50.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.1 ttmm -137.02 68.14 1.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.785 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.6 t 64.9 141.01 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.844 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 109' ' ' VAL . . . -107.17 23.57 26.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.56 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.47 HG22 ' HB3' ' A' ' 156' ' ' GLU . 8.9 m -73.44 63.02 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.939 HG13 HG12 ' A' ' 153' ' ' VAL . 62.0 t -52.2 126.11 7.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.195 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -95.95 -26.22 15.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.788 179.909 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.547 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 173.05 161.61 0.13 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.104 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.663 HG12 HG13 ' A' ' 153' ' ' VAL . 3.8 mt -124.68 132.84 70.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.546 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.0 mp -99.54 -47.95 4.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.634 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.804 HG21 HD23 ' A' ' 152' ' ' LEU . 42.4 t -40.76 127.65 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.13 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.481 ' O ' ' O ' ' A' ' 142' ' ' SER . 33.3 mt-10 -66.43 62.36 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.826 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 140' ' ' VAL . 42.3 t -31.48 152.92 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.379 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 83.78 -5.33 79.29 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.887 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.571 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -129.36 -176.24 0.52 Allowed Pre-proline 0 C--N 1.332 -0.191 0 CA-C-O 120.977 0.418 . . . . 0.0 110.866 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 15.5 Cg_exo -67.75 155.51 69.66 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.893 2.395 . . . . 0.0 112.023 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 88' ' ' VAL . 37.1 t -101.86 146.92 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.2 OUTLIER -113.7 137.46 51.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.968 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -42.83 126.18 3.67 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 67.07 59.31 0.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.891 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.487 ' HB3' HG22 ' A' ' 140' ' ' VAL . 2.5 mm-40 -122.81 117.05 28.82 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.546 ' HG2' HD22 ' A' ' 139' ' ' LEU . 60.8 Cg_exo -50.76 87.05 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.745 2.297 . . . . 0.0 112.435 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.805 HD11 ' HA ' ' A' ' 85' ' ' SER . 10.1 mt -61.51 -50.83 71.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.939 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.939 HG12 HG13 ' A' ' 135' ' ' VAL . 1.2 t -155.66 118.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.156 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.753 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -88.77 116.53 30.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.558 HD13 ' HD2' ' A' ' 81' ' ' HIS . 3.8 mt -83.48 139.6 17.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.144 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.623 ' OXT' HD11 ' A' ' 78' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.856 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.65 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 27.8 tp10 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.817 0.341 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.49 -178.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.6 m -84.56 10.01 12.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.021 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.96 -128.41 47.63 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.845 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.4 m80 -100.22 158.68 15.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.759 0.314 . . . . 0.0 110.801 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.745 HG23 HG12 ' A' ' 154' ' ' VAL . 0.9 OUTLIER -133.66 102.11 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.143 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.478 ' O ' HD12 ' A' ' 152' ' ' LEU . 2.9 t -86.34 113.83 24.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.093 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -101.93 147.81 26.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.004 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.545 ' HA ' HD21 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -37.73 136.31 0.74 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.084 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.79 -42.6 0.41 Allowed 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.874 2.383 . . . . 0.0 112.27 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.407 ' O ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -170.99 66.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.831 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.588 HG22 ' HA ' ' A' ' 147' ' ' GLU . 55.2 t 55.16 162.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.136 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.581 ' N ' HG23 ' A' ' 146' ' ' VAL . . . 152.19 -172.23 31.46 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.239 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.457 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.7 m -110.74 95.4 5.53 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.718 0.294 . . . . 0.0 110.647 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CZ ' HD13 ' A' ' 138' ' ' ILE . 62.7 t80 -62.32 164.81 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.098 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.511 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 41.4 m-85 -164.89 170.28 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.776 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.537 ' CZ ' ' HG2' ' A' ' 104' ' ' GLU . 0.6 OUTLIER -108.99 -14.2 14.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.921 179.916 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 1.025 ' OG1' ' HB1' ' A' ' 99' ' ' ALA . 13.2 t -178.37 144.87 0.49 Allowed Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.85 0.357 . . . . 0.0 111.412 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.57 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 20.4 Cg_exo -65.26 -152.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.882 2.388 . . . . 0.0 112.217 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.601 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -122.47 -72.79 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.083 179.839 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.601 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 23.8 Cg_endo -61.27 77.97 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.502 2.134 . . . . 0.0 112.372 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.4 OUTLIER 85.38 45.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.785 -179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 1.025 ' HB1' ' OG1' ' A' ' 94' ' ' THR . . . -59.59 -53.66 55.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.302 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.28 22.72 13.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 54.82 104.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.366 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.733 ' HE2' HD12 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -56.59 -164.92 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.719 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.527 HG21 ' HD3' ' A' ' 108' ' ' LYS . 2.2 mm -69.72 86.27 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.044 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.537 ' HG2' ' CZ ' ' A' ' 93' ' ' ARG . 2.2 mt-10 -81.56 174.17 11.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.976 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.555 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.5 t -64.1 149.91 10.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.18 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.06 -29.21 5.65 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.405 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.546 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 26.1 tt0 -106.77 156.46 18.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.508 0.194 . . . . 0.0 110.78 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.903 ' CG ' HG23 ' A' ' 135' ' ' VAL . 1.8 mmtm 154.16 -178.52 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.109 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.81 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 133' ' ' GLY . 84.2 t -155.65 -94.06 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.3 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.502 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 0.3 OUTLIER -152.99 178.98 9.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.872 0.368 . . . . 0.0 111.069 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 46.3 t -43.12 142.27 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.161 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.43 -25.78 13.08 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.677 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.72 145.91 29.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.837 0.351 . . . . 0.0 110.973 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.481 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -62.63 -165.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 179.926 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.9 tp -149.98 -71.05 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.545 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 p 177.62 163.15 0.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.837 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.733 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.6 mt -98.01 139.17 20.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.214 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 125' ' ' ASN . 4.4 t -86.32 -23.01 7.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.473 ' H ' HG22 ' A' ' 117' ' ' ILE . 0.6 OUTLIER 53.28 40.19 30.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.935 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.614 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -92.59 93.0 8.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.943 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.531 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.7 OUTLIER 85.89 20.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.585 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.76 42.41 6.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.99 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.614 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -107.25 12.27 28.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.84 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.509 ' O ' ' N ' ' A' ' 126' ' ' GLN . 23.2 mmt 37.58 54.45 1.45 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.863 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.467 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.7 t-20 -65.48 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.76 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.517 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 10.0 pt20 -71.73 98.59 1.97 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.819 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 128' ' ' GLU . 6.1 mm -70.83 158.4 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.347 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 127' ' ' ILE . 25.0 mt-10 -135.89 115.16 12.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.729 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HE3' ' A' ' 108' ' ' LYS . . . -36.68 104.95 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.251 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -94.15 -21.1 19.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.785 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.662 ' O ' HD13 ' A' ' 155' ' ' ILE . 11.0 mmtt -119.29 105.55 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.67 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 131' ' ' LYS . 1.4 m 54.24 162.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.412 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.502 ' C ' ' HB3' ' A' ' 108' ' ' LYS . . . -128.49 88.8 0.32 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.131 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.541 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.3 OUTLIER -162.39 103.93 1.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.584 0.231 . . . . 0.0 110.745 179.888 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.903 HG23 ' CG ' ' A' ' 108' ' ' LYS . 80.8 t -80.13 120.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.767 0.318 . . . . 0.0 111.19 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.44 ' HG2' ' CB ' ' A' ' 156' ' ' GLU . 1.6 tmtt? -91.88 -47.11 7.49 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.959 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.49 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -176.57 165.35 2.6 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.472 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.642 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 3.9 mt -119.1 150.64 21.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.846 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 1.003 HD12 ' CG ' ' A' ' 151' ' ' PRO . 4.3 mt -125.33 -34.74 2.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.208 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.512 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 31.6 t -49.64 -31.48 6.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.126 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.482 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 13.9 mt-10 68.02 93.61 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.898 0.38 . . . . 0.0 110.504 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.465 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.2 OUTLIER -37.16 160.35 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 -179.784 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.76 4.24 46.06 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.257 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 3.2 tt0 -113.66 134.62 22.0 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.057 0.456 . . . . 0.0 110.947 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 72.9 Cg_endo -76.7 94.41 1.05 Allowed 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.842 2.361 . . . . 0.0 112.405 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.581 HG23 ' N ' ' A' ' 89' ' ' GLY . 6.3 m -44.91 149.31 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.056 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.588 ' HA ' HG22 ' A' ' 88' ' ' VAL . 5.5 mt-10 -119.37 45.74 2.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 49.9 t80 62.35 140.96 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 84' ' ' ARG . 2.1 t0 59.91 43.09 15.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.792 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.478 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -117.51 118.43 35.33 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.643 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 1.003 ' CG ' HD12 ' A' ' 139' ' ' LEU . 12.4 Cg_endo -56.37 92.75 0.05 OUTLIER 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.619 2.213 . . . . 0.0 112.256 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.545 HD21 ' HA ' ' A' ' 85' ' ' SER . 0.2 OUTLIER -70.29 -39.52 74.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.039 -179.934 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 HG13 ' A' ' 135' ' ' VAL . 54.2 t -160.64 113.04 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.339 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.745 HG12 HG23 ' A' ' 82' ' ' ILE . 8.1 m -86.75 118.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.845 HD12 ' HB2' ' A' ' 81' ' ' HIS . 16.6 mt -72.82 141.63 16.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.229 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.44 ' CB ' ' HG2' ' A' ' 136' ' ' LYS . 51.0 tt0 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.568 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.816 0.341 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.47 HG23 ' O ' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -149.3 124.11 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.138 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -127.51 3.62 6.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.082 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 79' ' ' SER . . . 35.52 -155.63 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.62 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.583 ' CD2' ' HB3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -151.73 104.05 2.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 0.0 110.792 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.837 HG23 HG12 ' A' ' 154' ' ' VAL . 4.0 mt -79.4 142.1 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.228 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 10.5 t -119.7 106.99 20.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.065 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.443 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -93.77 153.37 18.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.987 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.502 ' CB ' HD11 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -84.13 106.65 8.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.914 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 33.2 Cg_endo -64.69 -19.8 64.82 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.897 2.398 . . . . 0.0 112.353 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.15 168.05 13.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.947 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.637 HG22 ' HA ' ' A' ' 147' ' ' GLU . 50.5 t -93.77 162.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.208 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.571 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.37 -154.15 25.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 1.3 m -117.85 120.3 37.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.759 0.314 . . . . 0.0 110.803 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.835 ' CD1' HD22 ' A' ' 152' ' ' LEU . 88.0 t80 -89.61 167.74 12.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.084 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.553 ' O ' ' CE2' ' A' ' 91' ' ' PHE . 62.6 m-85 -160.13 -165.73 1.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.752 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -127.86 -5.69 5.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.352 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.494 ' HB ' ' HA ' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -174.74 156.47 2.13 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.108 0.48 . . . . 0.0 111.488 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.539 ' O ' ' N ' ' A' ' 99' ' ' ALA . 89.1 Cg_endo -84.56 100.14 0.76 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 123.212 2.608 . . . . 0.0 112.686 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.451 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 1.0 OUTLIER -27.26 -63.2 0.17 Allowed Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.323 -179.855 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.451 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 71.2 Cg_exo -36.28 -67.68 0.1 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.737 2.291 . . . . 0.0 112.447 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.413 ' OD1' ' HG2' ' A' ' 95' ' ' PRO . 10.1 p30 -118.72 43.02 2.63 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.113 0.482 . . . . 0.0 109.911 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' A' ' 95' ' ' PRO . . . -43.45 107.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.966 -179.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -118.17 18.56 13.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.958 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.494 ' HA ' ' HB ' ' A' ' 94' ' ' THR . . . 65.55 83.73 0.16 Allowed 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.065 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.465 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 m-85 -50.49 -170.98 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.949 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 1.018 ' CG2' HG12 ' A' ' 109' ' ' VAL . 1.8 mm -65.97 100.47 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.091 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 40.3 mm-40 -113.44 -168.67 1.37 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.667 HG13 ' HA ' ' A' ' 137' ' ' ALA . 2.3 t -63.52 155.36 5.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.113 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 49.87 20.14 2.81 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.684 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 47.4 tt0 -103.13 168.05 9.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.704 0.287 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 6.9 tptt -94.05 134.98 35.89 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 1.018 HG12 ' CG2' ' A' ' 103' ' ' ILE . 10.4 m -124.84 124.62 68.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.45 ' N ' ' OD1' ' A' ' 110' ' ' ASN . 0.0 OUTLIER -121.09 147.98 44.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.867 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.1 t -56.72 101.17 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.047 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.6 -23.63 7.87 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.466 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.416 ' CG ' ' ND2' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -60.51 137.33 58.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.825 0.345 . . . . 0.0 110.872 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.658 ' O ' HD11 ' A' ' 103' ' ' ILE . 2.4 m -51.66 125.59 15.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.443 ' N ' ' O ' ' A' ' 127' ' ' ILE . 0.9 OUTLIER -80.23 -69.62 0.58 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.036 179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.5 OUTLIER 176.11 160.74 0.32 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.786 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 10.6 mt -86.6 152.0 3.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.981 0.42 . . . . 0.0 111.23 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.1 t -107.44 -21.24 5.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.599 179.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 39.66 71.31 0.18 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.037 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.514 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -99.15 -10.86 21.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.506 ' CG ' ' O ' ' A' ' 121' ' ' MET . 6.4 ptm 177.56 61.89 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.693 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.436 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 7.7 tppt? 45.94 29.04 0.68 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.609 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.555 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 16.0 ptt? -101.99 -3.42 27.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.094 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.47 ' O ' ' N ' ' A' ' 126' ' ' GLN . 6.2 mmt 43.89 38.19 2.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.727 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.89 ' O ' HG23 ' A' ' 118' ' ' VAL . 17.6 t30 -57.6 82.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.62 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.8 pt20 -95.75 131.23 42.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.258 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.512 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.6 mm -90.25 164.52 2.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.966 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.512 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.0 mp0 -124.54 124.69 42.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.789 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.415 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.79 138.64 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.133 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -114.19 -16.78 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.826 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.583 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -133.53 115.55 14.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 109' ' ' VAL . 0.3 OUTLIER -59.4 -171.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.47 -132.71 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 38.7 m -147.75 131.45 16.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.818 0.342 . . . . 0.0 110.921 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.864 HG23 ' CG1' ' A' ' 109' ' ' VAL . 82.0 t -63.86 122.9 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.109 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.659 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.08 -39.12 56.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 -179.917 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.749 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 164.11 158.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.304 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 152' ' ' LEU . 3.3 mt -104.91 137.09 35.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.006 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 5.8 mp -98.95 -36.25 9.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.531 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.796 HG21 HD23 ' A' ' 152' ' ' LEU . 47.2 t -52.64 122.78 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.229 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.487 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.3 mp0 -65.25 65.94 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.853 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -29.64 150.29 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.369 -179.555 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 80.89 -0.66 86.44 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.695 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 6.1 tt0 -126.34 147.7 61.0 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-O 120.825 0.345 . . . . 0.0 110.66 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 19.3 Cg_endo -58.63 100.09 0.11 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.809 2.339 . . . . 0.0 112.259 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.582 HG22 ' N ' ' A' ' 147' ' ' GLU . 11.5 p -64.86 165.92 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.094 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.637 ' HA ' HG22 ' A' ' 88' ' ' VAL . 21.4 mm-40 -125.91 177.92 6.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.916 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.477 ' CD1' ' N ' ' A' ' 149' ' ' ASP . 1.3 t80 -68.33 130.46 42.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.477 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 77.2 47.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.832 -179.969 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.422 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.7 OUTLIER -118.54 112.42 37.25 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.83 -179.873 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.449 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.4 Cg_exo -52.31 85.07 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.256 . . . . 0.0 112.303 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.835 HD22 ' CD1' ' A' ' 91' ' ' PHE . 11.5 mt -62.63 -46.65 87.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.957 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.468 HG22 ' CD1' ' A' ' 138' ' ' ILE . 3.4 t -151.58 122.85 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.837 HG12 HG23 ' A' ' 82' ' ' ILE . 3.2 m -101.05 116.6 44.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.163 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.557 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 2.4 mt -84.27 148.32 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.056 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.404 ' HG2' ' OXT' ' A' ' 156' ' ' GLU . 78.6 tt0 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.314 -0.85 . . . . 0.0 110.847 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.527 ' C6 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' N ' ' CD ' ' A' ' 77' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.75 0.31 . . . . 0.0 110.818 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.426 HG12 ' N ' ' A' ' 79' ' ' SER . 7.4 tt -171.39 154.36 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.426 ' N ' HG12 ' A' ' 78' ' ' ILE . 54.8 p -112.57 34.14 4.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.51 ' CA ' ' O ' ' A' ' 156' ' ' GLU . . . 53.76 -149.8 14.51 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.525 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.929 ' NE2' HD13 ' A' ' 155' ' ' ILE . 1.2 p80 -166.59 158.38 13.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.745 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.06 HG23 HG12 ' A' ' 154' ' ' VAL . 1.6 mt -114.28 129.86 69.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 99.2 t -97.31 95.66 4.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.243 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.483 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.6 mpt_? -84.16 160.06 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.947 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.488 ' N ' ' O ' ' A' ' 150' ' ' GLU . 0.1 OUTLIER -75.56 122.86 88.03 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.94 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.19 -29.6 21.56 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.95 172.16 19.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.749 HG22 ' HA ' ' A' ' 147' ' ' GLU . 67.0 t -57.69 149.71 4.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.988 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 146' ' ' VAL . . . 169.59 158.07 12.94 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.579 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -91.21 106.28 18.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.84 0.353 . . . . 0.0 110.979 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.539 ' CD1' HD22 ' A' ' 152' ' ' LEU . 63.8 t80 -78.73 166.73 22.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.685 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 5.3 m-85 -162.35 175.0 12.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.905 0.383 . . . . 0.0 111.143 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 3.1 mtm-85 -117.76 -20.99 8.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.754 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.65 HG22 ' HA ' ' A' ' 101' ' ' ALA . 13.5 p -140.95 109.37 6.46 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 52.6 Cg_exo -54.19 -149.68 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 0.0 112.18 179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.2 OUTLIER -34.87 137.52 0.37 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.959 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.517 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 73.7 Cg_exo -49.24 79.72 0.02 OUTLIER 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 123.032 2.488 . . . . 0.0 112.597 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 96' ' ' SER . 4.5 m-20 159.24 -21.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.171 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.491 ' CB ' ' HD2' ' A' ' 95' ' ' PRO . . . -45.2 168.76 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.841 0.353 . . . . 0.0 111.087 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.4 mtpt -101.28 40.44 1.29 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.912 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.885 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 53.04 109.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.599 ' CE2' ' HG3' ' A' ' 95' ' ' PRO . 0.5 OUTLIER -52.38 -167.18 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.819 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 1.033 HG21 HG13 ' A' ' 109' ' ' VAL . 3.5 mm -78.25 94.3 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.885 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -105.31 -174.63 2.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.983 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.743 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.7 t -45.46 142.6 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.37 -56.73 4.23 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.63 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.578 ' HG2' HG23 ' A' ' 103' ' ' ILE . 47.8 tt0 -56.72 168.53 0.59 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.671 0.272 . . . . 0.0 110.709 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.501 ' CD ' ' N ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER -121.29 163.14 19.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 1.033 HG13 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -132.52 125.46 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.07 179.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.402 ' O ' ' C ' ' A' ' 111' ' ' VAL . 12.7 m120 -100.88 132.42 46.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.029 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.803 HG23 ' OG ' ' A' ' 132' ' ' SER . 83.7 t -37.52 101.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.192 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.95 -12.12 9.94 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.452 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.16 140.98 30.51 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.801 0.334 . . . . 0.0 110.891 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.28 148.61 4.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.973 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 127' ' ' ILE . 4.0 tp -103.52 -73.62 0.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.587 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 179.35 159.17 0.66 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.55 HG13 ' HB3' ' A' ' 126' ' ' GLN . 13.3 mt -68.93 160.72 4.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.025 0.44 . . . . 0.0 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.0 t -122.25 -32.41 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.797 179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.526 ' HG3' ' CG2' ' A' ' 117' ' ' ILE . 12.7 mt-10 48.25 54.48 10.22 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.655 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.762 ' HB3' ' HE2' ' A' ' 123' ' ' MET . . . -79.42 -36.83 38.4 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 12.7 ptm -141.47 53.99 1.52 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.528 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.431 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 46.98 25.42 0.47 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.489 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.762 ' HE2' ' HB3' ' A' ' 120' ' ' ALA . 8.8 ptt? -90.37 -25.88 20.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.071 -179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.486 ' SD ' ' HG2' ' A' ' 119' ' ' GLU . 0.9 OUTLIER 68.79 35.53 2.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.008 0.433 . . . . 0.0 110.468 -179.721 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.723 ' O ' HG23 ' A' ' 118' ' ' VAL . 4.2 p-10 -79.23 121.24 24.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.549 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.55 ' HB3' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -113.18 124.99 53.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 -179.732 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.562 HG22 ' N ' ' A' ' 128' ' ' GLU . 3.5 mm -67.75 166.72 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.287 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.562 ' N ' HG22 ' A' ' 127' ' ' ILE . 3.5 mp0 -136.12 114.89 12.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.866 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -39.92 150.02 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 12.9 p-10 -152.94 19.39 0.59 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.442 ' HB2' ' CE1' ' A' ' 81' ' ' HIS . 1.6 mtpt -119.83 -15.0 8.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.984 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.803 ' OG ' HG23 ' A' ' 111' ' ' VAL . 1.6 m 65.61 133.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.897 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 149.17 -176.85 27.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.476 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.61 ' C ' HG23 ' A' ' 155' ' ' ILE . 98.3 m -106.99 140.04 40.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.921 0.391 . . . . 0.0 110.822 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.663 HG13 HG12 ' A' ' 153' ' ' VAL . 97.2 t -73.05 115.76 14.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.136 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' HG13 ' A' ' 105' ' ' VAL . 1.5 tmtt? -71.16 -46.39 61.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.783 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.743 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.35 151.5 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.317 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.576 HG23 ' O ' ' A' ' 152' ' ' LEU . 4.6 mt -97.45 139.16 20.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.942 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER -102.35 -49.06 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.596 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.579 HG23 ' C ' ' A' ' 151' ' ' PRO . 24.2 t -36.41 129.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.231 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 142' ' ' SER . 12.8 mp0 -67.03 62.11 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.753 179.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 140' ' ' VAL . 7.0 t -32.19 153.71 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.117 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.87 -2.29 80.72 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.736 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 145' ' ' PRO . 10.0 mt-30 -131.96 159.64 71.19 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.825 0.345 . . . . 0.0 110.634 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 79.3 Cg_endo -77.88 112.5 3.29 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.721 2.281 . . . . 0.0 112.581 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.789 HG22 ' O ' ' A' ' 89' ' ' GLY . 17.4 m -67.19 175.54 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.909 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.749 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.9 mt-10 -142.01 61.23 1.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.82 0.343 . . . . 0.0 111.136 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.454 ' O ' ' O ' ' A' ' 147' ' ' GLU . 10.9 t80 55.29 157.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' N ' ' CG ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER 53.27 37.85 26.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.828 -179.958 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.574 ' OE1' HG22 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -112.92 114.09 49.32 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.684 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.579 ' C ' HG23 ' A' ' 140' ' ' VAL . 18.0 Cg_endo -59.56 91.93 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.727 2.284 . . . . 0.0 112.372 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.576 ' O ' HG23 ' A' ' 138' ' ' ILE . 8.0 mt -63.52 -52.09 62.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.081 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.663 HG12 HG13 ' A' ' 135' ' ' VAL . 2.7 t -154.08 126.78 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.388 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.06 HG12 HG23 ' A' ' 82' ' ' ILE . 3.5 m -103.62 121.66 55.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.88 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.929 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.3 mp -100.85 133.82 42.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.291 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.51 ' O ' ' CA ' ' A' ' 80' ' ' GLY . 1.6 tp10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.922 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.57 ' H72' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.802 0.335 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.2 pt -81.51 150.67 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.12 65.59 2.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.876 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -122.5 -147.92 7.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.525 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.544 ' O ' HD12 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -158.91 106.4 1.83 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.853 0.358 . . . . 0.0 110.875 -179.924 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.979 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -74.44 130.15 36.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' A' ' 152' ' ' LEU . 64.2 t -94.2 98.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.135 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 14.1 mtt180 -81.83 161.0 23.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.932 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.554 ' OG ' HD21 ' A' ' 152' ' ' LEU . 18.4 m -82.81 149.77 60.7 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.023 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.446 ' HD2' ' CD ' ' A' ' 147' ' ' GLU . 57.8 Cg_endo -87.69 -74.13 0.0 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 123.046 2.497 . . . . 0.0 112.561 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.471 ' O ' ' HB3' ' A' ' 147' ' ' GLU . 4.5 ttt -117.78 121.3 40.43 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.907 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.899 HG23 ' HB2' ' A' ' 148' ' ' PHE . 39.8 t -34.64 141.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.491 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.506 ' N ' ' HB2' ' A' ' 147' ' ' GLU . . . -161.3 -107.23 0.22 Allowed Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.042 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.467 ' O ' ' O ' ' A' ' 118' ' ' VAL . 3.8 m -161.32 95.25 1.02 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.857 0.36 . . . . 0.0 110.665 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.834 ' CD1' HD22 ' A' ' 152' ' ' LEU . 15.0 t80 -65.23 171.51 3.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.774 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.576 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 6.2 m-85 -172.42 153.61 2.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.874 0.369 . . . . 0.0 111.398 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.533 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 2.6 mtp85 -117.45 -23.37 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.806 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.55 ' CG2' ' HB2' ' A' ' 101' ' ' ALA . 7.3 p -140.8 105.4 6.3 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.409 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.599 ' HG3' ' CE2' ' A' ' 102' ' ' PHE . 31.6 Cg_exo -56.7 -145.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.508 2.138 . . . . 0.0 112.384 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.523 ' N ' ' C3 ' ' A' ' 222' ' ' BTN . 0.5 OUTLIER -25.62 142.0 0.04 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.633 -179.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_exo -45.71 -24.57 2.04 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.931 2.421 . . . . 0.0 112.523 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -110.25 55.4 0.65 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.868 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -118.12 -177.94 3.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.15 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 101' ' ' ALA . 1.6 mtpp -129.47 36.36 4.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.55 ' HB2' ' CG2' ' A' ' 94' ' ' THR . . . 56.81 126.69 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.138 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.762 ' HE2' HD12 ' A' ' 117' ' ' ILE . 5.8 m-85 -56.97 -93.5 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.785 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.688 HG21 ' CG1' ' A' ' 109' ' ' VAL . 21.3 mm -114.02 79.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.029 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.99 166.22 0.81 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.036 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.78 149.62 11.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.62 -10.69 49.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.456 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 47.2 tt0 -76.7 167.72 21.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -98.65 134.21 41.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.771 -179.975 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.688 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -131.77 122.67 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.152 -179.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.493 ' O ' ' N ' ' A' ' 112' ' ' GLY . 0.1 OUTLIER -121.95 137.25 54.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.763 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.475 HG23 ' OG ' ' A' ' 132' ' ' SER . 74.4 t -35.72 92.56 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 147.36 -13.41 1.41 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.552 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -95.84 162.87 13.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.802 0.334 . . . . 0.0 110.977 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.11 -174.15 1.83 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 127' ' ' ILE . 2.3 tp -147.61 -71.81 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.898 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.527 ' SG ' ' CE1' ' A' ' 91' ' ' PHE . 27.7 p -174.31 163.17 3.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.002 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.762 HD12 ' HE2' ' A' ' 102' ' ' PHE . 4.7 mt -101.76 138.92 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.332 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 90' ' ' THR . 28.9 t -83.83 -23.93 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.814 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.496 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 4.1 tt0 38.16 53.12 1.66 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.079 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.462 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -78.96 -71.24 0.45 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.715 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 4.8 ptm -104.03 34.24 3.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.499 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 12.3 tptt 63.04 34.92 13.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.686 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.54 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -103.26 -2.77 26.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.14 -179.786 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.521 ' O ' ' N ' ' A' ' 126' ' ' GLN . 34.5 mmt 54.74 44.02 29.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.874 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.54 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 26.5 t-20 -60.42 75.03 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.485 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.521 ' N ' ' O ' ' A' ' 124' ' ' MET . 3.5 pt20 -80.06 126.38 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.208 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.0 mm -90.17 143.54 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.045 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 129' ' ' ALA . 19.0 mp0 -114.98 110.58 19.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.418 ' HB1' ' HB ' ' A' ' 109' ' ' VAL . . . -36.83 111.37 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.058 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 0.7 OUTLIER -128.19 33.63 4.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.49 -13.17 10.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.475 ' OG ' HG23 ' A' ' 111' ' ' VAL . 0.9 OUTLIER 56.17 110.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 158.15 -175.18 35.39 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.475 ' C ' HG23 ' A' ' 155' ' ' ILE . 23.3 m -103.8 123.11 46.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.795 0.331 . . . . 0.0 110.939 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.685 HG13 HG12 ' A' ' 153' ' ' VAL . 85.2 t -62.21 121.93 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.101 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.639 ' HB3' HG23 ' A' ' 154' ' ' VAL . 0.4 OUTLIER -81.17 -53.33 6.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.683 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.53 154.32 0.49 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.146 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 152' ' ' LEU . 9.1 mt -101.38 146.19 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.02 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 10.1 mp -107.63 -43.51 4.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.591 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.906 HG21 HD23 ' A' ' 152' ' ' LEU . 53.8 t -45.15 123.39 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.243 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' A' ' 142' ' ' SER . 3.3 mp0 -66.61 62.35 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.825 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.533 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -31.52 152.81 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.513 -179.479 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 89.98 -13.07 65.64 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.076 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' OE1' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -111.69 158.18 37.26 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.939 0.4 . . . . 0.0 110.869 179.969 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 89' ' ' GLY . 73.9 Cg_endo -75.99 103.68 1.78 Allowed 'Trans proline' 0 N--CA 1.464 -0.256 0 C-N-CA 122.795 2.33 . . . . 0.0 112.294 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.661 ' HA ' HG13 ' A' ' 88' ' ' VAL . 8.1 p -171.22 156.25 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.928 0.394 . . . . 0.0 111.405 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.576 ' N ' ' HA ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER 172.37 31.06 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.221 -179.805 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.899 ' HB2' HG23 ' A' ' 88' ' ' VAL . 6.4 t80 -116.2 85.81 2.37 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.764 0.316 . . . . 0.0 110.692 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.415 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 77.04 31.51 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.65 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.746 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -109.43 108.59 60.04 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.451 179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 140' ' ' VAL . 81.4 Cg_exo -44.8 93.68 0.02 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.668 2.245 . . . . 0.0 112.531 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.906 HD23 HG21 ' A' ' 140' ' ' VAL . 6.2 mt -60.83 -51.99 66.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.771 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.685 HG12 HG13 ' A' ' 135' ' ' VAL . 2.4 t -156.18 118.82 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.958 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.979 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -95.33 122.61 46.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.159 -179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 81' ' ' HIS . 0.5 OUTLIER -96.64 139.22 19.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.084 179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.456 ' HG3' ' HD3' ' A' ' 136' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.525 ' S1 ' ' HB3' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.458 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 34.1 tt0 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.428 ' N ' ' CD1' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -64.67 -176.7 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.192 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.8 t -98.92 46.83 0.98 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.888 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -87.58 -167.33 43.44 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.562 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -143.12 118.0 9.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 110.765 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.8 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -101.36 131.8 48.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.172 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 151' ' ' PRO . 46.9 t -99.08 113.21 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.124 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.2 ptt180 -103.3 141.96 35.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.539 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -66.45 111.47 6.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.913 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.33 -6.98 19.72 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.662 2.242 . . . . 0.0 112.215 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.22 154.29 30.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.944 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.518 ' HA ' HG23 ' A' ' 146' ' ' VAL . 55.6 t -61.16 159.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.121 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.682 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 162.02 179.99 37.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.553 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 118' ' ' VAL . 1.1 m -102.71 100.03 10.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.803 0.335 . . . . 0.0 110.984 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.742 ' HE2' HD13 ' A' ' 138' ' ' ILE . 28.0 t80 -61.89 161.24 10.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.99 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD2' ' H2 ' ' A' ' 222' ' ' BTN . 35.9 m-85 -161.31 170.62 19.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.787 ' HD2' HD12 ' A' ' 138' ' ' ILE . 8.7 mtp-105 -129.01 -1.13 5.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 30.1 p -143.44 111.59 5.45 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.093 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.471 ' HG3' ' CD2' ' A' ' 102' ' ' PHE . 52.2 Cg_exo -54.37 -149.16 0.0 OUTLIER 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.828 2.352 . . . . 0.0 112.349 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 95' ' ' PRO . 57.9 m -33.42 154.36 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.167 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.76 -26.48 3.19 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.795 2.33 . . . . 0.0 112.426 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' A' ' 98' ' ' ASP . 1.7 p30 -115.65 55.57 0.78 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.409 ' HB1' ' HD2' ' A' ' 95' ' ' PRO . . . -102.96 -167.62 1.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.143 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.72 35.02 4.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.643 ' HB1' ' CD ' ' A' ' 104' ' ' GLU . . . 58.31 111.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.171 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.716 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.1 OUTLIER -58.6 -160.38 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.754 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 135' ' ' VAL . 3.9 mp -66.83 105.07 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.853 0.358 . . . . 0.0 111.103 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.643 ' CD ' ' HB1' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -116.48 -170.64 1.85 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.921 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.717 HG13 ' O ' ' A' ' 136' ' ' LYS . 2.4 t -58.34 136.32 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.233 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.59 -43.74 2.61 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.62 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 55.1 tt0 -60.28 167.73 2.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.743 0.306 . . . . 0.0 110.972 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.514 ' HG3' ' N ' ' A' ' 109' ' ' VAL . 3.1 ttpt -136.37 146.16 46.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 110.932 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.527 HG11 HG12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -134.1 -177.89 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.039 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.2 OUTLIER -127.83 170.07 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.972 -179.994 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.48 94.05 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.991 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 134.73 -23.79 3.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.423 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.2 OUTLIER -71.5 168.78 16.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.335 . . . . 0.0 110.944 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.716 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -61.21 -178.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.888 -179.899 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.645 ' H ' HG22 ' A' ' 114' ' ' THR . 4.1 tp -144.3 -69.19 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.052 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 1.3 m -174.25 155.15 2.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 124' ' ' MET . 5.0 mt -84.64 152.07 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.13 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.962 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.2 t -106.37 -32.72 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.86 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.468 ' HG3' ' S1 ' ' A' ' 222' ' ' BTN . 0.0 OUTLIER 42.48 66.49 0.74 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -100.1 2.96 43.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.06 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.454 ' HG3' ' O ' ' A' ' 121' ' ' MET . 23.5 ptm -177.61 36.57 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.719 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.501 ' HD3' ' CE ' ' A' ' 124' ' ' MET . 1.8 tppt? 61.26 37.32 17.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.604 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.489 ' HE3' ' CB ' ' A' ' 125' ' ' ASN . 2.6 ptt? -115.04 -5.62 12.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.034 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.562 ' HA ' HG23 ' A' ' 117' ' ' ILE . 1.0 OUTLIER 46.57 37.32 4.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.983 -179.745 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.962 ' O ' HG23 ' A' ' 118' ' ' VAL . 9.8 t30 -58.98 84.48 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.278 179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.501 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.98 143.33 27.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.358 -179.386 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 128' ' ' GLU . 4.5 mm -95.56 161.94 2.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.964 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -111.18 121.45 45.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.783 179.904 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -35.72 99.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.089 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -70.54 -26.9 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.84 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.544 ' HB3' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -125.17 133.46 52.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.833 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 32.2 p -85.54 163.51 18.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 137.98 -162.0 25.57 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.501 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 95.0 m -108.75 109.75 20.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.789 0.328 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.552 HG13 ' CG1' ' A' ' 153' ' ' VAL . 48.3 t -51.29 125.47 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.717 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -80.26 -46.92 15.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.77 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 168.09 0.13 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.272 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.787 HD12 ' HD2' ' A' ' 93' ' ' ARG . 13.3 mt -97.23 149.63 4.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.493 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.3 mp -117.49 -20.68 8.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.799 HG22 ' CG ' ' A' ' 150' ' ' GLU . 49.9 t -74.85 -41.22 46.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.133 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.507 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 6.1 mt-10 83.77 96.92 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.792 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.466 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -38.35 161.99 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 -179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 65.44 7.51 33.69 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -118.78 128.67 25.83 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.92 0.391 . . . . 0.0 110.88 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.6 Cg_endo -71.23 117.84 5.37 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.785 2.323 . . . . 0.0 112.436 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.518 HG23 ' HA ' ' A' ' 88' ' ' VAL . 19.7 m -68.05 154.3 8.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.009 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' HA ' HG22 ' A' ' 88' ' ' VAL . 3.7 mt-10 -128.2 65.35 1.39 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' O ' ' O ' ' A' ' 147' ' ' GLU . 2.1 t80 56.66 122.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.035 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 11.7 t0 66.8 60.15 0.56 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.799 ' CG ' HG22 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -119.24 110.66 37.49 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.814 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.714 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.8 Cg_exo -50.23 89.03 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.774 2.316 . . . . 0.0 112.313 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.539 HD11 ' HA ' ' A' ' 85' ' ' SER . 1.5 mt -65.37 -42.35 92.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 135' ' ' VAL . 15.7 t -155.85 129.71 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.248 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.8 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -109.13 118.58 56.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.553 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 1.0 OUTLIER -92.08 159.82 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.131 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.236 -0.888 . . . . 0.0 110.908 179.976 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.544 ' H2 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' A' ' 78' ' ' ILE . 79.3 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.845 0.355 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.471 HG23 ' O ' ' A' ' 78' ' ' ILE . 2.6 tp 38.97 95.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.12 8.79 9.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.981 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 155' ' ' ILE . . . -112.96 -139.37 7.43 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.535 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.765 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.0 p80 -172.82 116.44 0.3 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.771 0.32 . . . . 0.0 111.053 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.869 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -86.05 124.62 40.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.06 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 2.8 t -93.46 111.07 24.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.217 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.04 127.95 50.09 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.837 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.555 ' OG ' HG21 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -39.67 98.94 0.19 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.571 ' O ' ' CE2' ' A' ' 148' ' ' PHE . 50.2 Cg_exo -53.09 -50.27 14.62 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.246 . . . . 0.0 112.165 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ttt -120.18 147.16 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.812 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.58 HG12 ' N ' ' A' ' 89' ' ' GLY . 54.3 t -51.94 162.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.58 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 157.7 -116.99 0.75 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.419 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.726 HG23 ' N ' ' A' ' 145' ' ' PRO . 1.7 m -166.41 126.32 1.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.813 0.34 . . . . 0.0 110.854 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.797 ' CD1' HD22 ' A' ' 152' ' ' LEU . 39.6 t80 -82.7 169.03 16.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.032 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.433 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 14.4 m-85 -154.88 -179.35 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.92 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 41.0 mtp180 -144.96 12.7 1.43 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.166 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.702 HG22 ' HA ' ' A' ' 101' ' ' ALA . 33.4 p -152.25 127.63 4.89 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.059 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 99' ' ' ALA . 39.4 Cg_exo -59.99 -149.83 0.01 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.772 2.315 . . . . 0.0 112.229 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.524 ' HA ' ' N2 ' ' A' ' 222' ' ' BTN . 85.4 p -33.49 151.65 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.023 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.429 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 28.0 Cg_endo -62.92 57.66 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.786 2.324 . . . . 0.0 112.271 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 171.57 34.24 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.892 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.457 ' HB3' ' HD2' ' A' ' 95' ' ' PRO . . . -114.2 -170.54 1.74 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.095 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 7.1 ttpt -90.19 -68.76 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.994 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.702 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 173.09 128.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.201 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 117' ' ' ILE . 26.5 m-85 -51.57 -171.57 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.91 HG22 HG21 ' A' ' 135' ' ' VAL . 5.5 mm -67.51 100.08 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.9 0.381 . . . . 0.0 111.237 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -98.53 -162.67 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.957 179.924 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.768 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.2 t -68.73 148.96 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.203 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 68.74 5.13 43.83 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.515 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.72 HE21 HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.14 147.49 25.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.486 0.184 . . . . 0.0 110.576 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.517 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -115.93 146.66 41.89 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.352 . . . . 0.0 110.853 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 113' ' ' ASP . 7.6 p -151.96 127.44 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.216 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 35.1 p-10 -87.59 154.25 20.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.826 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.894 HG23 ' HB2' ' A' ' 132' ' ' SER . 68.2 t -51.47 127.51 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.021 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.03 2.71 34.0 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.533 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.488 ' HB3' HG23 ' A' ' 109' ' ' VAL . 0.4 OUTLIER -107.14 166.55 10.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.853 0.359 . . . . 0.0 110.95 -179.922 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.77 HG23 ' OE1' ' A' ' 126' ' ' GLN . 38.6 m -64.16 163.11 13.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.99 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.713 HD23 ' HB ' ' A' ' 127' ' ' ILE . 4.4 tp -135.12 -72.83 0.47 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.838 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.9 OUTLIER -171.65 167.27 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.846 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.57 HD12 ' CE2' ' A' ' 102' ' ' PHE . 5.4 mt -107.49 140.71 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.431 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 90' ' ' THR . 11.0 t -88.06 -24.56 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.18 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.511 ' N ' HG22 ' A' ' 117' ' ' ILE . 0.1 OUTLIER 53.37 40.27 31.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.298 179.721 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.534 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -72.0 109.65 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.626 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 1.5 ptt? 52.35 38.81 26.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.649 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.408 ' CA ' ' HE2' ' A' ' 122' ' ' LYS . 6.4 tppt? 64.94 50.53 1.91 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.606 ' HE3' ' ND2' ' A' ' 125' ' ' ASN . 11.0 ttp -99.08 -20.35 16.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.807 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt 49.34 37.74 12.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.606 ' ND2' ' HE3' ' A' ' 123' ' ' MET . 11.6 p-10 -77.69 85.28 4.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.77 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.4 OUTLIER -77.96 111.12 13.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.986 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.713 ' HB ' HD23 ' A' ' 115' ' ' LEU . 5.3 mm -69.22 156.47 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.289 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.465 ' N ' HG22 ' A' ' 127' ' ' ILE . 0.8 OUTLIER -124.54 111.63 15.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.826 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.435 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.09 129.66 0.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.199 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.651 ' HA ' HG13 ' A' ' 111' ' ' VAL . 12.0 p-10 -133.3 38.32 3.31 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.913 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.716 ' N ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -129.66 -37.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.894 ' HB2' HG23 ' A' ' 111' ' ' VAL . 9.6 t 75.82 87.7 0.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.81 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -170.59 -168.0 31.77 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.464 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.748 ' O ' HG23 ' A' ' 155' ' ' ILE . 15.8 m -104.3 141.24 36.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.779 0.323 . . . . 0.0 110.842 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.91 HG21 HG22 ' A' ' 103' ' ' ILE . 40.3 t -82.04 116.4 26.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.635 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -70.11 -39.69 75.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.768 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 166.0 175.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.324 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.639 HG23 ' O ' ' A' ' 152' ' ' LEU . 5.8 mt -120.3 138.6 50.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.984 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 4.1 mm? -102.66 -47.13 4.52 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.376 179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.747 HG23 ' C ' ' A' ' 151' ' ' PRO . 38.8 t -46.24 125.12 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.097 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.482 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.9 mp0 -65.95 62.97 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.968 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.522 ' N ' ' O ' ' A' ' 140' ' ' VAL . 6.3 t -32.05 154.18 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.322 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 81.98 -5.18 72.17 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.674 -179.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.611 ' C ' HG23 ' A' ' 90' ' ' THR . 3.6 tt0 -127.25 147.73 63.19 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-O 120.827 0.346 . . . . 0.0 110.494 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.726 ' N ' HG23 ' A' ' 90' ' ' THR . 19.4 Cg_endo -58.43 128.42 28.36 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.789 2.326 . . . . 0.0 112.293 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.555 HG21 ' OG ' ' A' ' 85' ' ' SER . 27.8 m -81.92 168.53 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.915 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.439 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -140.39 61.59 1.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.147 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.571 ' CE2' ' O ' ' A' ' 86' ' ' PRO . 1.3 t80 58.34 156.89 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.175 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 30.5 t0 42.06 47.47 3.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.519 ' HG3' HG22 ' A' ' 140' ' ' VAL . 0.8 OUTLIER -109.85 99.85 40.37 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.847 179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.747 ' C ' HG23 ' A' ' 140' ' ' VAL . 56.4 Cg_exo -51.19 83.17 0.02 OUTLIER 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.814 2.343 . . . . 0.0 112.414 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.797 HD22 ' CD1' ' A' ' 91' ' ' PHE . 15.3 mt -61.14 -52.37 65.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.621 HG22 HD11 ' A' ' 138' ' ' ILE . 89.8 t -144.91 138.37 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.268 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.869 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -119.26 120.96 65.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.916 179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.765 HD13 ' NE2' ' A' ' 81' ' ' HIS . 1.8 mp -110.46 146.39 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.239 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.41 ' HA ' ' HA3' ' A' ' 80' ' ' GLY . 4.4 tt0 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.524 ' N2 ' ' HA ' ' A' ' 96' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.837 0.351 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.793 HD11 ' HA ' ' A' ' 156' ' ' GLU . 5.0 tt -38.92 151.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.492 ' N ' HG12 ' A' ' 78' ' ' ILE . 24.7 m -98.77 36.44 1.67 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -132.95 -135.79 3.67 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 1.001 ' CE1' HD12 ' A' ' 155' ' ' ILE . 33.0 p80 -168.87 158.29 8.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.783 0.325 . . . . 0.0 110.85 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.839 HG23 HG12 ' A' ' 154' ' ' VAL . 1.1 mp -104.24 118.56 51.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.141 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.401 ' O ' ' N ' ' A' ' 152' ' ' LEU . 57.7 t -81.29 92.18 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.89 144.43 26.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.503 ' CB ' HG11 ' A' ' 146' ' ' VAL . 22.9 t -69.62 140.1 89.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.05 -57.43 0.28 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.281 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 8.6 ptt? -132.77 -177.42 4.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.562 HG12 ' N ' ' A' ' 89' ' ' GLY . 53.7 t -59.58 162.03 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.562 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.14 -151.72 19.08 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.42 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -139.13 107.48 5.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.787 0.327 . . . . 0.0 110.93 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.968 ' HB3' HG11 ' A' ' 140' ' ' VAL . 86.1 t80 -85.26 169.06 14.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.796 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.597 ' CE2' ' H72' ' A' ' 222' ' ' BTN . 40.9 m-85 -156.28 -172.07 3.95 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.949 0.404 . . . . 0.0 111.118 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.478 ' HG2' ' OG ' ' A' ' 142' ' ' SER . 2.8 mmm-85 -118.85 -30.27 5.11 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.444 179.414 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.874 HG22 ' HB2' ' A' ' 101' ' ' ALA . 1.1 p -143.18 138.05 15.32 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.435 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.616 ' HA ' ' H5 ' ' A' ' 222' ' ' BTN . 72.1 Cg_endo -78.09 50.07 3.19 Favored 'Trans proline' 0 N--CA 1.462 -0.356 0 C-N-CA 122.639 2.226 . . . . 0.0 112.46 -179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.964 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER 158.91 129.83 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.812 179.955 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -47.55 -21.45 2.22 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.838 2.359 . . . . 0.0 112.3 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -129.54 55.73 1.75 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.934 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.964 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -115.41 -172.7 2.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.098 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.456 ' O ' ' O ' ' A' ' 101' ' ' ALA . 5.2 pttp -109.39 19.92 18.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.904 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.874 ' HB2' HG22 ' A' ' 94' ' ' THR . . . 58.07 134.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.149 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.605 ' C ' HD12 ' A' ' 103' ' ' ILE . 29.7 m-85 -48.86 -94.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.685 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.731 HD13 ' C ' ' A' ' 114' ' ' THR . 2.9 mp -122.48 78.05 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.929 0.395 . . . . 0.0 110.942 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -49.53 156.15 0.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.21 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.529 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 66.5 t -61.49 154.88 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.263 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.446 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.11 -31.78 4.28 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.513 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.513 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 37.9 tt0 -104.71 164.98 11.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.607 0.241 . . . . 0.0 110.88 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.54 ' CB ' ' HA ' ' A' ' 134' ' ' THR . 0.2 OUTLIER 157.02 -170.88 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.0 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 110' ' ' ASN . 81.4 t -158.35 -97.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.316 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.523 ' HA ' ' N ' ' A' ' 133' ' ' GLY . 38.6 p-10 -150.44 175.51 11.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.799 0.333 . . . . 0.0 110.94 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 84.7 t -40.14 129.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.088 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 125.7 -25.24 5.64 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.58 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.85 141.9 31.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.962 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.731 ' C ' HD13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -63.08 -175.63 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.527 HD21 ' CG2' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -136.71 -71.52 0.45 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.594 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.8 OUTLIER 173.08 155.31 0.1 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.056 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.589 HD12 ' HB3' ' A' ' 95' ' ' PRO . 5.1 mt -79.21 143.97 11.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.182 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.8 t -98.74 -21.31 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.821 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 47.98 47.92 18.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.04 -179.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.672 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.65 88.16 5.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.549 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.529 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.27 19.32 0.05 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.369 -179.513 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.516 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 0.1 OUTLIER 65.47 52.44 1.38 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.605 -179.711 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.672 ' CE ' ' HB3' ' A' ' 120' ' ' ALA . 1.8 ptt? -119.6 13.42 12.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.016 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.42 ' C ' ' O ' ' A' ' 123' ' ' MET . 4.6 mmt 37.46 49.44 0.98 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.762 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.945 ' O ' HG23 ' A' ' 118' ' ' VAL . 21.9 t30 -72.69 71.27 0.99 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.932 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 1.7 pt20 -82.33 116.92 22.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 18.9 mm -78.31 149.15 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.294 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.447 ' CG ' ' HA ' ' A' ' 114' ' ' THR . 4.3 mt-10 -127.52 116.63 20.68 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.671 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB2' ' HE3' ' A' ' 108' ' ' LYS . . . -34.72 96.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.307 -179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.419 ' N ' ' O ' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -95.03 -12.93 25.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.704 179.625 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -128.65 96.54 4.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.372 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 22.8 t 62.05 157.41 0.05 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.086 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.523 ' N ' ' HA ' ' A' ' 110' ' ' ASN . . . -123.18 91.79 0.45 Allowed Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.052 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.54 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 0.2 OUTLIER -164.2 100.2 0.85 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.635 0.255 . . . . 0.0 110.668 179.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.532 HG23 ' CG ' ' A' ' 108' ' ' LYS . 51.5 t -82.34 117.32 28.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.883 0.373 . . . . 0.0 111.246 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.531 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.94 -42.75 17.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.807 179.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.61 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.36 144.03 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.42 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.893 HG23 ' O ' ' A' ' 152' ' ' LEU . 13.9 mt -98.81 137.68 25.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.025 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.528 ' CG ' ' HB2' ' A' ' 151' ' ' PRO . 3.4 mm? -84.33 -54.38 4.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.568 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.968 HG11 ' HB3' ' A' ' 91' ' ' PHE . 2.8 t -35.7 139.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.873 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 144' ' ' GLN . 0.8 OUTLIER -78.35 47.34 0.68 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.3 -179.736 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.478 ' OG ' ' HG2' ' A' ' 93' ' ' ARG . 5.0 t 32.45 96.32 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.711 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.565 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 101.36 -29.73 11.9 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.411 -0.9 . . . . 0.0 112.426 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.53 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 7.8 tt0 -53.38 142.49 39.32 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-O 120.826 0.346 . . . . 0.0 110.813 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 26.6 Cg_endo -62.44 95.62 0.15 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.68 2.253 . . . . 0.0 112.299 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.503 HG11 ' CB ' ' A' ' 85' ' ' SER . 18.7 t -37.82 151.31 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 148' ' ' PHE . 4.6 mt-10 -128.71 150.89 50.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.849 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 149' ' ' ASP . 0.2 OUTLIER -36.34 107.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.963 -179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 0.6 OUTLIER 71.48 73.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.002 179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.15 111.64 30.4 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.695 179.884 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.528 ' HB2' ' CG ' ' A' ' 139' ' ' LEU . 84.1 Cg_exo -45.21 92.37 0.02 OUTLIER 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.692 2.261 . . . . 0.0 112.301 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.893 ' O ' HG23 ' A' ' 138' ' ' ILE . 96.8 mt -65.53 -58.44 5.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.008 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.878 HG13 ' CG1' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -150.9 109.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.839 HG12 HG23 ' A' ' 82' ' ' ILE . 2.8 m -79.58 120.86 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.035 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 1.001 HD12 ' CE1' ' A' ' 81' ' ' HIS . 37.5 mt -89.16 140.86 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.218 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.793 ' HA ' HD11 ' A' ' 78' ' ' ILE . 54.3 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.132 -0.937 . . . . 0.0 110.859 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.616 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.842 0.353 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.7 tp -50.62 129.23 8.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.5 m -144.87 21.86 1.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.995 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -98.83 -134.22 8.38 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.544 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.743 ' HE1' HG22 ' A' ' 83' ' ' VAL . 19.0 p80 -170.25 -168.94 0.78 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.752 0.311 . . . . 0.0 110.758 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.046 HG23 HG12 ' A' ' 154' ' ' VAL . 2.3 mt -131.66 112.49 20.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.272 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.743 HG22 ' HE1' ' A' ' 81' ' ' HIS . 42.2 t -70.32 109.16 2.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.145 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.2 OUTLIER -70.69 173.3 7.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.937 -179.997 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.704 ' OG ' HG22 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -111.6 86.76 7.25 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.087 -179.955 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.614 ' O ' HG23 ' A' ' 88' ' ' VAL . 45.2 Cg_exo -55.41 -140.7 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.789 2.326 . . . . 0.0 111.995 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -69.14 60.29 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.901 0.381 . . . . 0.0 110.194 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 89' ' ' GLY . 0.6 OUTLIER -83.14 -173.38 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.664 -179.209 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.683 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -155.15 -57.53 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.914 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.451 ' O ' ' O ' ' A' ' 118' ' ' VAL . 0.5 OUTLIER -140.8 113.43 8.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.69 0.281 . . . . 0.0 110.442 179.613 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.823 ' HB2' HG11 ' A' ' 146' ' ' VAL . 79.9 t80 -85.34 163.96 18.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.98 0.419 . . . . 0.0 111.31 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 55.7 m-85 -157.7 -174.85 5.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.705 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.492 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 2.4 mmm-85 -117.99 -19.54 9.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.883 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.489 ' CB ' ' HA ' ' A' ' 101' ' ' ALA . 9.5 t -179.78 150.37 0.56 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.893 0.377 . . . . 0.0 111.3 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.969 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 72.4 Cg_endo -84.81 86.8 1.12 Allowed 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.877 2.385 . . . . 0.0 112.32 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.5 OUTLIER -26.8 -55.62 0.21 Allowed Pre-proline 0 N--CA 1.465 0.277 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.856 -179.779 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.445 ' HD3' ' CB ' ' A' ' 96' ' ' SER . 71.6 Cg_exo -48.47 80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.821 2.347 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.4 OUTLIER 61.01 62.87 1.35 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.76 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.969 ' HB2' ' O ' ' A' ' 95' ' ' PRO . . . -112.61 167.0 10.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.68 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -128.57 27.24 5.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.21 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 94' ' ' THR . . . 67.11 101.2 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.206 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CD2' ' HD3' ' A' ' 95' ' ' PRO . 1.2 m-85 -52.17 -167.98 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.572 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.2 mm -66.07 82.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.047 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.73 177.51 8.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.088 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.411 HG22 ' HA ' ' A' ' 137' ' ' ALA . 44.8 t -67.55 150.67 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.181 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.59 -13.69 40.12 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.512 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.479 ' CG ' ' N ' ' A' ' 108' ' ' LYS . 49.1 tt0 -87.19 167.46 14.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.786 0.326 . . . . 0.0 110.824 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.3 OUTLIER -97.0 174.67 6.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.859 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.572 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -158.92 168.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.191 -179.972 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.492 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 0.7 OUTLIER -169.39 132.08 1.23 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.884 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 1.022 HG22 ' O ' ' A' ' 130' ' ' ASP . 29.7 t -35.74 93.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.178 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 110' ' ' ASN . . . 150.32 -40.69 0.82 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.541 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.62 160.06 30.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 110.958 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.538 ' HA ' ' CG ' ' A' ' 128' ' ' GLU . 0.3 OUTLIER -68.48 -175.42 0.65 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.493 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.98 -69.63 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.99 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.52 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER 177.03 159.63 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.54 ' CD1' ' HB3' ' A' ' 95' ' ' PRO . 3.9 mt -75.65 145.85 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.995 0.426 . . . . 0.0 111.428 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.555 HG13 ' CG1' ' A' ' 88' ' ' VAL . 30.7 t -98.04 -33.56 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 179.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.553 ' HG2' ' H2 ' ' A' ' 222' ' ' BTN . 0.7 OUTLIER 38.88 59.8 1.54 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.117 -179.852 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.401 ' HB3' ' CE ' ' A' ' 123' ' ' MET . . . -93.25 -4.27 52.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.977 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -173.47 41.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.468 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 5.9 tppt? 60.87 25.22 15.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.279 -179.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.661 ' HE3' ' OD1' ' A' ' 125' ' ' ASN . 10.6 ptt? -97.75 -1.63 42.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.226 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.511 ' HA ' HG23 ' A' ' 117' ' ' ILE . 0.0 OUTLIER 35.33 37.38 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.012 0.434 . . . . 0.0 110.719 179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.661 ' OD1' ' HE3' ' A' ' 123' ' ' MET . 15.3 p-10 -71.31 87.93 0.85 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.595 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.506 ' HB3' HG13 ' A' ' 117' ' ' ILE . 2.5 pt20 -82.54 135.32 35.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.579 HG22 ' N ' ' A' ' 128' ' ' GLU . 7.7 mm -86.05 162.98 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.251 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.579 ' N ' HG22 ' A' ' 127' ' ' ILE . 19.8 mt-10 -122.45 125.0 44.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.736 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.55 127.85 0.62 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.116 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 1.022 ' O ' HG22 ' A' ' 111' ' ' VAL . 0.3 OUTLIER -107.62 -17.16 14.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.808 179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.15 113.27 16.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.492 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -57.11 178.31 0.07 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.945 -179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.02 -169.19 13.24 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.405 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 97.4 m -113.2 107.84 16.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.825 0.345 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.654 HG13 HG12 ' A' ' 153' ' ' VAL . 63.7 t -43.17 125.73 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.099 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -76.72 -46.72 24.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.902 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.97 160.04 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.407 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.713 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 20.5 mt -99.05 151.59 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.544 ' CB ' ' HG2' ' A' ' 151' ' ' PRO . 5.1 mp -119.14 -37.94 3.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.033 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.608 HG11 ' CB ' ' A' ' 91' ' ' PHE . 41.1 t -46.48 -35.04 2.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.183 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 2.4 mt-10 68.53 95.31 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.447 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.48 ' OG ' ' HA ' ' A' ' 92' ' ' TYR . 6.8 t -32.2 152.81 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.168 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.19 8.94 62.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.593 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.471 ' HG3' ' O ' ' A' ' 141' ' ' GLU . 0.8 OUTLIER -106.8 153.82 40.53 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 121.064 0.459 . . . . 0.0 111.028 -179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.38 100.8 1.43 Allowed 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.945 2.43 . . . . 0.0 112.561 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.869 HG23 ' CB ' ' A' ' 150' ' ' GLU . 7.8 p -111.38 136.9 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.69 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.529 ' CB ' ' O ' ' A' ' 88' ' ' VAL . 3.6 pt-20 177.06 92.33 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.726 0.298 . . . . 0.0 111.222 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.516 ' N ' ' O ' ' A' ' 86' ' ' PRO . 2.0 t80 77.54 105.47 0.07 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.855 0.36 . . . . 0.0 111.536 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 81.77 53.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.578 179.307 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.869 ' CB ' HG23 ' A' ' 146' ' ' VAL . 0.1 OUTLIER -147.49 124.2 5.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 111.091 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.544 ' HG2' ' CB ' ' A' ' 139' ' ' LEU . 41.9 Cg_endo -67.89 87.81 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.826 2.35 . . . . 0.0 112.301 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.617 ' CD2' ' CD1' ' A' ' 91' ' ' PHE . 7.3 mt -60.39 -53.29 59.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.985 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.654 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -156.89 129.56 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.083 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.046 HG12 HG23 ' A' ' 82' ' ' ILE . 3.4 m -100.04 121.47 50.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 17.5 mm -86.32 151.03 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.258 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 . . . . . 0 C--O 1.25 1.093 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.885 -179.969 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.557 ' H4 ' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 . . . . . 0 C--O 1.23 0.052 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 tt -98.49 132.05 44.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.141 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 41.2 t -105.32 40.54 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.945 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -125.8 -150.47 7.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.508 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 1.005 ' NE2' HD13 ' A' ' 155' ' ' ILE . 2.8 p80 -171.81 163.99 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.825 0.345 . . . . 0.0 110.916 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.78 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mm -116.82 118.36 58.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' A' ' 152' ' ' LEU . 6.3 t -89.91 93.34 4.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.033 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 7.4 ptt180 -88.56 145.65 25.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.951 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.585 ' HA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -75.5 109.87 9.0 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.881 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 40.7 Cg_endo -67.78 -52.24 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.719 2.279 . . . . 0.0 112.393 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.8 mmm -109.55 135.3 50.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.066 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 147' ' ' GLU . 49.0 t -48.24 156.97 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.099 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.457 ' N ' ' CG1' ' A' ' 88' ' ' VAL . . . 175.3 -142.62 6.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.506 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.1 m -141.51 102.8 4.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.821 0.343 . . . . 0.0 110.971 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.612 ' CE2' HD13 ' A' ' 138' ' ' ILE . 19.3 t80 -64.05 168.5 5.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.574 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 20.6 m-85 -173.14 165.37 4.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.939 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -128.05 -4.28 5.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.627 ' CA ' ' HB1' ' A' ' 99' ' ' ALA . 4.2 p -153.19 97.57 2.8 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.611 ' HG2' ' CE2' ' A' ' 102' ' ' PHE . 24.4 Cg_exo -62.08 113.92 2.09 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.699 2.266 . . . . 0.0 112.037 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.509 ' HB3' ' CD ' ' A' ' 97' ' ' PRO . 9.9 t -29.54 -61.25 0.23 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.389 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.509 ' CD ' ' HB3' ' A' ' 96' ' ' SER . 15.1 Cg_endo -57.43 78.05 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.802 2.335 . . . . 0.0 112.067 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.458 ' N ' ' O ' ' A' ' 96' ' ' SER . 23.6 t0 62.47 47.2 5.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.703 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.627 ' HB1' ' CA ' ' A' ' 94' ' ' THR . . . -38.38 -68.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.369 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 99' ' ' ALA . 6.9 mmtm 63.54 16.65 9.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.765 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 59.62 102.4 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.104 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.899 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.3 OUTLIER -57.68 -87.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.724 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.899 HD13 ' O ' ' A' ' 102' ' ' PHE . 8.0 mm -136.57 67.79 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.046 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -55.46 168.5 0.38 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.987 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 135' ' ' VAL . 52.9 t -65.29 147.57 12.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.17 -7.73 76.92 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.442 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.871 ' O ' HG23 ' A' ' 134' ' ' THR . 37.1 tt0 -89.31 167.93 12.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.713 0.292 . . . . 0.0 110.861 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.45 ' HD2' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -81.75 155.96 25.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.995 -179.914 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.576 ' CG1' HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -148.72 85.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.084 -179.958 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.451 ' OD1' ' HB2' ' A' ' 113' ' ' ASP . 32.4 p-10 -81.57 140.22 34.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.925 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.615 HG23 ' HB2' ' A' ' 132' ' ' SER . 15.6 t -43.88 108.45 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 120.68 -14.8 9.82 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HB2' ' OD1' ' A' ' 110' ' ' ASN . 0.4 OUTLIER -81.27 154.05 26.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.994 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -66.73 -170.64 0.11 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.94 -179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.5 tp -147.46 -69.44 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.912 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.4 p -176.88 155.02 1.19 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.953 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.501 HG13 ' HB3' ' A' ' 126' ' ' GLN . 11.3 mt -82.19 139.57 17.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.036 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.927 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.3 t -95.33 -21.77 5.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.205 179.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 118' ' ' VAL . 4.5 tt0 33.16 89.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.328 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.812 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -121.27 14.79 11.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.694 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.494 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 1.8 ptp 158.95 41.81 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.45 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.9 tppt? 60.28 18.4 7.94 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.035 0.445 . . . . 0.0 110.368 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.812 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 7.3 ptt? -81.08 -22.36 39.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.042 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.55 ' SD ' ' H2 ' ' A' ' 222' ' ' BTN . 1.8 tpp 59.46 39.08 22.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.905 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.927 ' O ' HG23 ' A' ' 118' ' ' VAL . 0.9 OUTLIER -69.57 72.7 0.35 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.604 179.763 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.559 ' OE1' ' CZ ' ' A' ' 102' ' ' PHE . 26.9 pt20 -81.42 133.9 35.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.231 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 5.6 mm -81.64 154.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.002 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -133.08 114.14 13.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.84 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.513 ' CB ' ' HB ' ' A' ' 109' ' ' VAL . . . -47.44 125.48 8.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.031 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 3.2 p-10 -132.39 28.94 4.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 132' ' ' SER . 0.5 OUTLIER -126.25 -2.52 6.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.019 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.615 ' HB2' HG23 ' A' ' 111' ' ' VAL . 0.4 OUTLIER 59.02 132.68 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.853 179.974 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 109' ' ' VAL . . . 141.91 -155.28 25.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.474 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.871 HG23 ' O ' ' A' ' 107' ' ' GLN . 96.8 m -134.56 132.85 39.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.906 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.708 HG13 HG12 ' A' ' 153' ' ' VAL . 72.2 t -53.37 137.77 13.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.14 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.9 -51.55 5.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.483 ' HA ' HG11 ' A' ' 105' ' ' VAL . . . -172.75 175.08 3.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.612 HD13 ' CE2' ' A' ' 91' ' ' PHE . 4.4 mt -126.23 149.03 30.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.055 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.8 mm? -119.51 -32.67 4.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.948 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.855 HG11 HG12 ' A' ' 146' ' ' VAL . 53.5 t -55.77 -32.02 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.3 mt-10 68.9 94.08 0.07 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.876 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.4 OUTLIER -38.17 161.45 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 66.18 7.78 40.0 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.264 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.452 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 1.1 tm0? -119.38 134.93 23.76 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.866 0.365 . . . . 0.0 110.854 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.452 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 25.3 Cg_endo -62.39 110.58 1.08 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.776 2.317 . . . . 0.0 112.26 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.855 HG12 HG11 ' A' ' 140' ' ' VAL . 18.4 m -64.23 149.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 88' ' ' VAL . 1.8 mt-10 -129.82 150.98 50.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.846 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.419 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.7 t80 -35.21 117.5 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 73.1 71.98 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.472 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.2 OUTLIER -136.48 109.8 9.56 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.98 179.933 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 77.6 Cg_exo -50.12 88.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.721 2.281 . . . . 0.0 112.293 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.585 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -60.31 -51.65 68.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.978 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.708 HG12 HG13 ' A' ' 135' ' ' VAL . 1.4 t -157.11 115.56 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.162 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.78 HG12 HG23 ' A' ' 82' ' ' ILE . 3.3 m -87.07 125.97 40.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.024 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 1.005 HD13 ' NE2' ' A' ' 81' ' ' HIS . 2.0 mp -106.6 139.36 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.158 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.887 -179.972 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.55 ' H2 ' ' SD ' ' A' ' 124' ' ' MET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.867 0.365 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.4 pt -80.47 -179.14 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.455 ' O ' ' O ' ' A' ' 80' ' ' GLY . 0.3 OUTLIER -115.14 -28.14 7.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.921 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 79' ' ' SER . . . 32.62 -154.5 0.01 OUTLIER Glycine 0 N--CA 1.453 -0.214 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.773 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 1.088 ' ND1' HD12 ' A' ' 155' ' ' ILE . 2.0 t-80 179.91 98.38 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.906 0.384 . . . . 0.0 110.707 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 154' ' ' VAL . 2.9 mt -89.64 138.17 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.244 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.828 HG22 ' HE1' ' A' ' 81' ' ' HIS . 2.5 t -108.8 118.59 56.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 149' ' ' ASP . 15.0 mtm180 -105.06 123.12 47.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -45.47 102.98 0.32 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.933 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -56.29 -50.2 12.79 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.78 2.32 . . . . 0.0 112.366 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.516 ' HG2' ' N ' ' A' ' 88' ' ' VAL . 56.2 ttm -120.14 161.62 20.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.988 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.871 HG22 ' HA ' ' A' ' 147' ' ' GLU . 48.1 t -72.83 155.98 6.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.042 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' HG12 ' A' ' 118' ' ' VAL . . . 172.36 -121.83 0.9 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.446 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.7 m -160.75 105.61 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.829 0.347 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.621 ' H ' HG13 ' A' ' 146' ' ' VAL . 34.0 t80 -62.47 157.16 20.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.833 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.423 ' N ' ' CG ' ' A' ' 91' ' ' PHE . 4.2 m-85 -161.59 169.75 21.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.962 0.41 . . . . 0.0 111.118 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.01 -38.88 0.96 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.845 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.561 ' HB ' ' HB1' ' A' ' 99' ' ' ALA . 2.0 p -119.33 90.39 42.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.127 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.545 ' CB ' ' S1 ' ' A' ' 222' ' ' BTN . 35.2 Cg_endo -65.67 117.59 4.75 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.621 2.214 . . . . 0.0 112.238 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.528 ' OG ' ' CD ' ' A' ' 97' ' ' PRO . 0.3 OUTLIER -34.91 -59.9 0.58 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.987 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.528 ' CD ' ' OG ' ' A' ' 96' ' ' SER . 19.4 Cg_endo -58.96 69.13 0.05 OUTLIER 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.805 2.337 . . . . 0.0 112.455 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.8 t0 81.22 47.92 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.308 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.561 ' HB1' ' HB ' ' A' ' 94' ' ' THR . . . -55.7 93.93 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.986 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.78 30.85 1.29 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.88 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 54.66 89.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.055 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.562 ' CE1' ' HA ' ' A' ' 116' ' ' CYS . 4.0 m-85 -51.39 -169.95 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.797 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG21 HG21 ' A' ' 109' ' ' VAL . 1.8 mm -64.54 71.93 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.065 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 102' ' ' PHE . 2.4 mt-10 -60.34 172.74 0.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.061 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.504 HG22 ' HA ' ' A' ' 137' ' ' ALA . 84.2 t -65.32 152.63 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.188 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 65.46 7.49 33.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.626 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.461 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 51.4 tt0 -88.42 167.35 13.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.48 ' O ' HG13 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -101.27 139.0 37.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.951 179.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.81 HG21 HG21 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -165.76 176.16 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.987 179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 133' ' ' GLY . 0.9 OUTLIER -169.52 -157.69 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.912 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.753 HG22 ' HA ' ' A' ' 131' ' ' LYS . 12.2 t -65.2 133.43 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 129' ' ' ALA . . . 77.42 13.22 83.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.581 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 129' ' ' ALA . 0.3 OUTLIER -102.43 114.51 28.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.691 0.281 . . . . 0.0 110.946 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 113' ' ' ASP . 0.3 OUTLIER -34.26 152.77 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.173 -179.921 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.9 tp -116.88 -72.46 0.69 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.562 ' HA ' ' CE1' ' A' ' 102' ' ' PHE . 6.1 p 177.46 157.63 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.934 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.761 HD13 ' S1 ' ' A' ' 222' ' ' BTN . 4.4 mt -74.92 144.6 11.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.362 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.981 HG23 ' O ' ' A' ' 125' ' ' ASN . 18.5 t -97.24 -24.4 4.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.624 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.469 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 1.6 tt0 34.69 55.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.457 ' O ' ' HB3' ' A' ' 121' ' ' MET . . . -70.6 -16.95 62.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.915 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.475 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 7.9 ptt? 175.12 50.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.661 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.533 ' HE2' ' CE ' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.04 34.15 4.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.785 -179.762 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.553 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 11.0 ttp -104.19 -17.78 14.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.714 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.57 ' HA ' HG23 ' A' ' 117' ' ' ILE . 2.0 mmt 52.7 43.13 31.68 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.108 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.981 ' O ' HG23 ' A' ' 118' ' ' VAL . 6.7 t30 -70.49 74.65 0.55 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.525 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.495 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 14.2 pt20 -79.82 112.09 16.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.152 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 19.7 mm -75.35 156.33 6.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.008 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 128' ' ' GLU . 5.7 pt-20 -125.4 111.8 15.55 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.786 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 113' ' ' ASP . . . -38.95 112.51 0.24 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.197 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.413 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 4.3 p-10 -101.46 22.4 12.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.736 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.753 ' HA ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 167.89 77.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.624 -179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.778 ' HA ' HD13 ' A' ' 155' ' ' ILE . 0.3 OUTLIER -125.9 -154.87 0.65 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -179.754 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 109' ' ' VAL . . . 168.95 -54.18 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.116 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.5 m -153.81 85.42 1.17 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.805 0.336 . . . . 0.0 110.778 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.683 HG13 HG12 ' A' ' 153' ' ' VAL . 95.9 t -45.6 124.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.128 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -82.57 -49.02 10.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.553 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 177.0 166.24 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.015 0.435 . . . . 0.0 111.542 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.551 ' O ' HD13 ' A' ' 139' ' ' LEU . 8.5 mt -115.02 154.1 16.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.702 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 138' ' ' ILE . 2.0 mm? -120.94 -26.16 5.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.221 -179.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.617 HG11 ' CB ' ' A' ' 91' ' ' PHE . 44.9 t -53.77 -50.4 51.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.212 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.7 OUTLIER 84.06 99.46 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.699 -179.843 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.553 ' HA ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -39.5 161.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 -179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 69.49 3.75 41.69 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.519 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.4 tt0 -117.06 141.82 29.0 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 120.866 0.365 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.519 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 45.1 Cg_endo -68.34 128.86 18.05 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 0.0 112.282 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.621 HG13 ' H ' ' A' ' 91' ' ' PHE . 4.1 m -88.65 151.02 3.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.104 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.4 mp0 -135.39 157.03 47.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 0.3 OUTLIER -44.3 120.86 2.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.928 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.469 ' HA ' ' HB3' ' A' ' 84' ' ' ARG . 9.6 m-20 77.43 60.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -128.37 116.08 19.92 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.812 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.483 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 52.9 Cg_exo -52.22 83.48 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.683 2.255 . . . . 0.0 112.317 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.582 HD23 HG21 ' A' ' 140' ' ' VAL . 9.9 mt -66.82 -45.59 77.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.683 HG12 HG13 ' A' ' 135' ' ' VAL . 2.0 t -159.8 122.47 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 82' ' ' ILE . 3.7 m -94.59 125.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.09 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 1.088 HD12 ' ND1' ' A' ' 81' ' ' HIS . 34.0 mt -95.34 142.36 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.289 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.424 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 5.6 tt0 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.871 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.761 ' S1 ' HD13 ' A' ' 117' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.841 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.528 HG23 ' O ' ' A' ' 78' ' ' ILE . 0.0 OUTLIER -114.21 123.28 69.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.263 -179.957 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.92 7.59 8.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.441 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . -70.42 -151.67 0.73 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.476 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 155' ' ' ILE . 0.7 OUTLIER -159.82 -163.66 1.19 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.797 0.332 . . . . 0.0 110.888 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.74 HG23 HG12 ' A' ' 154' ' ' VAL . 3.6 mt -143.96 112.07 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.183 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.96 113.25 8.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.112 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -88.33 138.19 31.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.868 179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.705 ' OG ' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -63.56 108.97 2.08 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.94 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 51.0 Cg_exo -55.4 -66.08 0.1 OUTLIER 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 2.294 . . . . 0.0 112.286 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.9 mtt -120.19 -175.32 2.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.833 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 146' ' ' VAL . 84.7 t -90.77 144.36 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.091 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.492 ' HA3' ' HA ' ' A' ' 120' ' ' ALA . . . -174.35 -117.98 0.49 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.491 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 4.2 m -160.21 117.34 2.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.846 0.355 . . . . 0.0 110.91 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.819 ' HE2' HD13 ' A' ' 138' ' ' ILE . 0.1 OUTLIER -68.48 161.05 28.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.896 -179.935 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.544 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 17.7 m-85 -166.47 -69.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.922 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.627 ' CZ ' HD12 ' A' ' 138' ' ' ILE . 5.0 mtp180 77.87 37.86 0.21 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.071 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.566 HG22 ' HA ' ' A' ' 101' ' ' ALA . 9.4 p -148.5 108.25 3.57 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.907 0.384 . . . . 0.0 111.13 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 96' ' ' SER . 58.7 Cg_endo -72.08 52.23 1.81 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.687 2.258 . . . . 0.0 112.374 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.644 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER 163.81 132.4 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.646 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -46.87 -22.15 1.84 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.638 2.225 . . . . 0.0 112.242 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 43.6 p30 -147.61 62.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.758 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.644 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -108.73 -155.44 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -114.65 29.95 7.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.851 179.947 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.566 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 57.85 139.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.299 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 1.05 ' CZ ' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -49.74 -94.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.841 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.759 ' O ' HG22 ' A' ' 103' ' ' ILE . 1.2 mp -111.64 73.32 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.869 0.366 . . . . 0.0 110.962 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -37.97 154.7 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.997 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.509 HG23 ' NH2' ' A' ' 93' ' ' ARG . 72.9 t -60.66 142.79 15.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.164 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 89.68 -18.35 47.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.536 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.435 ' C ' ' HG2' ' A' ' 108' ' ' LYS . 48.1 tt0 -72.15 167.64 19.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.738 0.304 . . . . 0.0 110.805 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.538 ' HD3' HG23 ' A' ' 134' ' ' THR . 0.0 OUTLIER -139.72 140.09 36.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.936 -179.922 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -145.69 -156.44 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.007 179.923 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.506 ' H ' HG12 ' A' ' 109' ' ' VAL . 6.0 p-10 -139.09 142.6 38.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.837 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.524 HG13 ' HA ' ' A' ' 130' ' ' ASP . 97.4 t -36.69 124.45 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 122.18 -18.9 8.3 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.579 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.17 147.78 23.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.796 0.332 . . . . 0.0 110.975 -179.936 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 1.05 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -48.82 -178.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.983 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -149.54 -76.52 0.15 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 6.9 m -158.01 156.8 31.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.543 ' CG1' ' HB3' ' A' ' 126' ' ' GLN . 3.7 mt -101.16 131.84 48.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.021 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.559 HG23 ' HB3' ' A' ' 125' ' ' ASN . 23.6 t -77.54 -21.66 14.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.768 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.507 ' H ' HG22 ' A' ' 117' ' ' ILE . 2.0 tp10 46.5 39.3 6.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.967 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.492 ' HA ' ' HA3' ' A' ' 89' ' ' GLY . . . -59.11 -91.83 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.699 179.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . . . . . . . . . 1.5 ptp -90.92 26.22 2.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.396 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 74.28 26.08 1.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.588 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.699 ' HE2' ' ND2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -95.46 13.36 26.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.909 -179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.5 ' CE ' ' OE1' ' A' ' 119' ' ' GLU . 0.0 OUTLIER 45.57 65.63 1.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.121 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.699 ' ND2' ' HE2' ' A' ' 123' ' ' MET . 0.8 OUTLIER -72.49 57.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.915 0.388 . . . . 0.0 110.477 179.647 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.543 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 3.5 pt20 -67.31 98.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.091 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 115' ' ' LEU . 30.7 mm -67.39 154.0 8.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.738 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.425 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.9 mt-10 -122.51 112.78 18.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.878 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.82 113.74 0.23 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.089 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' HA ' HG13 ' A' ' 111' ' ' VAL . 6.1 p-10 -100.03 -18.78 16.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.1 mttm -130.27 87.53 2.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.457 ' HG ' HG21 ' A' ' 155' ' ' ILE . 2.2 p 61.56 139.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.921 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -94.07 19.11 55.02 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.538 HG23 ' HD3' ' A' ' 108' ' ' LYS . 34.4 m -89.25 85.66 6.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.795 0.331 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.422 HG13 HG12 ' A' ' 153' ' ' VAL . 63.3 t -76.4 135.13 27.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.19 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -87.32 -45.23 10.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.899 -179.944 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 171.17 173.33 0.08 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.214 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.819 HD13 ' HE2' ' A' ' 91' ' ' PHE . 87.1 mt -120.1 157.16 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.038 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.496 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 2.6 mm? -119.83 -33.24 4.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.963 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.929 HG21 HD23 ' A' ' 152' ' ' LEU . 80.8 t -55.9 -41.24 66.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.216 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 85.87 101.88 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.87 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.495 ' HB2' ' HD3' ' A' ' 93' ' ' ARG . 1.4 t -48.26 163.21 0.07 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.779 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 71.03 1.39 40.36 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.675 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.5 OUTLIER -120.41 158.19 51.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.874 0.369 . . . . 0.0 110.895 179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 58.1 Cg_endo -71.21 135.18 26.5 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.804 2.336 . . . . 0.0 112.432 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.736 HG12 HG11 ' A' ' 140' ' ' VAL . 16.7 m -92.07 142.74 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.611 ' HA ' HG22 ' A' ' 88' ' ' VAL . 2.7 tt0 -117.93 147.9 42.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.934 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -48.95 116.62 1.73 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.776 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 19.3 t70 85.59 56.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.916 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 0.3 OUTLIER -132.14 121.12 17.54 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.93 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.9 Cg_exo -50.85 86.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.752 2.301 . . . . 0.0 112.154 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.929 HD23 HG21 ' A' ' 140' ' ' VAL . 92.3 mt -64.12 -50.8 66.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.981 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.422 HG12 HG13 ' A' ' 135' ' ' VAL . 2.5 t -153.55 125.88 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.085 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.74 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -102.08 122.66 54.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.16 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.552 HG22 ' N ' ' A' ' 156' ' ' GLU . 44.7 mm -84.32 160.94 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.203 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.552 ' N ' HG22 ' A' ' 155' ' ' ILE . 10.9 tt0 . . . . . 0 C--O 1.248 1.015 0 CA-C-O 118.171 -0.918 . . . . 0.0 110.876 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.504 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.798 0.332 . . . . 0.0 111.0 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.9 pt -56.31 173.1 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.15 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.1 t -127.75 21.52 6.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.475 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . 53.37 -118.03 7.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.433 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.933 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -146.79 133.78 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.815 0.341 . . . . 0.0 110.844 -179.9 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 81' ' ' HIS . 1.3 mp -125.62 93.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.984 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.447 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.7 t -89.31 123.47 41.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.149 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.59 170.85 7.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' ' CG1' ' A' ' 146' ' ' VAL . 0.6 OUTLIER -107.06 118.38 54.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.973 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 87' ' ' MET . 57.3 Cg_endo -71.34 132.4 20.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.342 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.428 ' CG ' ' N ' ' A' ' 88' ' ' VAL . 37.1 ttp 65.18 163.47 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.826 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.909 HG13 ' O ' ' A' ' 146' ' ' VAL . 39.5 t -75.76 145.07 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -166.02 -143.44 3.74 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 26.2 m -141.28 112.02 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 110.888 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.679 ' CE2' HD13 ' A' ' 138' ' ' ILE . 20.1 t80 -77.63 171.73 14.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.572 ' CG ' ' O ' ' A' ' 91' ' ' PHE . 21.9 m-85 -168.61 165.17 12.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.46 ' O ' ' HB2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -121.71 -32.55 3.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.814 179.77 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.723 HG22 ' HA ' ' A' ' 101' ' ' ALA . 20.8 p -132.46 92.36 28.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.509 ' HA ' ' C3 ' ' A' ' 222' ' ' BTN . 51.8 Cg_endo -69.57 -168.72 0.28 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.646 2.231 . . . . 0.0 112.066 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.537 ' O ' ' N ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER 31.58 102.05 0.02 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.609 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.558 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 57.3 Cg_exo -30.17 86.68 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.24 2.626 . . . . 0.0 112.325 179.231 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.558 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 9.2 m-20 94.55 42.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.551 -179.438 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 96' ' ' SER . . . -77.35 -148.3 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.079 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -108.63 16.69 22.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.82 0.343 . . . . 0.0 111.042 -179.944 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.723 ' HA ' HG22 ' A' ' 94' ' ' THR . . . 58.56 132.4 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.218 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.526 ' CE2' HD12 ' A' ' 117' ' ' ILE . 1.2 m-85 -72.41 -168.01 0.39 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.644 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.94 HG21 ' CG1' ' A' ' 109' ' ' VAL . 16.3 mm -70.67 78.0 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.029 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -57.24 152.22 14.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.959 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 106' ' ' GLY . 71.7 t -58.96 154.04 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.19 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 105' ' ' VAL . . . 87.77 -16.1 52.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.544 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.473 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 27.2 tt0 -94.79 167.74 11.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.751 0.31 . . . . 0.0 110.849 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.473 ' N ' ' HG2' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -95.5 164.85 12.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.917 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.94 ' CG1' HG21 ' A' ' 103' ' ' ILE . 2.3 m -142.69 110.51 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -96.12 134.93 38.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.5 HG22 ' C ' ' A' ' 130' ' ' ASP . 72.9 t -44.41 105.52 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.183 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.93 -7.36 3.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -103.49 157.6 16.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.892 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.51 -160.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.706 HD22 HG21 ' A' ' 127' ' ' ILE . 0.6 OUTLIER -157.66 -70.1 0.09 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.931 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.47 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.2 m -178.86 157.37 0.89 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.527 HG13 ' CB ' ' A' ' 126' ' ' GLN . 4.6 mt -103.15 152.22 6.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.971 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HB3' ' A' ' 125' ' ' ASN . 3.5 t -100.01 -26.16 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.926 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.401 ' N ' HG22 ' A' ' 117' ' ' ILE . 15.9 tt0 40.54 61.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.535 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.94 -12.25 42.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.126 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.439 ' HG3' ' O ' ' A' ' 121' ' ' MET . 1.7 ptm -165.22 34.37 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.77 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.655 ' HE2' ' HE3' ' A' ' 124' ' ' MET . 0.0 OUTLIER 68.87 11.4 8.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.929 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.535 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 3.4 ptt? -80.67 -15.79 55.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.655 ' HE3' ' HE2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.29 59.77 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.56 ' HB3' HG23 ' A' ' 118' ' ' VAL . 58.4 t-20 -64.05 66.44 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.604 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.527 ' CB ' HG13 ' A' ' 117' ' ' ILE . 4.3 pt20 -75.65 120.58 21.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.017 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.706 HG21 HD22 ' A' ' 115' ' ' LEU . 0.5 OUTLIER -89.37 143.3 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.96 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -115.67 114.2 24.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.53 124.43 14.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.5 ' C ' HG22 ' A' ' 111' ' ' VAL . 49.5 p30 -145.19 24.53 1.44 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.868 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.42 -11.61 13.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 63.5 135.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.833 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.2 -168.87 24.72 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.497 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.564 ' C ' HG23 ' A' ' 155' ' ' ILE . 3.9 m -116.54 127.23 54.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.786 0.327 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 153' ' ' VAL . 54.1 t -59.24 115.36 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.158 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.546 ' HB3' HG23 ' A' ' 154' ' ' VAL . 3.9 tmtp? -69.92 -58.9 3.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.985 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -174.4 171.6 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.258 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.679 HD13 ' CE2' ' A' ' 91' ' ' PHE . 7.1 mt -116.81 140.74 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.024 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 8.7 mp -109.39 -35.68 6.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.081 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' A' ' 150' ' ' GLU . 73.4 t -49.12 -32.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.158 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.475 ' HB2' ' O ' ' A' ' 140' ' ' VAL . 7.1 mt-10 68.01 91.42 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.849 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.463 ' O ' ' O ' ' A' ' 141' ' ' GLU . 0.1 OUTLIER -39.34 163.05 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.617 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 63.94 9.12 32.37 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.278 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.528 ' CG ' ' HD2' ' A' ' 145' ' ' PRO . 12.6 tt0 -116.76 141.64 28.51 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.817 0.342 . . . . 0.0 110.695 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 144' ' ' GLN . 27.4 Cg_endo -62.42 96.12 0.15 Allowed 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.686 2.257 . . . . 0.0 112.27 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.909 ' O ' HG13 ' A' ' 88' ' ' VAL . 72.8 t -38.61 161.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.08 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.565 ' N ' HG12 ' A' ' 146' ' ' VAL . 0.2 OUTLIER -143.21 139.67 30.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.408 ' C ' ' O ' ' A' ' 147' ' ' GLU . 1.0 OUTLIER -36.4 120.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.821 179.865 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 68.75 61.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.624 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.883 ' HB3' HG22 ' A' ' 140' ' ' VAL . 4.1 mm-40 -118.97 113.68 35.65 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.78 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.652 ' O ' HG23 ' A' ' 140' ' ' VAL . 72.1 Cg_exo -50.85 98.59 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.713 2.275 . . . . 0.0 112.448 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.731 HD23 HG21 ' A' ' 140' ' ' VAL . 88.3 mt -68.22 -54.08 20.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.905 HG13 HG13 ' A' ' 135' ' ' VAL . 53.5 t -154.1 112.41 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.135 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 154' ' ' VAL . 4.4 m -93.79 114.42 30.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.089 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.906 HD12 ' HB2' ' A' ' 81' ' ' HIS . 2.7 mt -82.1 152.18 4.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.195 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 136' ' ' LYS . 2.6 tt0 . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.905 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.509 ' C3 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.787 0.327 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.0 tt -58.67 125.27 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.118 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.4 t -91.91 53.93 2.31 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' C ' ' ND1' ' A' ' 81' ' ' HIS . . . -90.41 176.76 41.97 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.699 ' HB2' HD12 ' A' ' 155' ' ' ILE . 1.9 m80 -147.16 112.0 5.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.851 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.821 HD13 ' N ' ' A' ' 82' ' ' ILE . 1.0 OUTLIER -91.92 85.52 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.047 179.933 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.5 t -70.17 85.25 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.099 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.406 ' NH1' ' OD2' ' A' ' 149' ' ' ASP . 0.0 OUTLIER -77.24 150.73 35.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.803 ' HA ' HD11 ' A' ' 152' ' ' LEU . 1.2 t -63.3 126.36 89.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.906 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -73.74 -27.07 12.96 Favored 'Trans proline' 0 N--CA 1.464 -0.209 0 C-N-CA 122.749 2.299 . . . . 0.0 112.419 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.7 ptm -145.6 -172.62 3.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.095 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.872 HG13 ' O ' ' A' ' 146' ' ' VAL . 47.6 t -100.54 145.81 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.988 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 178.07 -110.33 0.29 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.503 ' HA ' HG23 ' A' ' 146' ' ' VAL . 21.1 m -164.38 122.91 1.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.331 . . . . 0.0 110.907 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.732 ' HB2' HG11 ' A' ' 140' ' ' VAL . 19.1 t80 -84.08 173.37 11.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.743 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.567 ' CE2' ' S1 ' ' A' ' 222' ' ' BTN . 6.3 m-85 -169.39 179.08 4.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.03 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' O ' HG23 ' A' ' 94' ' ' THR . 4.5 mtm180 -152.05 17.52 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.105 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.595 HG23 ' O ' ' A' ' 93' ' ' ARG . 2.5 p -161.61 101.43 1.2 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 120.912 0.387 . . . . 0.0 111.526 -179.604 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.467 ' HG2' ' HA ' ' A' ' 99' ' ' ALA . 65.9 Cg_endo -74.23 115.75 4.41 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.729 2.286 . . . . 0.0 111.833 179.532 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.522 ' O ' ' N ' ' A' ' 98' ' ' ASP . 2.6 t -29.16 -60.78 0.23 Allowed Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.544 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 96' ' ' SER . 12.2 Cg_endo -56.05 74.02 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.853 2.369 . . . . 0.0 112.323 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 96' ' ' SER . 0.6 OUTLIER 68.46 51.36 0.66 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.076 179.843 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.54 ' HB1' ' CA ' ' A' ' 94' ' ' THR . . . -54.06 98.59 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.89 0.376 . . . . 0.0 111.005 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.59 38.9 1.02 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' A' ' 102' ' ' PHE . . . 57.18 98.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.195 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.439 ' CE2' ' HA ' ' A' ' 116' ' ' CYS . 0.2 OUTLIER -54.43 -166.66 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.807 179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.52 HG22 HG21 ' A' ' 135' ' ' VAL . 4.2 mm -69.95 86.38 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -94.64 170.13 9.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.011 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.573 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -47.85 141.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.213 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 88.19 -53.93 4.2 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.514 ' HG2' ' N ' ' A' ' 108' ' ' LYS . 48.2 tt0 -72.17 167.68 19.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.739 0.304 . . . . 0.0 110.632 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 1.016 ' HG2' HG23 ' A' ' 135' ' ' VAL . 0.0 OUTLIER 170.33 -160.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.867 0.365 . . . . 0.0 111.269 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.836 HG13 ' N ' ' A' ' 110' ' ' ASN . 1.2 p 176.98 -153.61 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.719 -179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.836 ' N ' HG13 ' A' ' 109' ' ' VAL . 20.8 p-10 -106.15 167.7 9.63 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.858 0.361 . . . . 0.0 110.824 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 15.4 t -56.12 133.78 20.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 123.63 -30.86 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.499 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.616 ' HB2' HG11 ' A' ' 109' ' ' VAL . 0.2 OUTLIER -74.13 164.62 26.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.854 0.359 . . . . 0.0 111.019 179.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -68.34 -176.06 0.7 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.2 tp -141.45 -72.02 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.039 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 126' ' ' GLN . 0.8 OUTLIER -175.63 157.02 1.99 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.96 -179.927 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 124' ' ' MET . 4.9 mt -92.53 133.28 34.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.308 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.509 HG23 ' O ' ' A' ' 125' ' ' ASN . 7.7 t -85.6 -16.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.762 179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.456 ' OE1' ' S1 ' ' A' ' 222' ' ' BTN . 2.3 tt0 44.0 37.49 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.827 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.537 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -64.19 102.97 0.56 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.699 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.537 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 6.0 ptp 51.88 28.34 5.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.554 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' MET . 11.3 tppt? 78.37 62.27 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.677 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.537 ' CE ' ' HB2' ' A' ' 125' ' ' ASN . 9.9 ttp -123.43 -2.61 8.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.027 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.517 ' CE ' ' H62' ' A' ' 222' ' ' BTN . 19.2 mmt 42.81 39.83 1.85 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.816 0.341 . . . . 0.0 111.006 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.537 ' HB2' ' CE ' ' A' ' 123' ' ' MET . 19.7 t-20 -64.73 65.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.808 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 124' ' ' MET . 20.9 pt20 -71.72 103.51 3.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.993 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.2 mm -73.85 160.61 5.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.26 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.51 ' O ' ' N ' ' A' ' 130' ' ' ASP . 15.0 mt-10 -122.07 127.08 49.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -36.3 91.68 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.31 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 128' ' ' GLU . 10.5 p-10 -74.1 -19.1 60.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.667 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.545 ' HB2' ' CD1' ' A' ' 155' ' ' ILE . 0.2 OUTLIER -121.79 120.67 35.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.76 179.929 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.3 t -67.95 171.15 7.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.978 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 115.95 -162.78 12.47 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.476 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.569 ' HA ' ' CB ' ' A' ' 108' ' ' LYS . 37.0 m -111.88 142.48 44.22 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 1.016 HG23 ' HG2' ' A' ' 108' ' ' LYS . 41.5 t -76.24 131.12 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.941 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -82.82 -43.48 16.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.625 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 172.97 158.93 0.11 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.389 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.617 ' CD1' HG22 ' A' ' 153' ' ' VAL . 4.2 mt -112.19 136.92 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.817 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 151' ' ' PRO . 10.5 mp -100.61 -48.49 4.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.707 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.755 HG21 HD23 ' A' ' 152' ' ' LEU . 44.3 t -35.06 128.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.215 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 142' ' ' SER . 1.2 mp0 -66.98 61.64 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.091 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -35.33 158.32 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.06 -179.726 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 70.85 4.35 54.06 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.942 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.475 ' HG2' ' HD3' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -140.82 176.84 2.23 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 120.871 0.367 . . . . 0.0 110.724 -179.874 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HD3' ' HG2' ' A' ' 144' ' ' GLN . 32.4 Cg_exo -57.96 159.32 18.36 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.735 2.29 . . . . 0.0 112.206 179.841 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.872 ' O ' HG13 ' A' ' 88' ' ' VAL . 88.6 t -120.7 157.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.036 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.871 ' HA ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -126.06 153.97 43.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.911 -179.96 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.475 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 26.2 t80 -58.63 120.81 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.3 t70 82.31 53.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.889 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' N ' ' A' ' 152' ' ' LEU . 0.1 OUTLIER -118.08 108.32 42.46 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.638 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 139' ' ' LEU . 85.2 Cg_exo -43.77 88.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.674 2.249 . . . . 0.0 112.435 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.803 HD11 ' HA ' ' A' ' 85' ' ' SER . 6.4 mt -62.21 -53.91 48.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.013 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.617 HG22 ' CD1' ' A' ' 138' ' ' ILE . 4.7 t -151.17 117.4 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.201 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 154' ' ' VAL . 3.8 m -90.53 115.62 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.045 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.699 HD12 ' HB2' ' A' ' 81' ' ' HIS . 23.3 mt -84.19 155.5 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.129 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.441 ' N ' HG22 ' A' ' 155' ' ' ILE . 4.5 tt0 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.938 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.567 ' S1 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.755 0.312 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.415 ' CG1' ' H ' ' A' ' 80' ' ' GLY . 6.2 tt -126.61 126.57 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.14 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -98.69 7.28 46.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.061 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.439 ' HA3' ' OXT' ' A' ' 156' ' ' GLU . . . 79.94 -132.36 11.29 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.449 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.667 ' HD2' HD13 ' A' ' 155' ' ' ILE . 0.0 OUTLIER -137.68 105.79 5.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.881 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.144 HG23 HG12 ' A' ' 154' ' ' VAL . 4.1 mt -86.61 134.18 28.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 57.7 t -101.98 89.71 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -90.1 144.73 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.655 ' HB2' HD11 ' A' ' 152' ' ' LEU . 47.8 t -73.69 110.94 10.18 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 50.1 Cg_exo -53.51 -42.86 62.45 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.799 2.333 . . . . 0.0 112.383 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.1 ptp -125.3 172.33 9.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.927 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 147' ' ' GLU . 40.1 t -67.34 162.45 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.058 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.6 ' C ' HG22 ' A' ' 146' ' ' VAL . . . 166.75 -136.33 4.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.509 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 119' ' ' GLU . 5.4 m -148.45 121.39 8.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.797 0.332 . . . . 0.0 110.864 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.692 ' CD1' HD22 ' A' ' 152' ' ' LEU . 20.5 t80 -87.35 170.83 11.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.729 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.524 ' CD2' ' H61' ' A' ' 222' ' ' BTN . 10.7 m-85 -161.64 174.73 12.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.036 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -136.62 6.63 2.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.017 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.638 HG22 ' HA ' ' A' ' 101' ' ' ALA . 15.9 p -152.27 118.23 3.07 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.521 ' HG3' ' CZ ' ' A' ' 102' ' ' PHE . 52.7 Cg_exo -54.92 -147.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.717 2.278 . . . . 0.0 112.165 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.452 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.8 p -34.18 140.49 0.26 Allowed Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.961 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD3' ' H2 ' ' A' ' 222' ' ' BTN . 3.0 Cg_exo -36.52 -28.98 0.08 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.241 2.627 . . . . 0.0 112.271 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.452 ' N ' ' O ' ' A' ' 96' ' ' SER . 34.0 m-20 -122.65 60.42 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.807 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.406 ' CB ' ' HB2' ' A' ' 95' ' ' PRO . . . -107.54 -153.46 0.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.144 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.33 31.41 5.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.005 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.763 ' HB1' ' OE2' ' A' ' 104' ' ' GLU . . . 60.35 134.88 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.338 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.578 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.5 OUTLIER -77.12 -168.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.671 179.887 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.555 HG23 ' HG2' ' A' ' 107' ' ' GLN . 3.5 mm -68.74 93.89 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.949 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.763 ' OE2' ' HB1' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -90.37 -178.27 5.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 137' ' ' ALA . 42.7 t -62.45 136.2 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.448 ' O ' ' HD2' ' A' ' 108' ' ' LYS . . . 93.8 -10.69 72.09 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.555 ' HG2' HG23 ' A' ' 103' ' ' ILE . 3.4 tp-100 -86.92 157.84 19.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.531 0.205 . . . . 0.0 110.693 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.504 ' N ' ' HG3' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -152.81 99.28 2.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.757 0.313 . . . . 0.0 111.084 -179.815 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.518 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 10.9 m -107.58 166.08 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.41 ' O ' ' C ' ' A' ' 111' ' ' VAL . 7.5 p30 -101.74 153.24 19.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.816 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.41 ' C ' ' O ' ' A' ' 110' ' ' ASN . 51.0 t -35.64 136.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.6 -18.62 29.57 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.471 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -87.09 161.79 17.93 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.519 HG23 ' OE1' ' A' ' 126' ' ' GLN . 0.3 OUTLIER -71.52 -177.47 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.817 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.3 tp -139.53 -71.77 0.39 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.911 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.578 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.1 m -177.32 154.84 1.06 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 126' ' ' GLN . 11.3 mt -87.87 145.9 6.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.133 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 125' ' ' ASN . 3.9 t -98.46 -21.7 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.791 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 119' ' ' GLU . 2.8 tt0 41.27 38.63 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.055 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.507 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -64.95 -77.07 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.782 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.447 ' O ' ' CG ' ' A' ' 121' ' ' MET . 0.1 OUTLIER -98.6 35.41 1.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.548 179.674 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.472 ' HD2' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 60.26 41.16 16.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.615 -179.652 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE3' ' HB2' ' A' ' 125' ' ' ASN . 0.0 OUTLIER -116.92 15.15 15.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.933 -179.822 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.511 ' O ' ' N ' ' A' ' 126' ' ' GLN . 27.7 mmt 39.02 45.65 1.03 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.767 ' O ' HG23 ' A' ' 118' ' ' VAL . 54.3 t-20 -59.9 76.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.591 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.519 ' OE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -83.18 114.14 21.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.218 -179.698 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 115' ' ' LEU . 10.3 mm -76.65 148.46 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' A' ' 129' ' ' ALA . 40.7 mt-10 -116.5 115.14 25.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.921 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.93 98.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.1 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -102.84 36.84 2.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 132' ' ' SER . 5.4 mttp 169.62 62.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.592 ' O ' HG21 ' A' ' 155' ' ' ILE . 16.9 t 74.42 130.78 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.824 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.518 ' HA3' ' CG2' ' A' ' 109' ' ' VAL . . . -104.6 27.07 20.57 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.596 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 9.0 m -74.26 62.88 0.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.883 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.651 HG22 ' CG1' ' A' ' 153' ' ' VAL . 76.4 t -50.73 110.81 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.167 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.9 OUTLIER -73.18 -29.52 62.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.75 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 168.8 160.32 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.191 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.617 HD11 HG22 ' A' ' 153' ' ' VAL . 2.9 mt -118.62 133.89 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.431 ' N ' HD12 ' A' ' 139' ' ' LEU . 7.9 mp -103.16 -49.55 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.611 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.645 HG21 HD23 ' A' ' 152' ' ' LEU . 43.7 t -41.25 127.04 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.987 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' A' ' 142' ' ' SER . 69.4 mm-40 -65.62 61.71 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.215 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.586 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -35.62 158.56 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.99 -179.739 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 78.26 -3.66 61.55 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.888 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.438 ' CB ' ' CD ' ' A' ' 145' ' ' PRO . 0.5 OUTLIER -133.06 176.88 2.57 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.894 0.378 . . . . 0.0 110.581 -179.941 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 144' ' ' GLN . 16.1 Cg_exo -67.77 133.95 31.01 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.795 2.33 . . . . 0.0 112.178 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.6 HG22 ' C ' ' A' ' 89' ' ' GLY . 16.4 m -95.16 178.09 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.001 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.672 ' HA ' HG22 ' A' ' 88' ' ' VAL . 9.1 tt0 -141.75 164.52 29.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.013 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 148' ' ' PHE . 0.6 OUTLIER -56.06 119.76 6.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.915 179.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.5 t0 76.34 66.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.86 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -130.5 108.19 15.95 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.949 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.618 ' C ' HG23 ' A' ' 140' ' ' VAL . 59.4 Cg_exo -51.64 87.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.861 2.374 . . . . 0.0 112.367 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.692 HD22 ' CD1' ' A' ' 91' ' ' PHE . 7.4 mt -68.13 -54.41 18.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.84 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.651 ' CG1' HG22 ' A' ' 135' ' ' VAL . 17.0 t -142.41 112.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.144 HG12 HG23 ' A' ' 82' ' ' ILE . 2.2 m -94.73 116.66 36.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 81' ' ' HIS . 1.1 mt -86.11 145.69 7.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.124 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OXT' ' HA3' ' A' ' 80' ' ' GLY . 5.2 tt0 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.524 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.82 0.343 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 4.3 tp -155.22 121.61 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.9 p -114.12 12.69 17.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 60.91 -103.27 0.5 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.568 ' NE2' HD12 ' A' ' 155' ' ' ILE . 10.4 p80 -171.32 -166.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.825 0.345 . . . . 0.0 110.987 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.011 HG23 HG12 ' A' ' 154' ' ' VAL . 7.8 mt -140.36 114.73 6.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.068 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.615 HG23 ' O ' ' A' ' 153' ' ' VAL . 5.8 t -71.92 97.27 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.529 ' HB2' ' NH1' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -90.47 126.12 35.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.843 -179.96 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.885 ' HA ' HD11 ' A' ' 152' ' ' LEU . 21.5 t -50.19 107.83 0.88 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.008 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -53.87 -39.88 82.72 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.802 2.334 . . . . 0.0 112.072 179.801 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -132.17 -165.78 1.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.663 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 146' ' ' VAL . 56.4 t -95.25 155.23 3.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.206 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.453 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 172.09 -130.02 1.85 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.418 179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.461 ' CA ' HG23 ' A' ' 146' ' ' VAL . 0.7 OUTLIER -153.88 114.69 4.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 179.963 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 140' ' ' VAL . 25.1 t80 -67.35 169.09 9.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.513 ' HA ' ' CB ' ' A' ' 142' ' ' SER . 3.4 m-85 -168.91 158.45 8.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.09 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.527 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 1.3 mpp_? -111.4 -23.0 11.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.772 179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.535 ' N ' ' HD3' ' A' ' 95' ' ' PRO . 14.9 p -133.72 60.1 44.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.745 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.758 ' HB2' HD12 ' A' ' 117' ' ' ILE . 31.3 Cg_exo -60.34 64.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.955 2.437 . . . . 0.0 112.342 -179.797 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.525 ' N ' ' O ' ' A' ' 94' ' ' THR . 1.1 m 156.61 107.63 0.0 OUTLIER Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.581 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -47.81 -21.38 2.47 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.642 2.228 . . . . 0.0 112.274 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.51 7.6 44.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.45 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -86.34 -148.67 0.13 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.932 179.91 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.668 ' O ' ' HB2' ' A' ' 101' ' ' ALA . 3.3 ptmm? -151.94 -48.49 0.11 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.895 0.379 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 100' ' ' LYS . . . 163.2 101.85 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.221 -179.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.558 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 1.7 m-85 -52.15 -168.67 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.622 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.81 HG22 ' CG2' ' A' ' 135' ' ' VAL . 2.7 mt -62.09 112.54 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.864 0.364 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.485 ' HG3' ' HG2' ' A' ' 93' ' ' ARG . 0.0 OUTLIER -125.38 -175.1 3.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.976 -179.873 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.728 HG22 ' HA ' ' A' ' 137' ' ' ALA . 2.8 t -54.32 125.89 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.183 -179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 98.74 -47.87 1.38 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.669 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.481 ' O ' ' HG2' ' A' ' 108' ' ' LYS . 18.9 tt0 -48.83 149.65 1.73 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.527 0.203 . . . . 0.0 110.732 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.641 ' HD3' HG23 ' A' ' 134' ' ' THR . 1.1 mtmm -146.74 103.74 3.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 120.757 0.313 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 110' ' ' ASN . 2.7 p -112.46 175.93 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.961 179.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.69 ' H ' HG22 ' A' ' 109' ' ' VAL . 1.2 m-20 -96.99 152.16 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.073 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.776 HG22 ' H ' ' A' ' 132' ' ' SER . 2.9 t -49.86 139.81 4.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.22 -37.52 3.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.491 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.56 160.21 17.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.775 0.321 . . . . 0.0 110.936 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -58.56 170.8 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.875 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 127' ' ' ILE . 1.4 tp -129.14 -61.73 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.976 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.558 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 0.6 OUTLIER 178.22 157.73 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.075 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 95' ' ' PRO . 6.2 mt -101.02 135.01 39.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.007 179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.4 t -85.98 -18.11 9.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.557 179.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.433 ' OE1' ' HA ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 41.96 54.11 4.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.677 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -88.46 110.13 20.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 179.798 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.534 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 2.3 ptt? 48.94 42.24 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.704 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.593 ' CE ' ' HE1' ' A' ' 124' ' ' MET . 0.7 OUTLIER 59.96 65.21 1.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.834 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.677 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 26.7 ttp -120.49 -19.77 7.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.161 -179.835 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.593 ' HE1' ' CE ' ' A' ' 122' ' ' LYS . 3.0 mmt 58.6 38.25 25.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.956 0.408 . . . . 0.0 110.647 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.524 ' O ' HG23 ' A' ' 118' ' ' VAL . 35.9 t30 -68.56 72.16 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.697 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.548 ' HB3' ' CG1' ' A' ' 117' ' ' ILE . 20.3 pt20 -83.48 121.21 26.89 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.131 -179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 115' ' ' LEU . 8.4 mm -87.07 165.45 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.011 179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.8 mp0 -134.55 125.51 27.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.998 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.0 116.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -104.78 -13.27 15.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.877 179.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 46.4 mttm -144.65 69.62 1.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.776 ' H ' HG22 ' A' ' 111' ' ' VAL . 0.0 OUTLIER 76.32 164.02 0.25 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.82 -179.974 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.618 ' HA3' HG12 ' A' ' 109' ' ' VAL . . . -121.93 25.33 6.82 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.636 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.641 HG23 ' HD3' ' A' ' 108' ' ' LYS . 62.5 m -86.49 82.17 8.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.819 0.342 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.81 ' CG2' HG22 ' A' ' 103' ' ' ILE . 53.1 t -69.57 137.75 23.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.996 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.518 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -97.66 -33.03 11.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 -179.994 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.728 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 172.66 158.92 0.11 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.33 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.667 HD13 ' CE2' ' A' ' 91' ' ' PHE . 6.1 mt -113.56 140.23 34.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.165 179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.575 HD22 ' HG2' ' A' ' 151' ' ' PRO . 5.5 mp -106.21 -40.81 5.52 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.933 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 91' ' ' PHE . 63.7 t -50.78 -58.4 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 140' ' ' VAL . 0.4 OUTLIER 85.67 96.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.848 -179.915 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.527 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 2.1 t -40.05 162.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.803 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 74.66 -3.01 45.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.613 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.458 ' HB2' ' O ' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -116.71 150.23 45.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.825 180.0 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.407 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 41.5 Cg_endo -67.39 130.28 22.09 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.286 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.745 HG11 ' OG ' ' A' ' 85' ' ' SER . 41.5 t -81.28 153.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 50.4 mm-40 -132.08 137.15 47.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 -179.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.433 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -36.13 114.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.964 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.3 OUTLIER 79.16 64.96 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.99 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.455 ' O ' ' N ' ' A' ' 152' ' ' LEU . 1.6 tt0 -128.82 121.74 21.12 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.575 ' HG2' HD22 ' A' ' 139' ' ' LEU . 50.0 Cg_exo -55.23 80.26 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.708 2.272 . . . . 0.0 112.312 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.885 HD11 ' HA ' ' A' ' 85' ' ' SER . 3.6 mt -56.97 -48.2 78.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.615 ' O ' HG23 ' A' ' 83' ' ' VAL . 54.7 t -157.99 117.18 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.011 HG12 HG23 ' A' ' 82' ' ' ILE . 3.0 m -90.08 118.51 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.568 HD12 ' NE2' ' A' ' 81' ' ' HIS . 12.1 mt -99.31 154.01 4.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.421 ' N ' HG22 ' A' ' 155' ' ' ILE . 29.2 tt0 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.552 ' H5 ' ' HA ' ' A' ' 95' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' ILE . 8.3 pt-20 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.808 0.337 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.667 HD12 ' N ' ' A' ' 79' ' ' SER . 0.6 OUTLIER 34.77 -158.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.643 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.667 ' N ' HD12 ' A' ' 78' ' ' ILE . 1.5 m -93.46 58.88 2.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.985 -179.822 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -159.03 -165.25 15.71 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.382 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.565 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -165.92 147.68 7.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.795 0.331 . . . . 0.0 110.884 179.942 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.041 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -103.53 116.82 47.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 153' ' ' VAL . 30.3 t -77.09 93.59 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.102 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -83.11 126.4 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -45.19 110.24 1.06 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.959 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.561 ' O ' ' CE1' ' A' ' 148' ' ' PHE . 76.9 Cg_exo -49.79 -65.98 0.14 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.841 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.5 ptp -119.86 176.01 5.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.594 HG12 ' N ' ' A' ' 89' ' ' GLY . 72.3 t -64.64 162.45 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.215 -179.898 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 160.41 -145.56 11.32 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.328 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 118' ' ' VAL . 0.2 OUTLIER -144.2 112.37 6.37 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.85 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.027 ' HB3' HG11 ' A' ' 140' ' ' VAL . 58.4 t80 -81.24 169.43 17.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.712 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.63 ' CE2' ' H2 ' ' A' ' 222' ' ' BTN . 5.3 m-85 -165.07 -179.45 5.71 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.897 0.38 . . . . 0.0 111.054 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 12.2 mmm-85 -120.1 -19.04 7.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.985 179.916 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 65.0 p -138.95 120.92 10.22 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.001 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.759 ' HB3' HD12 ' A' ' 117' ' ' ILE . 74.2 Cg_endo -76.07 50.44 2.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.869 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.867 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER 160.23 148.31 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.946 179.969 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.11 -19.75 12.63 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.771 2.314 . . . . 0.0 112.326 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -149.54 53.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.867 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -94.83 -169.43 2.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.105 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.446 ' O ' ' O ' ' A' ' 101' ' ' ALA . 0.1 OUTLIER -109.49 24.79 12.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.988 -179.949 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.522 ' HB1' ' CG ' ' A' ' 104' ' ' GLU . . . 58.07 129.4 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.201 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.851 ' CE1' HG21 ' A' ' 114' ' ' THR . 0.8 OUTLIER -68.38 -88.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.83 179.923 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 103' ' ' ILE . 18.3 mm -116.54 82.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.973 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.522 ' CG ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 mm-40 -73.69 160.62 31.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.5 t -57.5 151.32 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.161 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 63.11 14.28 52.54 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.589 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.531 ' O ' ' CB ' ' A' ' 108' ' ' LYS . 6.4 tt0 -111.94 -124.14 0.28 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 110.576 -0.157 . . . . 0.0 110.576 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.927 ' HE2' HG22 ' A' ' 135' ' ' VAL . 2.6 tptt 85.06 -161.09 0.01 OUTLIER 'General case' 0 C--N 1.335 -0.05 0 CA-C-O 120.867 0.365 . . . . 0.0 111.024 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 108' ' ' LYS . 0.0 OUTLIER 179.93 -89.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.082 -179.952 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 0.6 OUTLIER -156.48 175.02 14.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.854 179.935 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 132' ' ' SER . 58.9 t -65.95 101.94 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 155.04 -26.38 0.62 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HB3' ' A' ' 128' ' ' GLU . 0.1 OUTLIER -79.46 172.49 13.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.914 -179.962 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.851 HG21 ' CE1' ' A' ' 102' ' ' PHE . 0.2 OUTLIER -77.76 172.67 13.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.952 -179.927 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.65 HD23 ' SG ' ' A' ' 116' ' ' CYS . 0.7 OUTLIER -124.16 -64.74 1.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 -179.947 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.65 ' SG ' HD23 ' A' ' 115' ' ' LEU . 0.8 OUTLIER 168.95 157.04 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.032 -179.985 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.759 HD12 ' HB3' ' A' ' 95' ' ' PRO . 7.1 mt -84.96 143.38 11.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.166 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 125' ' ' ASN . 4.6 t -97.85 -20.74 5.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.88 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER 35.92 61.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.994 179.905 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.731 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -89.34 -9.08 51.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.093 179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.423 ' SD ' ' SD ' ' A' ' 123' ' ' MET . 0.0 OUTLIER -172.31 35.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.834 179.965 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 9.9 tppt? 67.87 15.55 9.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.731 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.2 ptt? -87.1 -8.27 57.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.071 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 126' ' ' GLN . 5.5 mmt 53.43 39.11 29.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.885 179.895 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 29.3 t30 -58.22 78.12 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.689 179.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.515 ' N ' ' O ' ' A' ' 124' ' ' MET . 6.3 pt20 -88.03 125.51 34.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 -179.731 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.542 HG22 ' N ' ' A' ' 128' ' ' GLU . 14.3 mm -89.41 165.9 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.542 ' N ' HG22 ' A' ' 127' ' ' ILE . 2.2 mp0 -126.86 123.21 36.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -41.94 128.28 3.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.112 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.716 ' C ' HG22 ' A' ' 111' ' ' VAL . 3.3 p30 -139.14 22.08 2.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.815 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.715 ' HB2' HD13 ' A' ' 155' ' ' ILE . 4.1 mmtp -107.57 -21.52 12.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.771 ' HB2' HG23 ' A' ' 111' ' ' VAL . 45.8 t 65.86 126.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 108' ' ' LYS . . . 131.11 -156.95 22.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.474 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.9 ' O ' HG23 ' A' ' 155' ' ' ILE . 86.4 m -115.77 157.69 23.97 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.824 0.345 . . . . 0.0 111.034 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.927 HG22 ' HE2' ' A' ' 108' ' ' LYS . 67.2 t -85.06 133.7 28.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -83.31 -51.89 7.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.901 179.956 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.576 ' O ' HG22 ' A' ' 154' ' ' VAL . . . 179.79 147.78 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.221 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.566 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 4.1 mt -103.64 136.74 35.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.989 179.861 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.842 HD22 ' HG2' ' A' ' 151' ' ' PRO . 7.8 mp -87.85 -55.42 3.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.599 179.732 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.027 HG11 ' HB3' ' A' ' 91' ' ' PHE . 86.7 t -32.7 135.96 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.216 -179.698 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 142' ' ' SER . 0.2 OUTLIER -77.58 51.8 0.93 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.965 -179.826 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 141' ' ' GLU . 4.9 t 33.12 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.377 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 104.18 -28.11 16.56 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.057 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG2' ' HD2' ' A' ' 145' ' ' PRO . 0.1 OUTLIER -39.41 127.99 1.38 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 0.0 110.687 179.897 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.457 ' HD2' ' HG2' ' A' ' 144' ' ' GLN . 33.6 Cg_endo -64.82 88.69 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.671 2.248 . . . . 0.0 112.269 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.497 HG13 ' HB2' ' A' ' 150' ' ' GLU . 93.3 t -34.93 155.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 147' ' ' GLU . 0.0 OUTLIER -147.44 47.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 -179.876 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.561 ' CE1' ' O ' ' A' ' 86' ' ' PRO . 0.3 OUTLIER 64.25 122.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.92 179.927 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.426 ' HB2' ' O ' ' A' ' 148' ' ' PHE . 1.2 m-20 71.0 60.5 0.18 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.048 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.497 ' HB2' HG13 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -126.44 105.62 24.23 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.775 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.842 ' HG2' HD22 ' A' ' 139' ' ' LEU . 86.0 Cg_exo -46.48 86.18 0.02 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.286 0 C-N-CA 122.648 2.232 . . . . 0.0 112.257 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.622 HD22 ' CD2' ' A' ' 91' ' ' PHE . 51.0 mt -66.74 -45.14 79.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.079 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.747 HG12 HG13 ' A' ' 135' ' ' VAL . 0.9 OUTLIER -159.7 132.21 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.13 -179.945 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.041 HG12 HG23 ' A' ' 82' ' ' ILE . 4.1 m -113.57 117.34 55.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.001 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.9 HG23 ' O ' ' A' ' 134' ' ' THR . 5.4 mt -83.93 145.41 8.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.143 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 136' ' ' LYS . 6.3 tt0 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.263 -0.875 . . . . 0.0 110.835 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.63 ' H2 ' ' CE2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.806 0.336 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.571 ' C ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -112.62 136.32 49.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.069 -179.898 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.64 88.63 2.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 162.28 154.29 7.49 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.552 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.775 ' C ' HD12 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -157.12 168.0 28.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.361 . . . . 0.0 110.893 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.995 HG23 HG12 ' A' ' 154' ' ' VAL . 1.2 mp -114.43 110.01 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 153' ' ' VAL . 20.1 t -72.94 88.83 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.184 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 22.2 ptt180 -78.3 152.78 32.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 1.006 ' OG ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -96.93 102.96 13.22 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.008 179.99 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.19 -51.42 0.35 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.718 2.279 . . . . 0.0 112.312 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 2.5 tpp -89.22 111.75 22.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.503 HG12 ' N ' ' A' ' 89' ' ' GLY . 56.0 t -41.95 158.61 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.136 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.503 ' N ' HG12 ' A' ' 88' ' ' VAL . . . 168.16 -155.2 25.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.473 -179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.555 HG22 ' HA2' ' A' ' 143' ' ' GLY . 0.5 OUTLIER -121.22 122.6 40.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.812 0.339 . . . . 0.0 110.966 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 92' ' ' TYR . 17.7 t80 -71.49 167.81 18.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.874 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.631 ' N ' ' CD1' ' A' ' 91' ' ' PHE . 3.6 m-85 -167.82 -177.84 3.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.787 0.327 . . . . 0.0 111.291 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HG2' ' CE1' ' A' ' 91' ' ' PHE . 6.1 mtm180 -156.05 20.65 0.37 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.011 -179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.587 HG23 ' O ' ' A' ' 93' ' ' ARG . 16.1 p -161.48 100.89 1.22 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.814 0.34 . . . . 0.0 110.942 -179.873 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.566 ' HD3' ' CD2' ' A' ' 102' ' ' PHE . 74.1 Cg_endo -76.02 52.05 3.31 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.794 2.329 . . . . 0.0 112.406 179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.771 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER 168.15 124.53 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.999 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -47.71 -21.35 2.33 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.753 2.302 . . . . 0.0 112.38 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 39.8 p30 -128.46 28.02 5.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.771 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -80.82 -170.1 2.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.185 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -95.76 -85.89 0.32 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -171.36 124.17 0.59 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.235 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 116' ' ' CYS . 0.3 OUTLIER -55.31 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.875 -179.997 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.876 HG22 HG21 ' A' ' 135' ' ' VAL . 49.4 mm -66.65 77.37 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.909 0.385 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.418 ' OE2' ' NH1' ' A' ' 93' ' ' ARG . 0.1 OUTLIER -69.01 -179.48 1.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.943 -179.938 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 136' ' ' LYS . 3.2 t -68.58 139.83 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.185 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.73 -23.66 10.05 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.639 ' NE2' HD13 ' A' ' 103' ' ' ILE . 49.4 tt0 -66.83 167.66 11.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.76 0.314 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.455 ' N ' ' CG ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -100.52 157.8 16.39 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.867 0.365 . . . . 0.0 110.974 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.628 HG13 HD12 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -152.17 104.13 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.071 -179.948 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -99.81 141.47 32.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 53.0 t -38.89 105.26 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.125 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.13 6.31 7.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.524 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.49 162.72 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.866 0.365 . . . . 0.0 110.999 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.36 175.93 9.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.518 ' CB ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -138.33 -67.53 0.47 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.898 179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.59 ' HA ' ' CD2' ' A' ' 102' ' ' PHE . 1.3 m -177.57 153.86 0.92 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.255 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.549 HD13 ' HN1' ' A' ' 222' ' ' BTN . 7.1 mt -90.98 157.47 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.264 179.932 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.494 HG12 ' HA3' ' A' ' 89' ' ' GLY . 38.5 t -111.24 -22.8 4.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.823 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.41 ' C ' ' O ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER 36.58 53.57 1.05 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.941 -179.964 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.628 ' HB3' ' HE1' ' A' ' 123' ' ' MET . . . -83.16 -0.51 49.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.452 ' HB3' ' O ' ' A' ' 120' ' ' ALA . 1.0 OUTLIER 178.11 43.25 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.815 -179.986 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.413 ' HE2' ' HA ' ' A' ' 122' ' ' LYS . 6.2 tppt? 59.8 21.53 10.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.867 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.628 ' HE1' ' HB3' ' A' ' 120' ' ' ALA . 1.7 ptt? -91.28 -18.59 24.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.96 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.504 ' O ' ' N ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER 60.01 37.14 21.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.9 -179.958 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.554 ' HB2' ' HE3' ' A' ' 123' ' ' MET . 43.9 t30 -55.87 82.15 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.45 179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.504 ' HB3' HG13 ' A' ' 117' ' ' ILE . 1.9 pm0 -88.95 129.27 35.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.335 -179.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.518 ' O ' ' CB ' ' A' ' 115' ' ' LEU . 13.5 mm -85.73 140.52 15.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.813 179.81 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -117.97 111.95 19.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.844 -179.956 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -42.54 140.7 1.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.1 p-10 -147.42 30.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -120.96 -10.81 9.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.956 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.08 90.49 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.917 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -172.53 -154.3 10.11 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.493 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.508 ' C ' HG23 ' A' ' 155' ' ' ILE . 4.5 m -125.11 139.29 53.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.876 HG21 HG22 ' A' ' 103' ' ' ILE . 70.6 t -71.52 132.03 33.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.425 ' O ' HG13 ' A' ' 105' ' ' VAL . 0.1 OUTLIER -85.37 -46.59 10.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.912 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.468 ' O ' HG22 ' A' ' 154' ' ' VAL . . . -175.85 174.93 2.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.168 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CD1' HG22 ' A' ' 153' ' ' VAL . 2.8 mt -135.17 132.85 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.03 179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.64 HD23 ' HB2' ' A' ' 151' ' ' PRO . 1.3 mm? -87.96 -58.71 2.47 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.198 179.391 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.712 HG11 HG22 ' A' ' 146' ' ' VAL . 1.4 t -69.0 105.92 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.478 179.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.59 ' HA ' ' CE1' ' A' ' 91' ' ' PHE . 12.7 mt-10 -124.48 147.47 48.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.927 0.394 . . . . 0.0 111.494 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.1 t 51.82 79.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.394 179.553 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.555 ' HA2' HG22 ' A' ' 90' ' ' THR . . . 41.15 27.39 0.22 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.463 -0.875 . . . . 0.0 112.449 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.546 ' HB3' ' CG1' ' A' ' 140' ' ' VAL . 0.6 OUTLIER -52.93 142.89 33.38 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.686 179.922 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.11 100.9 0.06 OUTLIER 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.731 2.287 . . . . 0.0 112.277 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.712 HG22 HG11 ' A' ' 140' ' ' VAL . 14.2 t -80.18 98.19 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.448 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 24.7 tt0 -103.09 141.34 35.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.514 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 8.2 t80 -36.27 116.69 0.42 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.843 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.514 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.6 t0 85.57 51.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.868 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.552 ' CD ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.03 114.74 32.09 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.775 179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.64 ' HB2' HD23 ' A' ' 139' ' ' LEU . 77.5 Cg_exo -49.73 97.65 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.707 2.272 . . . . 0.0 112.39 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.006 HD11 ' OG ' ' A' ' 85' ' ' SER . 65.9 mt -76.77 -54.97 5.93 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.752 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.637 HG22 ' CD1' ' A' ' 138' ' ' ILE . 16.8 t -150.07 96.31 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.092 179.91 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.995 HG12 HG23 ' A' ' 82' ' ' ILE . 3.6 m -79.55 120.7 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.508 HG23 ' C ' ' A' ' 134' ' ' THR . 3.0 mt -105.89 138.71 29.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.227 -0.892 . . . . 0.0 110.828 179.968 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 222' ' ' BTN . . . . . 0.593 ' H61' ' CD2' ' A' ' 92' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_